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Chapter 1
1.1 Bone
1.1.1 Embryonic development
The formation of the skeleton and the bones of the skull is one of the last events in the entire 
process of embryonic development. In mice, the development of the major organ systems is being 
initiated around embryonic day 8.5 (E8.5), whereas the initiation of bone development occurs only 
around E12. At E14.5 ossification is initiated and at E16.5 bone formation takes place in almost all 
major ossification centers of the skeleton and the skull. However, full ossification is only achieved 
approximately two weeks after birth (1).
Bone development can occur through two mechanisms of ossification: intramembranous 
ossification and endochondral ossification (Figure 1). In the process of intramembranous ossification, 
bone growth begins with the condensation of mesenchymal cells that expand and form a membranous 
structure. Subsequently, these mesenchymal cells differentiate directly into osteoblasts in the primary 
centers of ossification. Calcification by the mature osteoblasts is not coordinated but occurs in 
irregularly distributed patches. These mature osteoblasts form the endosteum, while at the periphery 
mesenchymal cells continue to differentiate, following the same steps, to form the periosteum (Figure
1A).
During endochondral ossification, the condensed embryonic mesenchymal cells first 
differentiate into chondroblasts, which secrete the cartilaginous matrix (cartilage model). 
Subsequently, the chondroblasts proliferate, differentiate into chondrocytes and eventually become 
hypertrophic and undergo programmed cell death. Osteoclasts then resorb the cartilage matrix and 
adjacent mesenchymal stem cells differentiate to osteoblasts, which form new bone in the primary 
center of ossification. Subsequent ossification occurs in the same fashion in secondary centers of 
ossification (Figure 1B) (2).
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Figure 1. Bone Development.
Schematic diagrams of the initial phases of (A) Itramembranous or (B) Endochondral ossification. See text for details. (Adopted 
from Baron (2003), see ref. 2)
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The majority of the long bones are derived from mesenchymal cells of the somites and are 
formed through endochondral ossification, while the majority of the bones in the skull are derived 
from mesenchymal cells from the neural crest and are formed by the process of intramembranous 
ossification. However, no lineage relationship exists between the origin of the mesenchyme and the 
type of bone that it forms (1).
1.1.2 Osteoblast differentiation, transcriptional regulation and marker genes
1.1.2.1 Stages o f osteoblast differentiation
Mesenchymal stem cells (MSCs) have the potential to differentiate into various cell types 
including osteoblasts, chondroblasts, myoblasts, adipocytes and fibroblasts, depending on the 
signaling cascades activated during the initial phase of differentiation (for review see ref. 3). In the 
process of osteoblast differentiation, several stages can be distinguished (Figure 2): self renewal, in 
which the MSCs maintain an undifferentiated phenotype; lineage commitment, in which the MSCs 
receive the primary signal to differentiate to osteoprogenitor cells; proliferation, in which a subset of 
the osteoprogenitor cells differentiate to pre-osteoblasts; matrix maturation, in which the pre­
osteoblasts differentiate to mature osteoblasts that secrete the extracellular matrix; mineralization, in 
which hydroxyapatite crystals are deposited in the extracellular matrix and osteoblasts differentiate 
either into osteocytes, that are completely embedded in the mineralized matrix and support the bone 
structure, or in lining cells that form the protective bone surface; and finally apoptosis, in which the 
osteocytes undergo programmed cell death. The osteoclast, which is responsible for bone resorption, 
is derived from cells of the mononuclear/phagocytic lineage (4) and will not further be discussed here.
1.1.2.2 Transcriptional regulation and marker genes o f Self Renewal
Factors maintaining the undifferentiated state of MSCs include LIF (leukemia inhibitory 
factor) (for review see ref. 5), Sca-1/Ly6a (stem cell antigen 1/lymphocyte antigen 6) (6), and 
interleukin 18 (IL-18) (7). Moreover, transcriptional regulators, including members of the helix-loop- 
helix (HLH) family such as Twist and the Id (inhibitor of differentiation) proteins, have been 
proposed as mediators in maintenance and expansion of the mesenchymal progenitor population (8­
10) (Figure 2). In general, factors promoting proliferation of the MSC will be inhibitory for the final 
differentiation stages.
1.1.2.3 Transcriptional regulation o f Lineage Commitment, Proliferation and Maturation
Many extracellular factors, including the bone morphogenetic proteins (BMPs), are known to 
induce differentiation of MSCs to osteoprogenitor and osteoblast cells, and their action will be 
discussed elsewhere in this chapter.
Important transcriptional regulators of the differentiation of osteoprogenitor cells to mature 
osteoblasts include Bapx1/Nkx3.2 (bagpipe homeobox protein 1), Msx-1/Hox 7.1 and Msx-2/Hox 8.1 
(muscle-segment homeobox proteins 1 and 2), the homeobox protein Hoxa2, Dlx-5 and Dlx-6 (distal- 
less like homeobox proteins 5 and 6), core-binding factor a1 (Cbfa1/Runx2/PEPB2aA/AML3) and 
osterix (Osx) (Figure 2). Bapx1 is one of the early markers for somite development and is expressed 
in all cartilaginous condensations during embryonic development (11). Moreover, Bapx1 has been 
shown to be required for bone development since Bapx1 knockout mice have deformed cranial bones 
and fail to initiate chondroblast differentiation of MSCs, resulting in severe malformations of the 
skeleton. The failure of Bapx1 knock-out mice to initiate chondroblast differentiation is reflected by 
the finding that expression of the transcription factor Sox-9, which is the most important transcription
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Figure 2. Stages of osteoblast differentiation.
Schematic diagram of the differentiation pathway of mesenchymal stem cells towards osteoblast cells, including factors that 
regulate differentiation and markers for the various stages of differentiation. See text for details. (Adopted from Lian J.B. et al 
(2003), see ref. 4)
factor for chondrogenesis, and the expression of markers for chondrocyte differentiation such as the 
type II collagen (Col2a1) gene is down-regulated (12, 13).
Msx-1 and Msx-2 have been shown to regulate bone development, since both Msx-1 and Msx- 
2 knock-out mice display severe defects in craniofacial bone development (14, 15). Moreover, Msx-2 
knock-out mice also have defects in endochondral bone formation, which is caused by defective 
proliferation and subsequent differentiation of progenitor cells (15). In addition, over-expression of 
Msx-2 in MSCs induces the differentiation of these cells to osteoblastic cells, as shown by the up- 
regulation of osteoblast markers and up-regulated matrix mineralization (16). Msx-1 and Msx-2 are 
highly expressed in MSCs and osteoprogenitor cells but much less in more differentiated cells, since 
Msx-1 expression must be down-regulated for progression of osteoblast differentiation in vivo (17­
19).
The homeobox protein Hoxa-2 has been described not so much as an initiator of osteoblast 
differentiation but more as a regulator of induced osteoblast differentiation. Hoxa-2 has been shown 
to negatively regulate intramembranous bone formation by inhibiting the expression of Sox-9 and 
Cbfa1, which is a key-regulator of osteogenesis (20). Dlx-5 and Dlx-6 were shown to be expressed in 
the developing limb bud as well as in all skeletal structures after the first cartilage formation (21). 
Moreover, Dlx-5 was shown not only to induce chondroblast differentiation (22), but also osteoblast 
differentiation (23, 24), and it is directly involved in the expression regulation of Cbfa1 and multiple 
osteoblast marker genes (25-27).
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Cbfal is a transcription factor of the Runx family of transcriptional regulators (28, 29) and its 
regulation and function in bone have been studied extensively over the last decade. The gene for 
Cbfal encodes three isoforms that are regulated by two promoters. The type I isoform is regulated by 
one promoter, whereas the type II and III isoforms are under the control of another promoter and are 
formed by different translational start sites (30). In addition, the type I isoform is constitutively 
expressed in non-osseous tissue and in osteoprogenitor cells, and its expression does not change 
during osteoblast differentiation. In contrast, the type II and III isoform transcripts increase 
specifically during differentiation of primary osteoblasts, and in response to BMP-2 treatment of 
osteoprogenitors (31, 32). Furthermore, regulation of the activity of the Cbfal protein through post- 
translational modifications (33) as well as through protein-protein interactions (34, 35) has been 
reported (see below).
Cbfal is a key regulator of bone development since Cbfa1 knock-out mice in which the 
function of all isoforms is disrupted, exhibit impaired chondroblast differentiation and complete 
absence of skeletal ossification due to a maturational arrest of osteoblasts (36). Moreover, most of the 
well-established bone markers are known target genes of at least one of the Cbfal isoforms (28, 30, 
36-39). Until recently, it was assumed that the impaired chondroblast differentiation and complete 
absence of skeletal ossification seen in Cbfa1 knock-out mice was caused primarily by the disruption 
of the function of the Cbfal type II isoform because of its bone-specific expression pattern. However, 
Xiao et al. (39) have shown that selective Cbfal type II-deficient mice have limited impairment of 
osteoblast maturation and form almost complete mineralized skeleton, which is characterized by 
severe abnormalities in endochondral bone formation and almost normal intramembranous bone 
formation. Specifically, Cbfal type II-null mice have almost normal chondroblast differentiation and 
maturation, but the subsequent osteoblast differentiation and maturation is severely impaired (39). 
Therefore, it is likely that Cbfal type I, which is constitutively expressed in osteoprogenitor cells, 
plays an important role in the early stages of mesenchymal cell development, whereas the “bone- 
specific” Cbfal type II is necessary for complete skeletogenesis and osteoblast differentiation, 
especially in the later stages of endochondral ossification (39).
In addition to Cbfal, the transcription factor Osx is specifically expressed in all developing 
bone. More specifically, Osx is expressed similarly to Cbfa1 in differentiating chondrocytes, but not 
in hypertrophic chondrocytes, and is expressed in all cell types of the osteoblastic lineage (28, 40). 
Like Cbfal, Osx is a key-regulator of bone development, since Osx knock-out mice display normal 
patterning of endochondral skeletal elements, but ossification of these elements is severely delayed. 
In addition, a lack of mineralized bone was observed in the skeletal elements formed by 
intramembranous ossification due to complete inhibition of osteoblast differentiation, and embryos 
died shortly after birth due to respiratory failure (40). Furthermore, expression of Cbfa1 was normal 
in Osx-null cells, while expression of several osteoblast marker genes was severely reduced or 
completely lacking. However, these cells expressed Sox9, Col2a1 and other chondroblastic markers, 
indicating that the cells that could not differentiate into osteoblasts acquired a chondroblastic 
phenotype (40). It has been assumed that Osx expression is regulated by Cbfal, since Osx is not 
expressed in Cbfa1-null mice while Cbfa1 is normally expressed in Osx-null mice (39, 40). However, 
reports on the mechanism of Osx regulation are scarce and the results contradictory, due to the 
existence of cell-type specific isoforms that arise by differential promoter use (27, 4l).
1.1.2.4 Marker genes o f Lineage Commitment, Proliferation and Maturation
Due to their importance in regulating the differentiation of osteoprogenitor cells to mature 
osteoblasts, the transcription factors Dlx5, Cbfal and Osx are considered to be marker genes for 
Lineage Commitment, Proliferation and Maturation. Furthermore, during osteoblast differentiation
-  l l  -
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several genes are expressed that are not involved in the regulation of differentiation, but encode 
proteins required for the function of the osteoblast (Figure 2). These marker genes for Proliferation 
and Maturation include Col1a (type I  collagen), Alp2 (alkaline phosphatase type liver/bone/kidney), 
osteocalcin (Ocn), osteopontin (Opn), bone sialoprotein (Bsp), dentin matrix protein 1 (Dmp1) and 
various proteoglycans such as decorin and lumican.
Col1a forms the major constituent of the organic component of the extracellular matrix 
(ECM). Synthesis of the ECM by osteoblasts contributes to cessation of cell growth leading to a 
“matrix maturation” state when induced expression of Alp2 and specialized bone proteins renders the 
ECM competent for mineral deposition. The subsequent up-regulation of calcium- and phosphate- 
binding proteins such as Ocn, Opn, Bsp and Dmp1 may function to regulate the ordered deposition of 
mineral, the amount of the hydroxyapatite crystals, and the size of the crystals (4, 42). In addition, 
expression regulation of the genes for the small leucine-rich proteoglycans decorin and lumican 
reflects the differentiation status. Decorin negatively regulates the capacity of the cells to mineralize 
the matrix and its expression is down-regulated with progression of differentiation (43, 44). In 
contrast, lumican is up-regulated during osteoblast differentiation and maturation (45). Furthermore, 
bone matrix synthesis supports both cell-cell and cell-matrix interactions that are mediated by 
transmembrane proteins and several classes of adhesion proteins. Of the integrins, which couple the 
extracellular matrix to cytoskeletal elements, the P1 integrins play a key role in early bone 
development and osteoblast differentiation by binding various collagens, which results in the 
induction of signals that lead to expression of genes characteristic for the osteoblast phenotype (46).
The mature osteoblast also expresses genes that do not function to regulate osteoblast 
differentiation or function, but form the major determinants for osteoclast differentiation. These 
include RANKL (receptor activator o f nuclear factor kB ligand), osteoprotegerin (Opg) and CSF-1 
(colony-stimulating factor 1) (for review see ref. 47). Binding of RANKL to its receptor Rank induces 
the differentiation of mononuclear/phagocytic lineage cells into osteoblasts, thus linking 
osteoblastogenesis to osteoclastogenesis (47). Opg is a secreted receptor of the tumor necrosis factor 
receptor family, and by competing with Rank for ligand binding, it acts as a decoy receptor for 
binding of RANKL, inhibiting osteoclast differentiation (47).
1.1.2.5 Transcriptional regulation and marker genes o f Mineralization
Maturation of osteoblasts into osteocytes, as well as osteocyte activity and survival, is 
regulated by the formation of gap junctions (48, 49). These gap junctions are formed mostly by the 
connexin 43 (Cx43) protein and provide metabolic and electric coupling of different osteocytes, as 
well as of osteocytes with osteoblasts and lining cells. Disruption of the formation of gap-junctions by 
Cx43-deficiency results in dysfunctional osteoblasts which leads to retarded ossification in the entire 
skeleton (50).
Osteocytes express genes that are also expressed in osteoblasts, but generally at a higher level. 
These include Cx43, the initiator of mineralization Dmp1 (51), positive regulators of mineralization 
such as Phex (phosphate-regulating gene with homologies to endopeptidases on the X-chromosome) 
(for review see ref. 52), and inhibitors of mineralization such as Of45/Mepe/osteoregulin 
(osteoblast/osteocyte specific factor 45) (53) and Ocn (54). Specific osteocyte markers include the 
E11 antigen gene, which is up-regulated during fracture healing and may therefore be involved in 
proliferation, migration, adhesion or differentiation (55); the gene for the actin filament fimbrin, 
which is expressed in the so-called osteocyte processes (thin cellular extensions) and maintains 
integrity of these processes (56); and Sost, which encodes a secreted glycoprotein that inhibits 
osteoblast differentiation and mineralization of the ECM (57, 58).
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It should be noted here that particularly (mature) osteoblasts are not all identical in their 
expressed gene repertoire (59, 60), and it has been suggested that extensive diversities between 
various osteoblasts might contribute to the heterogeneity in trabecular micro-architecture (61), site- 
specific differences in disease manifestation, and regional variations in the availability of osteoblasts 
to respond to therapeutic agents (62).
1.1.3 Hormonal Regulation o f osteoblast differentiation
Hormonal factors that are known to contribute to the induction of differentiation of MSCs to 
osteoprogenitor and osteoblast cells include PTH/PTHrP (parathyroid hormone/parathyroid hormone- 
related protein), Indian hedgehog (IHH), Vitamin D, retinoic acid (RA), sex steroids, glucocorticoids 
and leptin (Figure 2). PTH is synthesized and secreted almost exclusively by the parathyroid gland 
and regulates calcium homeostasis as an endocrine factor. Its access to the skeleton is via the 
circulation, and although PTH knock-out mice are viable, they show retarded bone development 
caused by poorly developed capillary invasion leading to reduced cartilage matrix mineralization and 
diminished numbers of osteoblast progenitor cells. In addition, apoptosis of cells of the osteoblast 
lineage is enhanced in these mice. It has been speculated that the anabolic effect of intermittent PTH 
administration in adults is due to enhanced recruitment, commitment, and/or proliferation of 
osteoprogenitors, as well as inhibition of apoptosis of cells of the osteoblast lineage, as observed in 
fetal bone development (63). Furthermore, it has been shown that the anabolic effects of PTH require 
Cbfa1-dependent signaling (64), and that the expression of several Cbfa1 target genes is regulated by 
PTH (for review see ref. 65).
In contrast to PTH, PTHrP is expressed in a variety of cells including proliferative and 
hypertrophic chondrocytes where it functions as a paracrine/autocrine factor. PTHrP is essential for 
normal endochondral bone formation since PTHrP knock-out mice die shortly after birth, and exhibit 
severe skeletal defects due to diminished chondrocyte proliferation, associated with premature 
chondrocyte maturation and accelerated bone formation (66). PTHrP expression is regulated by IHH, 
and PTHrP and IHH are speculated to control a negative feedback loop that regulates the rate and 
synchrony of chondrocyte differentiation (67). Mice lacking IHH expression show a similar but 
distinct phenotype from PTHrP knock-out mice, characterized by reduced chondrocyte proliferation 
and maturation as well as a failure of osteoblast development in endochondral bones, while in 
addition they die shortly after birth due to respiratory failure (68). IHH mediates its effects on 
endochondral bone growth by both PTHrP-dependent and -independent pathways and therefore the 
phenotype of IHH knock-out mice is more severe than that of PTHrP knock-out mice (69).
Vitamin D is a steroid made in the skin by the action of sunlight. Vitamin D itself is 
biologically inert and must undergo two successive hydroxylations in the liver and kidney, 
respectively, to become the biologically active 1,25 dihydroxy vitamin D3 {1,25(OH)2D3}. This 
biologically active form of vitamin D is the major regulator of calcium homeostasis in the body and 
protects the organism from calcium deficiency via effects on the intestine, kidney, parathyroid gland, 
and bone. The renal conversion of 1,25(OH)2D3 is tightly regulated by serum calcium levels through 
PTH and inorganic phosphate in a feedback loop (70). Biologically active vitamin D exerts its effect 
via a complex of the vitamin D receptor (VDR) and a retinoic acid X receptor (RXR) on osteoblasts. 
Mice lacking VDR show impaired bone formation after weaning and die within 15 weeks after birth 
(71). In general, 1,25(OH)2D3 is thought to inhibit osteoblast progenitor proliferation and to induce 
osteoblast differentiation in vivo. However, depending on the differentiation status of the cells, 
different effects of 1,25(OH)2D3 have been observed (for review see ref. 72). On the other hand,
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1,25(OH)2D3 does not have a direct active role in the mineralization process; it maintains normal 
levels of blood calcium and phosphate levels to ensure normal mineralization to occur. In addition, 
1,25(OH)2D3 stimulates the osteoblasts to produce RANKL, thereby stimulating osteoclast 
proliferation and maturation which results in balanced bone remodeling (70).
Retinoic acid (RA) is the most active metabolite of vitamin A, and multiple isomers of RA 
exist of which all-trans RA (T-RA) and 9-cis RA (9C-RA) are the most prominent. RA levels are 
tightly regulated by the activity of retinaldehyde dehydrogenases (RALDH/ALDHla) and the 
cytochrome P450RA (P450RA/CYP26) enzymes, which synthesize and degrade RA respectively (for 
review see ref. 73). This tight regulation of RA levels is necessary, since elevated or subnormal RA 
levels cause congenital malformations including severe skeletal defects (74, 75).
Two families of nuclear receptors have been identified that relate retinoic acid signaling: the 
RA receptors (RARa, -P and y) and the retinoid X receptors (RXRa, -P and y), which function 
predominantly as RAR/RXR heterodimeric transcription factors during embryonic development, 
although RXR homodimers have also been described to exists (76, 77). In the RAR/RXR 
heterodimer, RXR functions as an orphan receptor, whereas in RXR homodimers it is specifically 
activated by 9C-RA (78). However, it is currently unclear under which physiological conditions the 
RXRs act as 9C-RA-dependent receptors. Furthermore, RARs in the RAR/RXR heterodimer complex 
are activated by both T-RA and 9C-RA (78). In addition to the nuclear receptors, cytoplasmic retinol 
binding proteins (CRBPs) and cytoplasmic RA binding proteins (CRABPs) bind to retinol and RA 
respectively, which have roles in controlling RA availability in the nucleus (for review see ref. 79).
The RA receptors and binding proteins are expressed in distinct and sometimes overlapping 
spatiotemporal patterns during embryogenesis, and disruption of their function leads to several 
skeletal defects, predominantly abnormalities associated with endochondral bone formation (79). In 
particular, RA has been shown to regulate both chondroblast differentiation and chondrocyte 
hypertrophy. At the early stages of chondroblast differentiation, RA inhibits the expression and 
activity of Sox9 and subsequently reduces the expression of chondroblast marker genes, thus 
influencing the timing of condensation and chondroblast differentiation. In addition to this inhibitory 
effect on early stage chondroblast differentiation, RA positively regulates the maturation of 
chondrocytes by inducing the expression of Cbfa1 and its target genes, while simultaneously 
inhibiting the expression of Sox9 (79).
In addition to these effects on chondrogenesis, RA has also been described to enhance 
osteoblast differentiation, in part because RA induces the expression of BMPs, but also because RA 
and BMPs cooperate to induce differentiation of mesenchymal cells to osteoblasts (80-82). It has been 
hypothesized that this action of RA is mediated by the Ets transcription factors, which are 
differentially expressed throughout osteoblast differentiation. Furthermore, these factors are able to 
interact with Cbfa1 and show expression regulation by RA (83).
Sex steroids form a group of steroid hormones that consist of estrogens, androgens and 
progesterone. Particularly estrogen has been shown to play an important role in maintaining bone 
mass. It is believed, however, that the major effect of estrogen is not a stimulation of the bone 
forming osteoblasts, but primarily an inhibition of the proliferation and differentiation of the bone 
resorbing osteoclasts. In postmenopausal women, estrogen deficiency causes an increase in bone 
remodeling activity during which bone resorption is no longer coupled to bone formation, resulting in 
a net loss of bone (osteoporosis) (84). Recently it has been shown that also in men estrogen is very 
important for inhibiting bone resorption.
Androgens such as testosterone are known to enhance bone size in both men and women (for 
review see ref. 85). Androgens decrease bone resorption by acting directly on osteoclast function, and 
can regulate the production of bone-resorbing factors produced by mature osteoblasts (86).
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Progesterone levels also decrease at menopause, but direct evidence for an effect of progesterone in 
postmenopausal bone loss is still lacking. However, it has been shown that progesterone can promote 
bone formation in vivo both independently and in combination with estrogen. In addition, 
progesterone may have a similar effect on bone resorption as estrogens. Finally, it has been shown 
that progesterone consistently blocks glucocorticoid responses by binding to glucocorticoid receptors, 
but it has also been suggested that progesterone may act directly through the progesterone receptor in 
osteoblast cells (for review see ref. 87).
Glucocorticoids such as dexamethasone have been reported to promote the differentiation of 
MSCs to osteoblasts in vitro. However, in vivo it has been shown that glucocorticoids impair the 
differentiation of MSCs toward cells of the osteoblast lineage and prevent the terminal differentiation 
of osteoblastic cells. In addition, glucocorticoids stimulate apoptosis of mature osteoblasts. These two 
effects combined result in a decrease in the number of bone forming cells. Glucocorticoids also 
inhibit the function of the remaining mature osteoblasts. Furthermore, osteoclast proliferation and 
maturation is stimulated by glucocorticoids, resulting in increased bone resorption. This stimulation 
of bone resorption is most likely responsible for the initial bone loss in metabolic bone diseases 
observed after glucocorticoid exposure. The additional inhibition of bone formation by 
glucocorticoids will cause a decrease in bone remodeling and a continued increased risk of fractures 
(for review see ref. 88). In addition to these direct effects of glucocorticoids on osteoblasts and 
osteoclasts, glucocorticoids also indirectly inhibit bone formation by decreasing the expression of the 
growth factor IGF-I, which is a positive regulator of osteoblast function. This is an important 
mechanism that contributes to the decreased bone formation observed after glucocorticoid 
exposure(89).
Leptin is a signaling peptide that acts on the hypothalamus, thereby stimulating the 
sympathetic nervous system, which results in an attenuation of appetite and an enhancement of 
lipolysis in adipocytes, with concomitant heat production. Leptin is mainly produced in adipose 
tissue, but it is also expressed in and secreted by other tissues such as muscle, gastric epithelium, 
breast epithelium and bone (for review see ref. 90). Leptin exerts its effects via a specific receptor 
(OB-R1), which is expressed in cells of the hypothalamus, cerebral cortex, amygdala, thalamus, 
cerebellum and anterior pituitary as well as in tissues such as adipose, liver, kidney, heart, muscle and 
bone.
Leptin has been shown to be a regulator of bone formation, since mice deficient in leptin 
production or signal transduction are not only obese and hypogonadic, but also display a markedly 
elevated bone strength and mass, indicating that leptin negatively regulates bone formation. In 
contrast, however, leptin has also been shown to enhance proliferation, differentiation and 
mineralization of primary osteoblasts, and to prolong the life span of primary osteoblasts by inhibiting 
apoptosis. Furthermore, leptin has been shown to inhibit differentiation of osteoclasts, indicating that 
leptin positively regulates bone formation and remodeling (90).
Recently, a model has been proposed in which the effect of leptin on bone formation was 
proposed to be dependent on the concentration and mode of exposure, determined by the source from 
which leptin is reaching the bone cells. This model postulates that the central effect of leptin via the 
hypothalamus could act as a brake on the anabolic actions that hormones, local factors and mechano- 
sensing have on bone mass, while locally produced leptin promotes bone formation, thus ensuring a 
proper balance of bone mass in response to the nutritional status (90).
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1.1.4 Polypeptide growth factors in bone
Bone is a rich source of polypeptide growth factors that have important actions in the 
regulation of bone formation and bone resorption. These include insulin-like growth factors (IGFs), 
fibroblast growth factors (FGFs), platelet-derived growth factor (PDGF), transforming growth factor 
P (TGF-P) and the bone morphogenetic proteins (BMPs) (Figure 2).
Two insulin-like growth factors, IGF-I and IGF-II, have been identified, which are present in 
the systemic circulation and are synthesized by multiple tissues, including bone, where they act as 
local regulators of cell metabolism (for review see ref. 91). In the circulation, IGFs exist in a complex 
with IGF binding proteins (IGFBPs) and a non-IGF binding component termed acid-labile subunit 
(ALS) (for reviews see refs. 91, 92). IGFs have a general anabolic effect on bone remodeling, since 
mice lacking IGF-I exhibit decreased bone formation. IGFs modestly promote proliferation of cells of 
the osteoblastic lineage, and enhance the function of mature osteoblasts by increasing bone matrix 
synthesis. In addition, IGFs prevent apoptosis of osteoblasts resulting in a larger population of mature 
osteoblastic cells. Moreover, IGFs increase collagen synthesis by osteoblasts and inhibit collagen 
degradation by down-regulation of collagenases (93-96). PTH is the major inducer of IGF synthesis 
in osteoblasts, explaining the anabolic effect of PTH in bone (97). On the other hand, glucocorticoids 
inhibit IGF expression as mentioned above. The six IGFBPs are also produced by bone cells, and they 
can prolong the half life of IGFs in the circulation, either neutralize or enhance their biological 
activity, and mediate transport of IGFs to their target cells (92).
FGFs comprise a family of 22 structurally related proteins, which can be subdivided into 6 
subfamilies, all with similar functions but expressed in specific spatial and developmental patterns. 
Four distinct FGF receptor tyrosine kinases (FGFRs) bind and are activated by these various FGF 
family members. FGFs are considered important for neovascularization, wound healing and bone 
formation, and disturbances in FGF signaling result in various skeletal deformations (for review see 
ref. 98). For example, a point mutation in the transmembrane domain of FGFR3 forms the molecular 
basis for Achondrodysplasia, the most common genetic form of dwarfism in humans. During bone 
development, the four FGFRs have distinct, mostly non-overlapping expression patterns, but in 
general they are expressed in mesenchymal condensations, proliferating chondrocytes, hypertrophic 
chondrocytes, differentiating osteoblasts and mature osteoblasts. There is a strong overlap between 
the expression patterns of the various FGFs and their receptors (98). FGFs control the balance 
between undifferentiated and differentiated osteogenic cells by increasing the proliferation of 
immature cells and chondrocytes and by promoting the differentiation and apoptosis of more mature 
osteoblasts. In addition to the effects on bone formation, FGFs also directly regulate bone resorption 
by increasing osteoclast proliferation and activation of mature osteoclasts (98). Moreover, indirect 
actions of FGFs on bone development involve the regulation of IHH/PTHrP, which results in an 
inhibition of bone growth (99).
PDGF is a dimer of the products of four genes, PDGF-A, -B, -C and -D, and experimental 
evidence has been presented for -AA, -BB, -CC or -DD homodimers as well as for an -AB 
heterodimer. In addition, there are two PDGF receptors, a  and p. PDGFs and their receptors are 
expressed during embryogenesis in distinct patterns particularly in the mesoderm, and disturbances in 
PDGF signaling during embryogenesis result in severe growth deformations, generalized 
hemorrhages and embryonic death (for reviews see refs. 100, 101). PDGFs are implicated to play a 
role in inflammation, wound healing, angiogenesis, apoptosis and bone formation.
In bone, PDGF-AA, -AB and -BB are expressed in the osteoblast lineage cells and regulate 
the proliferation of pre-osteoblastic cells, which results in an increase in the number of osteoblastic 
cells, and subsequently bone collagen synthesis. However, these PDGFs do not have a direct
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stimulatory effect on the function of differentiated osteoblasts but instead inhibit the rate at which 
bone mineralization occurs. In addition, PDGFs enhance bone resorption by increasing osteoclast 
proliferation and by inducing the expression of specific collagenases and other matrix 
metalloproteases. Finally, PDGFs indirectly regulate bone formation by inhibiting the expression of 
IGF-I and -II and by stimulating the expression of interleukin 6 (IL-6), which enhances bone 
resorption by increasing osteoclast formation and recruitment (for review see ref. 102).
Three isoforms of TGF-P (TGF-P1, -P2, and -P3) have been described with very similar 
biological activities. TGF-P is the founding member of a family of growth factors which also include 
BMPs, activins, nodal and MIS/AMH (Mullerian inhibiting substance /anti-Mullerian hormone) (for 
review see ref. 103). Members of the TGF-P family are produced by a large variety of cell types, and 
are known to regulate cell migration, adhesion, proliferation, differentiation and apoptosis (for 
reviews see refs. 104, 105). Moreover, TGF-P family members have major roles during 
embryogenesis and skeleton formation, since mice deficient in genes belonging to this family or their 
signal transduction pathways often show early embryonic lethality, various skeletal disorders and 
holoprosencephaly, a forebrain malformation (106). The most important members of this family for 
bone formation are the BMPs, and their function, signal transduction and regulation will be discussed 
in detail below. In bone, TGF-P stimulates the replication of pre-osteoblasts, bone collagen synthesis, 
and it inhibits bone resorption by inducing osteoclast apoptosis. On the other hand, TGF-P opposes 
the effects of BMPs on osteoblastic cell differentiation and inhibits late-stage osteoblast 
differentiation (for review see ref. 107).
1.2 Bone Morphogenetic Proteins
1.2.1 BMPs in mesenchymal stem cell differentiation and osteoclast formation
As mentioned above, BMPs are members of the TGF-P family of growth factors. Over 20 
BMP family members have currently been identified, which can be classified in multiple subfamilies 
of highly related proteins. BMP-2, BMP-4 and the Drosophila homologue decapentaplegic (Dpp) 
constitute one such subfamily. A second subfamily is formed by BMP-5, BMP-6/Vgr1 (BMP- 
6/vegetal-related growth factor 1), BMP-7/OP1 (BMP-7/osteogenic protein 1) and BMP-8/OP-2, 
while a third is formed by GDF-5 (growth differentiation factor 5), GDF-6/BMP-13 and GDF- 
7/BMP-12.
Like all members of the TGF-P family, BMPs are synthesized as large precursors, which are 
processed and proteolytically cleaved to yield mature active protein homodimers (108). Proteolytic 
cleavage of BMPs is mediated by the pro-protein convertases furin and PC6 (109). All members of 
the TGF-P family are cysteine knot proteins. BMPs are distinguished from other members of the 
family by having, in general, seven conserved cysteines in the mature protein, rather than nine. BMPs 
are secreted as biologically active molecules, and not in a latent form such as TGF-Ps where the pro­
region remains non-covalently complexed with the mature region and therefore require extracellular 
proteolytic cleavage to obtain a biologically active protein (108). Although the BMPs were first 
identified by their ability to induce ectopic bone formation in vivo (110), these proteins are now 
known to be involved during embryonic development in mesoderm formation and patterning, left- 
right asymmetry, neural patterning, somite patterning, skeletal development, limb patterning and in
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the development of nearly all organs including tooth, lung, kidney, gut, skin and gonads (for review 
see ref. 108).
The primary function of BMPs in bone formation is to block the differentiation of MSCs to 
myoblasts and to induce their differentiation toward chondroblasts and osteoblasts (111-113). In order 
to inhibit MyoD-mediated myoblast differentiation, BMPs induce the expression of Msx-1 and the 
inhibitor of differentiation genes (Id1-3), which in turn inhibit the expression of the genes for MyoD 
and myogenin (114-118). To promote chondrocyte proliferation and differentiation during 
endochondral bone formation, BMPs induce or sustain the expression of the homeobox genes 
Bapx1/Nkx3.2, Dlx5, Sox9, Msx-1 and Msx-2 in parallel with or downstream of Hedgehog proteins 
(119-124). Furthermore, BMPs enhance the expression of Cbfa1 and Osx in chondrocytes (125, 126), 
and interactions between BMP signaling molecules (Smads) and the transcription factor Cbfa1 are 
necessary for proper chondrogenic differentiation (112).
BMPs stimulate osteoblast differentiation by repressing Bapx1 expression which results in a 
repression of chondroblast differentiation (127). In addition, they induce the expression of Dlx5 (23). 
Dlx5 then up-regulates the osteoblast specific transcription factors Cbfa1 and Osx in a direct manner 
(26, 27). Cbfa1 and Osx subsequently regulate the expression of osteoblast marker genes such as 
Alp2, Ocn, Col1a, Opn, Bsp, Dmp1 and Sost (28, 30, 37, 38, 40, 51, 128). Interaction of Smads with 
Cbfa1 is required for the targeting of Smads to the nucleus and subnuclear sites of active 
transcription, and thus for optimal osteoblast differentiation (129, 130). Mutations in Cbfa1 that 
inhibit its interaction with Smads result in severe defects in bone formation, due to inhibition of 
osteoblast differentiation (131). In addition, BMPs induce apoptosis of terminally differentiated 
osteoblasts by the action of Msx-2, a process that occurs independently of BMP-induced osteoblast 
differentiation, (132-134) (Figure 2).
BMPs are synthesized by many cells including osteoblasts, and play an autocrine role in 
chondroblast/osteoblast differentiation and function (135). Moreover, BMP expression is regulated by 
estrogens, retinoic acid and BMPs themselves. Promoters of various BMP genes also contain Cbfa1 
responsive elements (136-140), which suggests the existence of a positive feedback loop for 
regulating BMP expression in which Cbfa1 plays a central role.
BMPs also have both an indirect and a direct role in osteoclastogenesis. BMPs indirectly 
stimulate osteoclast differentiation by stimulating osteoblast differentiation, since inducers of 
osteoclastogenesis such as RANKL and CSF-1 are expressed by mature osteoblasts (47). Moreover, it 
has been shown that Cbfa1 is needed for optimal RANKL expression (141, 142). BMPs directly 
stimulate osteoclast differentiation by sensitizing the cells to the effects of RANKL on cell genesis 
and survival (143). To temper these effects, BMPs also induce the expression of osteoprotegerin (see 
above) and inhibit expression of collagenase (144, 145).
1.2.2 BMP receptors and signaling
Like the other members of the TGF-P family, BMPs exist mainly as homodimers and 
exert their effects through activation of specific heterotetrameric combinations of so-called type I and 
type II transmembrane serine/threonine kinase receptors: BMPs exert their effect through 
combinations of BMP type II receptor (BMPR-II), ActR-II or ActRIIB and the type I receptors Alk-3, 
Alk-6 or Alk-2. In contrast, activins signal through combinations of the activin type II or IIB receptor 
(Act-RII/Act-RIIB) and the type I activin receptor-like kinase 4 (Alk-4), while TGF-Ps elicit their 
effects through combinations of the TGF-P type II receptor (TGF-PR-II) and the type I receptors Alk-
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5 or Alk-1 (103) (Table 1). Upon ligand binding, the constitutive kinase of the type II receptor 
phosphorylates the GS-domain in the juxtamembrane region of the type I receptor which 
subsequently becomes activated (103).
Unlike TGF-Ps and activins, which first bind to the type II receptor after which a type I 
receptor becomes recruited to the complex and is subsequently activated (103), BMPs first bind to the 
type I receptor, and it has been hypothesized that two distinct modes of receptor binding mediate 
BMP signaling (Figure 3). It has been proposed that BMP type I and type II receptors are present on 
the cell surface as pre-existing heteromeric and homomeric complexes, including complexes of both 
type I and type II (BMPR-II/Alk-3, BMPR-II/Alk-6, Act-RII/Alk-3, Act-RII/Alk-6, Act-RIIB/Alk-3 
or Act-RIIB/Alk-6) and complexes of either type II (BMPR-II/BMPR-II, Act-RII/Act-RII, Act- 
RIIB/Act-RIIB, BMPR-II/Act-RII, BMPR-II/Act-RIIB or Act-RII/Act-RIIB) or type I receptor 
combinations (Alk-3/Alk-3, Alk-6/Alk-6, Alk3/Alk6) (146). Signal transduction through the receptors 
can be achieved either by binding to two preformed type I/II dimeric complexes, subsequently 
inducing a conformational change that activates this complex, or by binding to high affinity type I 
dimeric receptor complexes, subsequently recruiting unliganded BMPR-II homodimers into the 
complex (146). Furthermore, each of the different receptor oligomers may allow association of 
different cytoplasmatic proteins (Figure 3, indicated as X, Y and Z) that may participate in the 
regulation of distinct pathways. It has been proposed that binding of BMP to the pre-existing type I/II 
heterodimers initiates the Smad signal transduction pathway, while binding of BMP to ligand-induced 
type I/II heterodimers initiates Smad-independent signal transduction pathways such as the MAP- 
kinase (p38, ERK and JNK) pathways (147).
Two such cytoplasmic proteins that participate in the regulation of BMP-induced signaling 
pathways are Bram1 (BMP receptor associated molecule 1) and Xiap (X-chromosome-linked 
inhibitor of apoptosis protein), which specifically interact with type I BMP receptors in the 
cytoplasm. Both Bram1 and Xiap recruit Tab1 (Tak1 binding protein 1), an activator protein of Tak1 
(TGF-P activated kinase 1; a MAP kinase kinase kinase), to the receptor complex, indicating that 
Bram1 and Xiap are involved in the activation of the Tab/Tak/p38 pathway by BMPs (148, 149). In 
addition to the differential regulation mediated by pre-formed receptor complexes, the binding 
affinity of the various BMPs for type I receptors differs, and the level of receptor expression varies in 
different cell types. Moreover, the function of the type I receptors also varies according to cell type. 
This suggests that in addition to the mode of receptor oligomerisation, the specificity of the type I 
receptor can determine which signaling pathway is used as well (147).
Table 1. Receptor specificity of TGF-ft family members
Ligand Type II receptor Type I receptor
Activin ActR-II/ActR-IIB Alk-4 (ActR-IB)
TGF-ß TGF-ßR-II Alk-5 (TGF-ßR-I)
Alk-1
BMP BMPR-II Alk-3 (BMPR-IA)
ActR-II/ActR-IIB Alk-6 (BMPR-IB)
Alk-2 (ActR-I)
ActR-II, activin type II receptor; ActR-IIB, activin type IIB receptor; TGF-PR-II, TGF-P type II receptor; BMPR-II, BMP type II 
receptor; Alk 1-6, activin receptor-like kinases 1-6; ActR-I, activin type I receptor, ActR-IB, activin type IB receptor; TGF-PR-I, 
TGF-P type I receptor; BMPR-IA, BMP type IA receptor; BMPR-IB, BMP type IB receptor.
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Figure 3. Signal transduction via BMP receptors and regulation of BMP-induced signaling.
Signal transduction via BMP receptors can be mediated 1) by binding of BMP to two preformed type I/II dimeric complexes, 
subsequently inducing a conformational change that activates this complex, or 2) by binding of BMP to high affinity type I homo- 
/heterodimeric receptor complexes, subsequently recruiting unliganded BMPR-II homodimers into the complex. Furthermore, each 
of the different receptor oligomers may allow association of different cytoplasmatic proteins (indicated as X, Y and Z) which may 
participate in the regulation of distinct pathways. See text for details. Regulation of BMP-induced signaling is achieved by I) 
extracellular agonists and antagonists, II) pseudoreceptors, III) inhibitory Smads, IV) Smad binding proteins and IV) proteasomal 
degradation. See text for details. See page 134 for full color figure. (Adopted from Canalis et al. (2003), see ref. 209)
Upon receptor activation, members of the TGF-P family signal via Smads (Figure 3). Three 
classes of Smads exist: 1) receptor regulated Smads (R-Smads) that can be activated by BMPs (Smad-
1, -5 and -8) or TGF-P/activins (Smad-2 and -3); 2) a common mediator Smad (Co-Smad), Smad-4; 
and 3) inhibitory Smads (I-Smads), Smad-6 and -7 (for reviews see refs. 103, 150). Smad proteins 
contain three domains, an amino-terminal MAD homology domain MH1, a divergent proline-rich
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linker domain, and a carboxy-terminal MH2 domain. The MH1 domain is conserved between R- and 
Co-Smads, binds to several cytoplasmic partners and, for some R-Smads, has been shown to bind 
DNA and to interact with various nuclear proteins. The MH2 domain, which is highly conserved 
among all Smads, binds to cytoplasmic and nuclear proteins and is required for Smad oligomerization 
(for reviews see refs. 103, 150, 151). After activation of the type I receptor, R-Smads in the cytoplasm 
are recruited to the receptor complexes and are activated by phosphorylation of two serine residues in 
the carboxy-terminal SS(V/M)S motif (152-154). Activated R-Smads then form heteromeric 
complexes with Smad-4 and become efficiently translocated to the nucleus (for review see ref. 155).
Smad-4 can bind DNA on GTCT containing sequences, also termed Smad binding elements 
(SBEs), and artificial multimeric SBE containing promoters are efficient enhancers of BMP and TGF- 
P signaling (156, 157). Furthermore, BMP R-Smads have been reported to also bind GCAT motifs, 
GCCG-rich containing sequences, GGCG elements and CAGC elements in different target genes 
(158-162). Moreover, multimerization of SBE, GGCG and CAGC motifs has been shown to enhance 
sensitivity for BMP-induced signaling (161). However, the affinity of Smads for DNA binding to the 
above sequences is relatively weak (163), unless additional co-activators or co-repressors are present 
to efficiently regulate the expression of target genes (164).
Smad-mediated activation of transcription has been shown to be dependent on the general 
transcription co-activators CBP/p300 (CREB binding protein/p300) (Figure 3). Smad-1, -2, -3 and -4 
bind CBP/p300 through their MH2 domain, and phosphorylation of the R-Smads enhances Smad- 
dependent CBP/p300-mediated signaling (165-167). Moreover, CBP/p300 have intrinsic histone 
acetyltransferase activity (168), which suggests that they can potentiate Smad-dependent gene 
transcription by loosening the chromatin structure. In addition, it has been shown that activated R- 
Smads can bind the co-activator P/CAF (p300/CBP-associated factor), thereby enhancing 
transcriptional activity of the Smads. P/CAF, like CBP/p300, has intrinsic histone acetyltransferase 
activity and can bind to CBP/p300, thereby potentiating its effect on Smad-dependent transcription 
activation, possibly by increasing the affinity of R-Smads for their DNA binding sequences (169). 
Furthermore, it has been shown that the expression of several BMP response genes in their basal state 
is inhibited by the binding of Hoxc-8 to their promoter regions (144, 170). Hoxc-8 is capable of 
binding histone deacetylases (HDACs) rendering the chromosome transcriptionally inactive (171). 
Binding of activated R-Smad complexes to Hoxc-8 relieves the binding of Hoxc-8 to DNA and 
HDACs, while the subsequent recruitment of CBP/p300 by Smad-1 might be involved in the 
transcriptional activation of these BMP response genes (144, 170).
BMPs also elicit negative gene expression regulation, and recently it has been shown that 
Bapx1/Nkx3.2 is a BMP-dependent transcriptional repressor. Bapx1 associates with Smad-1 and -4 
upon receptor activation of the Smads, and subsequently this complex binds DNA on Bapx1/Nkx3.2 
response elements. Upon DNA binding, Bapx1 recruits HDAC1 in a Smad-4-dependent manner. It 
has been postulated that this association of Smad-1/4, Bapx1 and HDAC1 then represses the 
transcription of genes that inhibit chondrogenic differentiation, resulting in the induction of 
chondroblast differentiation (172).
Recently, it has been shown that endocytosis can play a role in signal transduction of multiple 
cytokine families (for review see ref. 173). Endocytosis of ligand/receptor complexes can either be 
mediated by clathrin-coated pits or by caveolae. Clathrin is the major protein in the formation of 
clathrin-coated pits, while caveolin is the major protein in the formation of caveolae. Clathrin- 
mediated endocytosis of TGF-P/receptor complexes is very important for signal transduction. SARA 
(Smad anchor for receptor activation) is a FYVE domain containing protein, which has been shown to 
bind to Smad-2 and -3 as well as the TGF-P receptor complex, thereby recruiting Smad-2/-3 to the 
receptor complex upon ligand binding (174). This recruitment of Smad-2/-3 to the receptor complex
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has been shown to take place at the plasma membrane, but SARA-mediated localization of the TGF- 
P/receptor/SARA/Smad-2 complex in the endosome is necessary for TGF-P receptor complexes to 
phosphorylate Smad-2 (175). The FYVE domain of SARA has been shown to be sufficient for early 
endosomal localization and activation of TGF-P receptor complexes, but this process can be enhanced 
by cooperation with Hsg/Hrs (hepatic growth factor-regulated tyrosine kinase substrate), another 
FYVE domain containing protein (176, 177). SARA is specific for TGF-P signaling and, at the 
moment, no homologue of SARA has been identified for BMP signaling.
In Drosophila, Dpp forms long-range concentration gradients in the developing wing 
extending over 40 cell diameters, which is required to specify cell fates along the anterior-posterior 
axis of the wing (173). This gradient is not formed by free diffusion, but rather employs clathrin- 
mediated endocytosis according to the so-called planar transcytosis model. Upon receptor binding, 
Dpp is internalized into early endosomes through dynamin-dependent endocytosis. Subsequently, a 
small percentage of these endosomes is degraded in the lysosome whereas the rest form so-called 
argosomes, membrane vesicles resembling exosomes, which are released on exocytic fusion with the 
plasma membrane. Subsequent rounds of endocytosis and exocytosis by the target cells establish 
spreading of Dpp over several cell diameters to form a gradient. The rate of lysosomal degradation in 
combination with the rate of endosomal trafficking thereby determine the maximal range of Dpp 
signaling (173).
In bone, caveolae and its structural protein caveolin have been identified in both chondrocytes 
and osteoblasts. In chondrocytes caveolin-1, -2 and -3 are expressed, whereas in osteoblasts only 
caveolin-1 and -2 are expressed (178, 179). The precise role of caveolae in the regulation of 
osteoblast differentiation is still largely unknown. However, in C2C12 mesenchymal progenitor cells 
it has been shown that inhibition of caveolin-mediated endocytosis of BMP/receptor complexes 
enhances BMP-induced osteoblast differentiation, indicating that this type of endocytosis negatively 
regulates BMP signaling (180).
1.3 Regulators of BMP signaling
To ensure that the BMPs are active at the right place and the right moment, tight regulation of 
their activities is needed. This regulation is achieved at three levels: extracellularly, at the membrane 
level, and intracellularly.
1.3.1 Extracellular regulation o f BMP activity
Regulation of BMP activity at the extracellular level usually occurs through binding of BMPs 
by extracellular proteins that block the molecular interfaces for binding of BMP to its type I and type 
II receptors. Such extracellular antagonists include noggin (181, 182), chordin (183-185), ventroptin 
(186) and DAN family members (57, 187, 188). In addition, BMP antagonists such as follistatin can 
exert their function by binding to both BMPs and their receptors, rendering an inert complex 
incapable of transmitting signals (189). Finally, extracellular regulation can be achieved by agonistic 
proteins, such as twisted gastrulation (190), that also bind BMPs and thereby enhance binding to their 
receptors (Figure 3).
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Noggin was first identified as a secreted protein capable of inducing dorsal development in 
Xenopus embryos (191). Noggin is a cysteine knot protein that binds with different affinities to BMP-
2, -4, -5, -6, and -7, GDF-5 and GDF-6 but not to other members of the TGF-P family (181, 192-194). 
Recently, it has been reported that noggin can associate with the cell surface through binding of 
heparan sulfate proteoglycans, where it remains functional for the binding and inhibition of BMPs 
(195). Noggin is released from the cell surface through the activity of the endosulfatase Qsulf1, which 
results in a restoration of BMP responsiveness in cells. However, binding of noggin to heparan sulfate 
proteoglycans is not essential for binding and antagonism of BMPs, but rather functions to regulate 
the in vivo diffusion of noggin and therefore the formation of gradients of BMP activity such as 
observed in early embryonic development (195, 196). In bone, BMPs can induce the expression of 
noggin in both chondroblastic and osteoblastic cells (197, 198), and noggin expression inhibits the 
differentiation of osteoblast lineage cells resulting in reduced bone formation and osteoporosis (198­
201).
Chordin was first identified as a secreted cysteine-rich protein that acts as a dorsalizing factor 
in Xenopus development (202). Chordin binds specifically to BMPs and not to other members of the 
TGF-P family (202). The biological activity of chordin resides in its cysteine-rich domains (CRs), 
especially in CR1 and CR3 (203, 204). In mice, three proteins with high homology to Xenopus 
chordin have been identified: mouse chordin (Chrd), chordin-like (Chl) and chordin-like 2 (Chl-2) 
(183-185). Chl is able to bind and inhibit BMP signaling in mice, but can also bind TGF-Ps. In 
comparison, Chl-2 interacts directly with BMPs but not with TGF-Ps. Moreover, the spatio-temporal 
expression pattern of Chl is distinct from that of Chrd, since expression of both Chl and Chl-2 is 
restricted to mesenchyme-derived cell types such as the chondrocytes of the developing skeleton 
during embryogenesis, whereas Chrd is predominantly expressed during early embryogenesis in the 
anterior primitive streak and subsequently in the node and axial mesoderm. In addition, Chrd has been 
shown to be essential for inner and outer ear development as well as for pharyngeal and 
cardiovascular organization (183-185, 205). Furthermore, it has been proposed that Chl-2 may 
negatively regulate the generation and maturation of chondrocytes and consequently endochondral 
ossification (185).
The activity of Chrd is proposed to be regulated by BMP-1, a metalloprotease first identified 
in bone extracts capable of inducing ectopic bone formation (110) and structurally unrelated to BMP 
growth factors. BMP-1 is the shorter, alternatively spliced, product of mTld (mammalian tolloid) that 
shows high similarity to Drosophila Tolloid (206) and Xenopus Xolloid, which can specifically 
cleave chordin and chordin/BMP complexes in order to release biologically active BMP (207). In 
mice, four BMP-1/tolloid-like proteases are known: BMP-1, mTld, Tll-1 (tolloid-like 1) and Tll-2 
(tolloid-like 2), of which only BMP-1 and Tll-1 are capable of cleaving chordin. Moreover, 
differences in enzymatic activity and expression domains of these proteases suggest that BMP-1 is the 
major chordin antagonist in early mammalian embryogenesis and in skeletogenesis (208).
Ventroptin is a BMP antagonist that is mainly expressed in the chicken ventral retina, where it 
plays a role in retinal patterning (186). Ventroptin has three CR domains, which are homologous with 
those of chordin. Moreover, ventroptin binds BMPs and has BMP-neutralizing activity similar to that 
of chordin and noggin (186). Although ventroptin is also expressed at other sites than the ventral 
retina, its role in skeletal development is unknown.
DAN (differential screening-selected gene aberrative in neuroblastoma) is a tumor suppressor 
gene expressed in cranial, facial and limb mesenchyme. Other proteins belonging to the DAN family 
of secreted glycoproteins include gremlin, cerberus, dante, caronte, PRDC (protein related to DAN 
and cerberus) and sclerostin (for review see ref. 209). In bone, gremlin is co-expressed with DAN in
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cranial, facial and limb mesenchyme, and gremlin has been shown to regulate chondrogenesis (210, 
211).
In contrast to other members of the DAN family, sclerostin, the product of the gene Sost, does 
not function as a classical BMP antagonist; unlike other BMP inhibitors that block BMP-induced 
osteoblast differentiation and matrix mineralization, sclerostin has no effect on osteoblast 
differentiation but specifically inhibits calcium deposition in the matrix, probably in concert with an 
as yet unidentified late phase BMP-induced gene (58). Mice over-expressing Sost exhibit low bone 
mass and decreased bone strength (57), and in humans homozygous loss-of-function mutations in Sost 
lead to the disease named sclerosteosis, which is characterized by increased bone density and 
progressive skeletal outgrowth in skull, mandible, ribs, clavicles and all long bones (212, 213). The 
related heterozygote humans are clinically normal, and can only be identified by minor changes on 
skull radiographs (214). Furthermore, it has recently been shown that patients with Van Buchem 
disease, which is clinically similar to sclerosteosis but less severe, show a homozygous 52 kb deletion 
downstream of SOST, and it has been hypothesized that this deletion results in down-regulation of the 
SOST gene product by a cis regulatory action or position effect (215-217). This suggests that the 
severity of sclerosteosis/Van Buchem disease is dependent on the amount of functional sclerostin 
present, such that a reduction to 50% of the normal amount of sclerostin has no clinical effects, while 
further reductions of the normal level of sclerostin result in Van Buchem disease (> 50% reduction) or 
sclerosteosis (100% reduction).
Follistatin was first identified as an activin-binding protein that inhibits activin function (218, 
219), but it can also bind and inhibit various BMPs (189, 220). In contrast to other BMP binding 
proteins, follistatin is noncompetitive with the BMP receptors for ligand binding, but forms a trimeric 
complex with BMP and its receptor, rendering the BMPs incapable of transducing a signal through 
their receptors (189). Activin can induce endochondral bone formation in vivo as well as 
osteoblastogenesis in vitro, and this activity can be inhibited by follistatin (221, 222). Mice deficient 
in the follistatin gene are retarded in growth, have skeletal defects of the hard palate and the ribs, and 
die within hours of birth due to respiratory failure (223).
Twisted gastrulation (Tsg) is a secreted cysteine-rich protein that was first identified in 
Xenopus as a BMP-binding protein that enhances BMP signaling (190). However, recent reports have 
shown that Tsg can also function as a BMP antagonist in Drosophila, zebrafish and Xenopus by 
binding to both chordin and BMPs, resulting in an enhanced function of chordin (224-226). In mice, 
Tsg has been reported to act as a BMP agonist in skeletogenesis but as a BMP antagonist in T-cell 
development. This was shown by the observation that Tsg-deficient mice exhibit severe growth 
retardation with delayed endochondral ossification as well as an atrophic thymus in which BMP 
signaling is enhanced (227).
1.3.2 Regulation o f BMPs at the membrane level
At the membrane level, pseudoreceptors can regulate the signaling capacity of various BMPs 
(Figure 3). Bambi/Nma (BMP and activin membrane-bound inhibitor/non-metastatic gene A) is a 
transmembrane protein that is related to the type I receptors of the TGF-P family, showing highest 
homology to BMP type I receptors, but it lacks an intracellular kinase domain (228). Homologues of 
this pseudoreceptor have been identified in zebrafish, Xenopus, humans and mice (228-232). In mice, 
Bambi is expressed in multiple tissues including bone, where it is expressed by osteoblasts (232). 
During embryonic development, Bambi is co-expressed with BMP-2 and BMP-4 and its expression is 
regulated by these BMPs (228, 229, 231). Bambi stably associates with all TGF-P family type II
- 24 -
Introduction in the Control of BMP Signaling on Osteoblast Differentiation
receptors, can bind TGF-P family ligands and inhibits BMP, activin as well as TGF-P signaling. It is 
believed that Bambi acts as a dominant-negative receptor whose effect is mediated by the shortened 
intracellular domain, which resembles the homodimerisation interface and prevents the formation of 
active receptor complexes (228, 229).
1.3.3 Intracellular regulation o f BMP activity
BMPs transduce their signal via specific R-Smads and the Co-Smad Smad-4. Intracellular 
modulation of Smad activity occurs by three mechanisms: inhibitory Smads, proteins binding 
signaling Smads, and degradation of signaling Smads (Figure 3).
1.3.3.1 Inhibitory Smads
The inhibitory Smad-6 and Smad-7 lack a C-terminal phosphorylation motif, and in addition 
to an entire MH2 domain they contain only short segments with MH1 domain homology (233, 234). 
Both Smad-6 and -7 can be induced by various members of the TGF-P family, but in general Smad-6 
is most potently induced by BMPs while Smad-7 is most potently induced by TGF-P (234, 235).
Over-expression experiments have shown that Smad-6 and -7 can bind to activated type I 
receptors of both TGF-P and BMPs, and interfere with the phosphorylation of R-Smads by competing 
with the R-Smads for receptor binding. Because of the inhibition of phosphorylation of the R-Smads, 
the subsequent heterodimerization and nuclear localization are also impaired (233, 234, 236). 
However, at low expression levels Smad-6 specifically blocks signaling by the BMP/Smad-1 
pathway. This inhibition does not occur through interfering with receptor-mediated phosphorylation 
of Smad-1, but by specifically competing with Smad-4 for binding to receptor-activated Smad-1. 
Smad-6 binding to receptor-activated Smad-1 yields a transcriptionally inert complex (237). 
Furthermore, it has been reported that Smad-6 can also function as a transcriptional co-repressor by 
binding to the homeobox protein Hoxc8 and the transcription co-repressor C-terminal binding protein 
(CtBP), thereby potentiating the repressor activity of both proteins (238, 239). In addition, both 
Smad-6 and Smad-7 were found to interact with HDACs, thereby inhibiting gene transcription 
directly (171). Conversely, Smad-6 activity can be regulated by Amsh (associated molecule with SH3 
domain of STAM). Upon BMP stimulation, Amsh interacts with Smad-6 in the cytoplasm thereby 
repressing the inhibitory function of Smad-6 (240).
1.3.3.2 Proteins binding to signaling Smads
Co-activators or repressors of Smad signaling can exert their effect through binding with 
Smads. This binding usually occurs via the MH2 domain of the Smads, but it can also occur via a 
combination of the MH2 and MH1 domains, via the MH1 domain alone, or via the linker region of 
the Smads. Proteins binding Smads through the MH2 domain include Oaz (Olf-1/EBF-associated zinc 
finger), Msg1 (melanocyte specific gene 1), the Ski family, Skip (Ski binding protein), Tob 
(transducer of ErbB2), Tgif (TG-interacting factor), Smad interacting protein-1 (Sip-1/Zeb-2/Zfhx1b), 
8EF1, Piasy (protein inhibitor of activated signal transducer and activator of transcription y), MAN1, 
Sane (Smad-1 antagonistic effector) and menin, while proteins binding both MH1 and MH2 include 
Snip-1 (Smad nuclear interacting protein 1) and Znf8 (zinc finger protein 8).
The multi-zinc finger protein Oaz specifically associates with BMP-activated R-Smads, and 
enhances Smad-mediated transcriptional activation of target genes in a cell-specific manner. Oaz can 
interact with Smad binding elements and it has been postulated that Oaz functions by enhancing the
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binding of the Smads to DNA (241-243). In addition, Oaz can associate with poly(ADP-ribose) 
polymerase 1, an association that is essential for Oaz-mediated BMP-dependent gene regulation 
(243).
Msg1 is a non-DNA-binding transcriptional activator that associates with Smad-4 in a TGF- 
P/BMP signaling-dependent manner. In addition, Msg1 also binds to CBP/p300, and it has been 
postulated that Msg1 functions to stabilize the Smad/CBP/p300 transcriptional activator complex 
thereby enhancing Smad-dependent gene transcription (244, 245). Furthermore, Msg1 is expressed in 
multiple tissues of mesodermal origin during development, including the limb bud, which indicates a 
possible role for Msg1 in skeletal development (246).
Members of the Ski family include Ski itself and Sno (ski-related novel gene) (247). Ski was 
first identified as the avian homologue of the viral transforming protein of the Sloan-Kettering 
retroviruses (v-Ski) (248). Subsequently, it was shown that Ski can induce oncogenic transformation 
and myogenesis in avian cells (249). Ski is uniformly expressed throughout the cell, but in association 
with other proteins it has DNA binding properties (250). Furthermore, Ski and Sno can form a 
complex via their C-terminal regions (251, 252). Ski represses BMP, TGF-P and activin signaling as 
well as activation of target genes in mammalian cells (253-256). Ski can bind Smad-1 to -5, but not 
the inhibitory Smad-6 and -7, and an interaction of Ski with Smad-1 to -5 is required for its repression 
of BMP/TGF-P/activin signaling (254, 256, 257). Furthermore, interaction of Ski with Smad-1, -2, -3 
and -5 requires receptor activation, while the interaction with Smad-4 is constitutive (254, 256, 257).
Two mechanisms are known by which Ski can inhibit signaling by TGF-P family members. 
First, Ski can bind to Smad-4 in the cytoplasm, where it induces a constitutive binding of Smad-2/-3 
with Smad-4. This binding is Smad-4-dependent, but independent of Smad phosphorylation, and 
inhibits ligand-dependent phosphorylation of Smad-2/-3 yielding inactive Smad complexes (258). 
Second, nuclear Smad/Ski/Sno complexes are able to bind to DNA at SBEs (254, 257). By 
recruitment of different co-repressors such as Hipk2 (homeodomain-interacting protein kinase 2) and 
N-CoR/SMRT, which are involved in the histone deacetylase macromolecular complex, nuclear Ski 
and Sno can repress signaling by TGF-P family members (259-261). Loss of Smad-4 binding by Ski 
completely abrogates the ability of Ski to inhibit BMP signaling, but it is still able to inhibit TGF-P 
signaling. This suggests that inhibition of BMP signaling occurs mainly through the first mechanism, 
while inhibition of TGF-P signaling results from a combination of both inhibition mechanisms (262).
Ski is involved in the morphogenesis of craniofacial structures as was shown by the defects in 
patterning of vertebral and cranial skeletal structures in Ski knock-out mice (263). Skip (Ski 
interacting protein) was first identified as a nuclear protein able to bind to Ski (264) and was 
subsequently shown to act as a transcriptional co-activator of EBNA2 (Epstein-Barr virus nuclear 
antigen 2) (265). In addition, Skip augments TGF-P dependent transcription by binding to Smad-2 
and -3, but this binding is not sufficient for complete activation of Smad-dependent transcription. 
Moreover, Skip competitively interacts with Ski/Sno for Smad-2/-3 binding, thereby relieving the 
Ski-mediated transcriptional repression of TGF-P (266). It is not known whether Skip also functions 
in BMP signaling, but it is likely that it is also able to bind Smad-1 and -5 in order to compete with 
Ski/Sno for transcriptional regulation of BMP target genes.
Tob is a member of the PC3/BTG/Tob family of genes, which are involved in cell replication 
and differentiation (267, 268). Tob preferably binds the inhibitory Smad-6 and -7, thereby enhancing 
the interaction of Smad-6 with activated type I BMP receptors, which results in the inhibition of BMP 
signaling (269). In addition, Tob can associate with Smad-1, -4, -5 and -8, resulting in recruitment of 
these Smads to nuclear bodies and repression of BMP-induced Smad-dependent transcription in 
osteoblasts (270). Tob expression is induced during osteoblast differentiation, which is indicative for
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a negative feedback loop in BMP signaling. Moreover, Tob-deficient mice have a greater bone mass, 
resulting from increased numbers of osteoblasts which are also more responsive to BMP-2 (270-272).
The homeodomain protein Tgif was first identified as a Smad -binding protein, capable of 
binding Smad-2 and -3. Binding of Tgif to Smad-2 was shown to inhibit Smad-2-mediated 
transcription because of competition of Tgif and CBP/p300 for Smad-2 (273). Interestingly, upon 
TGF-P stimulation, Tgif not only binds N-CoR with its associated histone deacetylase but also mSin3, 
thereby inhibiting Smad signaling in a manner similar to but distinct from Ski/Sno (273-275). 
Although Tgif can bind weakly to Smad-1 (273), it is not known whether Tgif can also bind Smad-5 
or -8 and function as a transcriptional repressor of BMP signaling. However, Tgif has been shown to 
activate signaling by Dpp, the Drosophila homologue of BMP2/4 (276), indicating that it might also 
function as a regulator of BMP signaling in mammals.
Sip-1 is a two-handed zinc finger homeodomain which is closely related to 8EF1/Zeb- 
1/Zfhx1a (277). Like 8EF1, Sip-1 binds DNA at two E-box sequences (CACCT and CACCTG) and 
inhibits transcription activation of its target genes in most cell types (277-279). Sip-1 and 8EF1 bind 
to Smad-1, -2, -3 and -5 upon activation of these R-Smads, but Sip-1 does not interact with Smad-4 
(277, 280). In contrast to Sip-1, 8EF1 synergizes with Smad proteins in cells of the osteoblast lineage 
in order to activate transcription and to promote osteoblastic differentiation (280). Moreover, 8EF1 
has been shown to be required for skeletal patterning, since mice deficient for the 8EF1 gene show 
defects in craniofacial, limb, ribs, sternum and vertebral bones (281). Sip-1 inhibits BMP-induced 
expression of Alp2 in osteoblastic cells and it has been suggested that extinguishing Sip-1 expression 
is a prerequisite for the induction of Alp2 (280, 282). These opposing effects of 8EF1 and Sip-1 arise 
from the differential recruitment of transcriptional co-activators (p300 by 8EF1) and co-repressors 
(CtBP by Sip-1) to the Smads during development (283).
Piasy associates with Smad-3, -4, -2 and -1 with different affinities, and can form stable 
complexes with Smad-3/-4, Smad-2/-4, and Smad-1/-4. In addition, Piasy can associate with HDAC1. 
The association of Piasy/Smad complexes with HDAC1 inhibits Smad transcriptional activity by 
selectively repressing a subset of TGF-P/BMP responses (284). In contrast, another member of the 
Pias family, Pias3, has recently been shown to activate TGF-P signaling by binding both Smad-3 and 
CBP/p300 in a ligand dependent manner. Therefore, it has been postulated that the differential action 
of Piasy and Pias3 is based on a similar mechanism as Sip-1/8EF, where recruitment of CBP/p300 
leads to the displacement of CtBP from 8EF1, which then binds CBP/p300 and activates transcription 
(285). Currently, the function of Piasy in bone development is unknown, but during embryonic 
development, Piasy is expressed in the developing limb bud indicating a possible role in bone 
formation (286).
The inner nuclear membrane protein MAN1 has been shown to repress BMP-4-mediated 
transcription activation in Xenopus, and to bind Smad-1, -5 and -8 with high affinity, Smad-2 weakly, 
and Smad-4 not at all (287). Currently, the molecular action of MAN1 in regulating BMP signaling is 
unknown, but it may compete with transcription factors and co-activators to bind R-Smads, or it may 
recruit additional co-repressors to the Smads and thereby repress BMP signaling (287).
Sane is a novel protein with sequence similarity to nuclear membrane proteins such as MAN1. 
Sane specifically inhibits BMP-mediated signaling and transcription activation both in Xenopus and 
in osteoblastic cells (288). Sane interacts with Smad-1 and -5, but not or only very weakly with 
Smad-2, -3 and -4. Unlike MAN1, Sane specifically binds type I BMP receptors in addition to the 
BMP-specific R-Smads, which implies that Sane functions in the cytoplasm. In concordance with 
this, Sane inhibits the phosphorylation and subsequent nuclear localization of BMP-specific R-Smads. 
The interaction with both a receptor and R-Smads makes Sane resemble SARA, but because of its
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antagonistic effect Sane most likely represents a new mode of regulating intracellular BMP signaling 
(288).
Menin is the product of Men1 and mutations in this gene are responsible for multiple 
endocrine neoplasia type 1. Menin has been shown to be a nuclear protein, which is widely expressed 
during development and in adult mammalian tissues (289-292). Recently, menin has been shown to 
bind a variety of proteins including JunD, Smad-1, -3 and -5, but not Smad-2 or -4. Interestingly, 
menin represses JunD-activated transcription, but enhances Smad-3-mediated transcription (293-295). 
In mice, menin has been shown to play an important role in development and bone formation, since 
homozygous Men1 knock-out mice are embryonically lethal (E14.5) exhibiting defects in 
cranial/facial development (296). Furthermore, it has been shown that menin has a dual role during 
osteoblast differentiation: in the early stages of osteoblast differentiation, menin mediates specifically 
the BMP-induced commitment of MSCs to the osteoblastic lineage, while during the late phase of 
differentiation it serves as an inhibitor of osteoblast maturation (295, 297).
To exert this positive effect on the commitment of MSCs to osteoblasts, menin not only 
interacts with Smad-1/-5 but also with Cbfa1, thereby enhancing the transcriptional activity of Smad- 
1/-5 and Cbfa1 on their target genes. In more differentiated cells, menin does not bind Smad-1/-5 or 
Cbfa1, but instead interacts with Smad-3 and blocks BMP-induced Smad-1/-5 and Cbfa1 
transcriptional activity (297).
Snip-1 is a nuclear protein that represses the CBP/p300-dependent transcriptional activation 
of multiple inducers including TGF-P family members (298, 299). Snip-1 specifically binds Smad-4 
upon receptor activation by TGF-P family. In addition, Snip-1 interacts with both CBP and p300 in a 
ligand dependent manner, and can compete with Smad-4 for binding to CBP/p300, thereby inhibiting 
Smad-dependent promoter activation (298).
The nuclear Kruppel-like zinc finger protein Znf8 interacts with Smad-1, -2, -3, -4 and -5 with 
different affinities, and interaction between Znf8 and Smads is enhanced upon phosphorylation of R- 
Smads. Interestingly, it has been shown that Znf8 specifically inhibits a subset of BMP responses. 
Currently, it is not known whether Znf8 functions as a transcriptional repressor, a general inhibitor 
such as Snip-1, or a co-repressor such as Ski and Tgif. Moreover, as a result of the different affinities 
of Znf8 for the various Smads, Znf8 might set thresholds for signaling, providing a new mechanism 
for cells to have different sensitivities for various ligands (300). Although Znf8 is ubiquitously 
expressed in mice during embryonic development, it is not known whether Znf8 can function in bone 
to inhibit BMP responses.
The transcription factor Yin Yang 1 (YY1) binds the MH1 domain of Smad-1, -2, -3 and -4 
with different affinities, and is able to inhibit TGF-P family member signaling by blocking the 
binding of activated R-Smads to their DNA binding sites. Furthermore, Smad-induced osteogenic 
differentiation has been shown to be repressed by ectopically expressed YY1, while it was enhanced 
upon knock-down of YY1 (301).
One of the few proteins that are known to bind Smads through the linker region is Smif 
(Smad-4 interacting factor), which is a ubiquitously expressed transcriptional co-activator that 
specifically binds to Smad-4 (302). The formation of a Smif/Smad-4 complex occurs in the cytoplasm 
and is enhanced by TGF-P/BMP treatment. Upon formation, the complex translocates to the nucleus 
and, in combination with CBP/p300, it activates transcription of target genes. Smif is not able to bind 
CBP/p300 directly, which implies that the recruitment of this co-activator occurs through Smad-4/R- 
Smad complexes. Furthermore, loss of Smif expression causes widespread defects in embryonic 
development implicating that Smif is involved in many, but not all, developmental processes in which 
TGF-P family members are involved (302).
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Recently, Ciz/Nmp4 (Cas interacting protein/nuclear matrix protein 4) has been identified as a 
Smad-binding protein and therefore capable of regulating signaling of TGF-P family members, but 
the molecular mechanism of its binding remains to be established. Ciz is a zinc finger protein that 
inhibits the transcriptional activation of Smad-1 and -5 on SBEs, thereby suppressing BMP-induced 
expression of Cbfa1, Alp2, Ocn and Col1a in osteoblastic cells (303, 304). In addition, Ciz expression 
is regulated by BMP2, which is indicative for a feedback loop to regulate BMP-signaling (304).
1.3.3.3 Degradation o f signaling Smads
Proteasome-mediated degradation of Smads and Smad binding proteins is an 
important element in the down-regulation of BMP/TGF-P signaling, and it has been shown that both 
ubiquitin-dependent and -independent pathways are involved in this regulation of BMP/TGF-P 
signaling. Smurf-1 (Smad ubiquitination regulatory factor 1) and Smurf-2 both are members of the 
HECT-family of E3 ubiquitin ligases and have been shown to inhibit BMP/TGF-P signaling (305­
307).
Presently, two mechanisms are known by which Smurfs regulate BMP/TGF-P signaling. 
First, Smurf-1 and Smurf-2 bind to activated R-Smads at their linker region and ubiquitinate the 
Smads, after which these are degradated by the proteasome. Smurf-1 binds Smad-1 and -5, while 
Smurf-2 binds with high affinity to Smad-1 and Smad-2, with intermediate affinity to Smad-3, but 
does not interact with Smad-4. Moreover, Smurf-1 is more potent in inhibiting BMP signaling than 
Smurf-2 (305-307). Furthermore, Smurf-2 can also interact with Smad-binding proteins such as Sno. 
Binding of Smurfs to Smad-binding proteins is mediated by activated R-Smads and ubiquitination of 
Smad-binding proteins by Smurfs targets them to the proteasome for degradation (308).
Second, Smurf-1 and Smurf-2 bind the inhibitory Smad-6 and -7 via their linker region, and 
can associate with type I receptors via these I-Smads. Binding of Smurf-1 or Smurf-2 to type I 
receptor/I-Smad complexes ubiquitinates both the receptor and the inhibitory Smads, and targets them 
to the proteasome for degradation (309-311). Recently, it has been shown that Smurf-1 inhibits 
osteoblast proliferation and differentiation in vivo and in vitro resulting in impaired bone formation 
(312-314). Inhibition of osteoblast proliferation and differentiation results from the finding that 
Smurf-1 not only degradates Smad-1 and -5 in osteoblastic cells, but is also able to bind and 
ubiquitinate the osteoblast specific transcription factor Cbfa1, which is followed by proteasomal 
targeting. Subsequent degradation of Cbfa1 results in severely reduced expression of Osx, Alp2, Ocn 
and Col1a, as well as in inhibition of the formation of bone nodules (312-314).
Arkadia is a RING finger domain protein with E3 ubiquitin ligase activity, but it 
shows no homology to other E3 ubiquitin ligases. Arkadia directly interacts with Smad-7 and induces 
its ubiquitination and subsequent degradation. In contrast to the Smurfs, Arkadia/Smad-7 complexes 
are not recruited to the type I receptors, and Arkadia does not degrade the receptors. Therefore, the 
effect of Arkadia is to enhance both BMP and TGF-P signaling (315).
Chip (Carboxyl terminus of Hsc70-interacting protein) is a U-box dependent E3 
ubiquitin ligase, which has initially been identified as a co-chaperon protein. Chip binds to the MH2 
domain of Smad-1, -2, -3 and -4 independent of receptor activation. Upon binding, the Smads become 
ubiquitinated and targeted to the proteasome for degradation. Chip-mediated degradation of Smad-1/- 
4 results in the inhibition of Smad-mediated transcription activation (316).
In addition to these ubiquitination-mediated degradation pathways, it has recently been shown 
that the Smad-binding protein Snip-1 can be degraded by the proteasome upon interaction with a 
complex that includes Smad-1, the proteasome P subunit HsN3 and the ornithine decarboxylase 
antizyme (Az), independent of ubiquitination. The formation of this Smad-1/HsN3/Az complex is
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enhanced by type I receptor activation, and Snip1 degradation is therefore Smad-1, Smad-4 and Az- 
dependent (317).
Mechanisms as described above suggest a balance of activated Smad complexes and repressor 
proteins in the cytoplasm and subsequently the nucleus, which is critical for regulation of the signal 
transduction pathways activated by TGF-P family ligands.
1.4 Other signaling routes in osteoblast differentiation and interactions
Other growth factors than BMP and TGF-P also play a role in osteoblast differentiation. 
These factors exert their effect through various signal transduction pathways. Most of the growth 
factors activate members of the different MAP-kinase signaling pathways, including p38, SAP/JNK 
and Erk1/2. Furthermore, the Wnt and Notch signaling pathways have been shown to be important 
regulators of osteoblast differentiation and therefore these pathways and their interactions with the 
BMP/Smad-pathway will also be discussed here.
1.4.1 MAP-kinases
For activation of the Erk1/2 MAP-kinase pathway, growth factor receptor complexes activate 
Ras, upon which Raf1, Mek1/2 and Erk1/2 are activated by stepwise phosphorylation. The Jnk MAP- 
kinase pathway is also activated through Ras by its ability to activate Rac1, resulting in the 
subsequent activation of Pak1/2, Map3K4, MKK7 and Jnk1-3. The p38 MAP-kinase pathway can be 
regulated through both Ras and Tak1. Ras activation leads to the activation of Rac1, which activates 
p38 through either Mekk1 and Mkk4 or Mlk1 and Map2K6, while activated Tak1 leads to the 
activation of p38 via MEK3/6 (for reviews see refs. 318-320).
In order to regulate gene expression, the Sap/Jnk, Erk1/2 and p38 MAP-kinase pathways 
employ amongst others the AP1 transcription factor complex, which is composed of dimers of Fos 
and Jun family members, as well as some members of the CREB/ATF families. Fos and Jun are 
nuclear effectors of the JNK and Erk1/2 MAP-kinase pathway, while CREB/ATF members are 
effectors of the p38 MAP-kinase pathway. The Fos proteins (c-Fos, FosB, Fra-1 and Fra-2) can only 
heterodimerize with members of the Jun family, whereas Jun proteins (c-Jun, JunB and JunD) can 
both homodimerize or heterodimerize with Fos members in order to form transcriptionally active 
complexes (for review see ref. 321).
In osteoblasts, MAP-kinase/AP1 activity has been shown to be induced by a variety of factors 
including PTH and vitamin D, but also by TGF-P and BMPs (322-324). BMP activation of the 
various MAP-kinase/AP1 pathways in osteoblasts has been shown to take place at multiple levels 
(Figure 4). BMP has been shown to differentially stimulate p38, Erk and JNK activity in osteoblastic 
cells; secondly, BMP stimulates the activity of several individual AP1 components, including c-Fos, 
FosB, Fra-1, Fra-2, JunB and ATF2; and thirdly, BMP induces the expression of the AP1 components 
c-Fos, c-Jun and JunB (117, 325, 326).
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Figure 4. Interactions of the MAPKinase and Smad signal transduction pathways.
To regulate osteoblast differentiation, multiple points of convergence between the MAPKinase and Smad pathways can be 
identified: I) BMPs differentially activate p38, Erk1/2 and Jnk, II) BMPs activate individual API components, III) BMPs regulate 
the expression of API components, IV) p38 MAPKinase stimulates Smad-1 phosphorylation, V) Erk1/2 MAPKinase activates the 
Cbfal protein, VI) Erk1/2 MAPKinase can phosphorylate R-Smads, and VII) Erk1/2 and Jnk MAPKinase can regulate the activity 
of Smad binding proteins. See text for details. See page 135 for full color figure
The differential activation of p38, JNK and Erk1/2 MAP-kinase pathways by BMPs may 
underlie the differential effects of these pathways on BMP-induced osteoblast differentiation. 
Recently, it has been postulated that BMP-induced activation of the Tab/Tak1/p38 MAP-kinase 
pathway is possibly mediated by Bram1 and/or Xiap (see above), providing a point of convergence of 
the p38 MAP-kinase and BMP signal transduction pathways (148, 149, 327, 328). Furthermore, p38 
MAP-kinase has been shown to be a positive regulator of osteoblast differentiation, since inhibition of 
this pathway results in down-regulation of the osteoblast marker genes Cbfa1, Alp2, Col1a, Ocn, Opn 
and Opg, as well as in down-regulation of matrix mineralization (322, 329-335). Possibly, this results 
from the convergence of these pathways at the level of Smad-1 phosphorylation, since inhibition of
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p38 MAP-kinase has been shown to suppress BMP-induced Smad-1 phosphorylation and its 
subsequent translocation to the nucleus (Figure 4) (332). It has been shown that JunB is required for 
optimal expression of Cbfa1 (335). Because JunB is a direct target gene of BMP2 and TGF-P (157), it 
is possible that expression of JunB is inhibited when Smad-1 phosphorylation and nuclear 
translocation is blocked by inhibition of p38 MAP-kinase. This will subsequently inhibit Cbfa1 
expression and hence osteoblast differentiation.
Recent data suggest that in addition to the p38 MAP-kinase pathway, also the JNK pathway 
positively regulates BMP-induced osteoblast differentiation, since inhibition of c-Jun phosphorylation 
decreased osteoblast differentiation, as shown by the down-regulation of Ocn expression. However, 
Alp2 expression was only slightly increased under these conditions and the effect on mineralization 
capacity of the cells was not determined (336).
In contrast to p38, Erk1/2 MAP-kinase has been shown to be mainly a negative regulator of 
osteoblast differentiation. Although complete inactivation of Erk1/2 activity inhibits osteoblast 
differentiation (337), this effect is mainly due to the complete inactivation of the Cbfa1 protein upon 
inhibition of Erk1/2 activity, since Erk1/2-mediated phosphorylation of Cbfa1 has been shown to be 
essential for Cbfa1 protein activity (Figure 4) (33). Surprisingly, partial inhibition of Erk1/2 MAP- 
kinase results in residual Cbfa1 activity, and enhancement of BMP-induced osteoblast differentiation, 
as shown by the up-regulation of Alp2 activity as well as matrix mineralization. Furthermore, 
expression of constitutively active MEK1, which activates Erk1/2, results in the down-regulation of 
BMP-induced osteoblast differentiation, as shown by repressed Alp2 activity (338).
Another point of convergence of the Erk1/2 MAP-kinase and Smad pathways may be at the 
level of the R-Smads: for TGF-P it has been shown that Erk1/2 can phosphorylate R-Smads at their 
linker region, and depending on the cell type, this can result in either a negative or a positive effect on 
activation of TGF-P signaling (339). In epithelial cells, it has furthermore been shown that Smad-1 
can be phosphorylated at its linker region following EGF-induced Erk1/2 activation, which causes 
nuclear exclusion of Smad-1/-4 complexes and therefore inhibition of BMP-induced transcriptional 
activity (340). It is not known, however, whether Smad-1 can be phosphorylated at the linker region 
in osteoblastic cells as a result of BMP-dependent or -independent activation of Erk1/2, nor if this 
phosphorylation regulates osteoblast differentiation in a positive or negative manner (Figure 4).
MAP-kinase and Smad pathways may furthermore be linked through the cytoplasmic and 
nuclear Smad binding proteins. For instance, Erk1/2 and Jnk have been shown to phosphorylate Tob, 
an inhibitor of BMP-induced osteoblast differentiation. Activation of Tob inhibits its anti-proliferative 
function in NIH3T3 cells (341, 342). However, it is not yet known whether phosphorylation of Tob in 
osteoblasts results in inhibition or enhancement of differentiation (Figure 4).
The various members of the AP1 complex are differentially expressed during osteoblast 
differentiation in vitro. Initially, all Fos and Jun proteins are highly expressed, but during late phase 
osteoblast differentiation, their levels decline and Fra-2 and JunD become the major proteins of the 
AP1 complex in fully differentiated osteoblasts (343). Furthermore, it has been shown that several of 
the individual components of the AP1-complex are important for bone formation during embryonic 
development, since a number of knock-out and transgenic mice display various bone phenotypes. In 
this respect, it has been shown that c-Fos knock-out mice display osteopetrosis (overly dense bones 
due to osteoclast deficiency), while transgenic mice with ectopic expression of Fra-1 exhibit 
osteosclerosis (overly dense bones due to increased numbers/activity of osteoblasts). Furthermore, 
transgenic mice with ectopic expression of c-Fos suffer from osteosarcomas. Finally, mice in which 
the c-Jun protein is inactivated, suffer from scoliosis, a side-to-side curvation of the spine.
Many genes related to the osteoblastic phenotype have been shown to contain AP1 binding 
sites in their promoters, and therefore to be regulated by this transcription factor complex (for review
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see ref. 344). Since many osteoblast marker genes are also regulated by Cbfa1, it is likely that AP1 
and Cbfa1 act in concert. Indeed, it has been shown that Cbfa1 and AP1 interact with each other and 
that this complex regulates collagenase-3 expression during osteoblast differentiation (345, 346).
To regulate the activity of the AP1 complex, activated R-Smad/Co-Smad complexes have 
been shown to interact with individual AP1-components, thereby not only stimulating transcriptional 
activity of target genes, but also enhancing the up-regulation of AP1 by the Erk1/2 pathway (322, 
347).
1.4.2 Wnt-signaling
Wingless/Wnt family members are secreted glycoproteins that bind and activate cell surface 
receptor complexes consisting of the Frizzled family of G-protein coupled receptors and the low- 
density lipoprotein receptor-related protein 5 and 6 (LRP-5 and -6) (Figure 5) (348). The family of 
Wnt proteins can be divided in two subfamilies: the P-catenin-dependent Wnts such as Wnt-1, -2, -3 
and -3a, and the P-catenin-independent Wnts such as Wnt-4, -5a, -5b, -6 and -7  (for review see ref. 
349).
In the P-catenin-dependent pathway, absence of Wnt signaling enables glycogen-synthase 
kinase 3 (Gsk-3) to phosphorylate P-catenin, thereby inducing the degradation of P-catenin by the 
ubiquitin-proteasome pathway (Figure 5). Upon activation of Wnt signaling, Gsk3 activity is inhibited 
by the protein disheveled (Dsh). This prevents P-catenin degradation, resulting in its accumulation, 
nuclear translocation and association with members of the Lef/Tcf (Lymphoid enhancer binding 
factor/T-cell-specific factor) transcription factor family, which function in P-catenin mediated gene 
transcription (349). In contrast, in the P-catenin-independent pathway, the receptor complex consists 
of Frizzled, or frizzled domain containing proteins, with the proteoglycan Knypek as a co-receptor. 
Activation of this P-catenin-independent pathway also leads to the activation of Dsh, but at different 
protein domains than in the P-catenin-dependent pathway. Subsequently, this differential activation of 
Dsh leads to the activation of the Jnk signal transduction pathway, as well as signal transduction 
pathways in which Ca2+ flux and small G-proteins are essential (349) (Figure 5).
Both the Wnt/P-catenin and Wnt/Ca2+ pathway have been shown to be important for bone 
formation, such that the P-catenin-dependent pathway has been shown to enhance osteoblast 
differentiation and possibly also chondroblast differentiation, whereas the Wnt/Ca2+ pathway 
enhances chondroblast differentiation and possibly inhibits osteoblast differentiation (349). The P- 
catenin-dependent pathway is known to enhance osteoblast differentiation, since inactivating 
mutations in the Wnt co-receptor LRP5 have been shown to decrease bone accrual during growth. 
Activating mutations cause a phenotype with increased bone mass (350, 351). Furthermore, secreted 
frizzled-related protein 1 (sFrp-1) is an antagonist of the Wnt/P-catenin canonical pathway and sFrp-1 
knockout mice display increased trabecular bone formation, caused by an inhibition of 
osteoblast/osteocyte apoptosis and enhanced osteoblast proliferation and differentiation (352, 353). In 
addition, BMP-mediated up-regulation of Alp2 is dependent on P-catenin. Activation of the P- 
catenin/Lef/Tcf pathway not only stimulates endochondral bone formation, but also participates in 
BMP-induced osteoblast differentiation, as shown by increased mineralization (354-356).
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Figure 5. Interactions of the Wnt and Smad signal transduction pathways.
Points of convergence between the Wnt and Smad pathway: I) BMPs induce the expression of Wnt signal transduction genes 
including Wnt, Frizzled and Lef1, II) Smad-4 is a co-activator of P-catenin, III) Lef/P-catenin regulates activity of Cbfa1, and IV) 
b-catenin regulates the activity of Smad binding proteins. See text for details. See page 136 for full color figure
The effects of P-catenin-dependent Wnt signaling on chondroblast differentiation are still 
controversial. It has been shown that constitutively active P-catenin induces ectopic endochondral 
bone formation, but on the other hand, over-expression of P-catenin-dependent Wnts results in 
inhibition of chondroblast differentiation both in vivo and in vitro (356, 357). Moreover, Wnt- 
dependent P-catenin and Ca2+ pathways can inhibit each other’s activity, which suggests that the 
relative levels of activity of these two pathways might be an important factor in the decision of cell 
fates (358).
Interaction of the Wnt and BMP/Smad signal transduction pathways occurs at various levels 
(Figure 5). BMPs induce the expression of Wnt and Frizzled during osteoblast differentiation, 
indicating that a Wnt autocrine loop may be operative during BMP-mediated osteoblast 
differentiation (355). It is not yet known, however, whether this expression is regulated by Smads or 
by MAP-kinases, or a combination of these two pathways. Furthermore, Lef1 expression has been 
shown to be induced by BMPs during tooth development, a process very similar to osteoblast
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differentiation (359), which suggests that Lef/Tcf transcription factors could also be induced by 
BMPs during osteoblast differentiation.
In addition, Smad-4 functions as a co-activator of P-catenin in Wnt-signaling. It has been 
shown that R-Smads and Smad-4 can interact with Lef/Tcf transcription factors and thereby mediate 
cooperative signaling between the TGF-P and Wnt pathways (360-362). Furthermore, Lef/P-catenin 
complexes have been shown to bind Cbfa1, thereby inhibiting the Cbfa1-dependent activation of the 
Ocn promoter (34). This indicates that various genes of which the expression is regulated by Cbfa1, 
are also regulated by the Wnt/P-catenin pathway.
Finally, the Wnt/P-catenin and Smad pathway may converge at the level of regulation of 
Smad-binding proteins, similarly to the convergence of the MAP-kinase and Smad pathways. In 
tumor cells, for instance, P-catenin has been shown to induce the transcription of Bambi, a negative 
regulator of BMP signaling, resulting in an inhibition of growth arrest in these cells (363). At the 
moment, it is not known, however, whether Wnt/P-catenin signaling also mediates the BMP-induced 
expression of Bambi in osteoblastic cells.
1.4.3 The Notch pathway
Notch is a single transmembrane protein receptor with a large extracellular domain containing 
multiple epidermal growth factor (EGF)-like repeats and three notch-specific repeats (LNRs). The 
small intracellular domain of Notch contains several functional domains, including ankyrin repeats 
flanked by nuclear localization repeats and a transactivating domain (TAD) (for review see ref. 364). 
Signaling-competent Notch is synthesized from a precursor protein by cleavage of the extracellular 
domain from the rest of the protein by a furin protease in the Golgi complex. The resulting parts of 
Notch are non-covalently linked by a calcium-dependent interaction in the absence of ligand binding 
(Figure 6). In addition to the Notch receptor, its ligands Delta and Serrate/Jagged are also single 
transmembrane proteins, requiring cell-cell contact for optimal signal transduction through the Notch 
receptors (Figure 6). Soluble ligands are known, but they have been shown to function as dominant 
negative proteins (364).
Upon ligand binding, the Notch receptor is subject to two additional proteolytic steps for 
complete activation. First, the bulk of the extracellular domain is cleaved off by the metalloprotease 
TACE (TNF-a-converting enzyme), leaving a membrane-tethered intracellular domain. Second, 
intramembranous cleavage by presinilin-dependent y-secretase releases the Notch intracellular 
domain (NICD), which subsequently translocates to the nucleus and binds to the transcription factor 
Cbf1/Su(H)/Rbp-J (Suppressor of Hairless/recombining binding protein suppressor of hairless) 
(Figure 6).
In the absence of Notch signaling, Cbf1 represses gene transcription through the recruitment 
of the co-repressor Smrt, a histone deacetylase (HDAC), and Skip (Ski interacting protein). NICD 
binds to the Cbf1/Smrt/HDAC/Skip complex and thereby displaces Smrt and its associated HDAC, 
resulting in a relieve of transcriptional repression (for reviews see refs. 364, 365). In addition, the 
NICD/Cbf1 complex recruits the co-activator Maml (Mastermind-like), which binds the 
transcriptional activator protein p300/CBP to form a NICD/Cbf1/Maml/p300 complex. The 
subsequent recruitment of P/CAF to this complex enhances Notch signaling (366, 367) (Figure 6).
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Delta, Serrâte/Jagged
direct target genes 
Hes-1 and Hey1
Figure 6. Interaction of the Notch and Smad signal transduction pathway.
The Notch intracellular domain (NICD) interacts with R-Smad/Co-Smad complexes in the nucleus thereby inducing the expression 
o f Notch transcription factors such as Hes-1. See text for details. See page 137 for full color figure
In vertebrates, the family of Notch receptors consists of four highly homologous proteins 
(Notch 1-4), and the ligands Delta and Serrate/Jagged consist of three and two family members, 
respectively (Delta-like-1, -2 and -4; Jagged-1, and -2). Activity of the Notch receptor is regulated by 
glycosylation at O-fucose residues through the action of the so-called fringe gene products. In 
vertebrates, the family of fringe genes consists of three members, lunatic fringe (Lfng), manic fringe 
(Mfng) and radical fringe (Rfng). O-fucosylation at the EGF-like repeats of Notch is essential for 
signaling, since loss of the fucose transferring protein (O-FucT-1) causes embryonic lethality of mice 
at mid-gestation as a result of severe defects in somitogenesis, vasculogenesis, cardiogenesis, and 
neurogenesis. Furthermore, inactivation of Lfng in mice causes defects in somitogenesis, skeletal 
defects and perinatal death (368-371). Strikingly, it has been suggested that the distribution of fringe 
proteins, rather than that of Notch receptors or its ligands, is the key determinant in the control of 
Notch signaling (372).
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Because inactivation of fringe genes causes skeletal defects in mice, it is likely that the Notch 
signal transduction pathway plays an important role in bone formation. However, reports on the 
effects of the various ligands and receptors on Notch signaling in osteoblast differentiation are still 
contradictory (373-375). On the one hand, it has been reported that over-expression of the NICD in 
osteoblastic cells impairs osteoblast differentiation (373, 374, 376), while others have reported that 
over-expression of the NICD stimulates osteoblast differentiation (375).
Members of the Hes/Herp (hairy and enhancer of split) family are primary target genes of 
Notch signaling and either homodimerize or heterodimerize to exhibit their effects (377, 378). Hes-1 
has been shown to be a negative regulator of osteoblast differentiation probably through interactions 
with the Groucho family of transcriptional repressors, which are also known to be involved in 
regulating Wnt signaling (379-382). On the other hand, the osteoblast specific transcription factor 
Cbfa1 has also been shown to bind Hes1, thereby releasing the inhibitory Groucho protein. 
Association of Hesl with Cbfal has been shown to stimulate the transactivating function of Cbfal on 
Ocn transcription (35).
Reports on the interaction of the Notch signal transduction pathway with the Smad-pathway 
are only scarce. It has been shown, however, that the NICD can interact with both TGF-P- and BMP- 
specific Smads (Figure 6). TGF-P can rapidly induce the expression of Hes1 in a NICD-and Smad- 
dependent manner. Furthermore it has been shown that NICD can bind to Smad-3 at its MH2-domain. 
This interaction is necessary for the activation of promoters containing both Notch- and Smad- 
binding elements (383). Moreover, it has been shown that Smad-1 and NICD also interact 
functionally to inhibit both myogenesis and BMP-induced osteogenesis of the C2C12 mesenchymal 
progenitor cell line, probably through up-regulation of specific Notch target genes (384).
In addition to the cross talk between TGF-P and Notch signal transduction pathways, it has 
been described that the Notch and Wnt pathways also functionally interact. Gsk-3, a negative 
regulator of Wnt/P-catenin signaling (see above), can phosphorylate the NICD and thereby inhibits 
the expression of Notch target genes. Moreover, Wnt-induced inactivation of Gsk-3 leads to an up- 
regulation of Hes-1 transcription (385). Furthermore, it has been shown that the NICD and Lef-1, an 
effector of Wnt signaling, can interact in vivo resulting in the activation of specific, Wnt/P-catenin 
independent, promoters (386). The importance of these interactions for bone development is not yet 
known, but certainly requires further investigation.
1.5 Clinical skeletal disorders associated with osteoblast differentiation
BMPs have critical functions during embryonic development in mice with respect to 
mesoderm formation and patterning, left-right asymmetry, neural patterning, somite patterning, 
skeletal development and limb patterning as well as in the development of nearly all organs including 
tooth, lung, kidney, gut, skin and gonads (108). Although it may be expected that BMPs exhibit 
similar functions in humans, it was only recently that clinical disorders have been described which are 
associated with BMPs. These disorders include fibrodysplasia ossificans progressiva (FOP) and a 
number of chondrodysplasias such as Hunter-Thompson Chondrodysplasia (HTC), Grebe Syndrome 
and Brachydactyly C (for review see ref. 387).
FOP is a severely disabling, autosomal dominant disorder, which only occurs sporadically. 
FOP is progressive with age and no treatments are currently available. FOP has three distinguishing
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features: 1) congenital malformations of the great toes; 2) heterotopic ossifications of soft connective 
tissues such as tendon, ligament, fascia and skeletal muscle; and 3) temporal progression of 
osteogenesis in characteristic anatomic patterns (for review see ref. 388). Patients with FOP have in 
fact two skeletons: one that is grossly normal and which is formed during embryogenesis, and a 
heterotopic one which is formed after birth and fuses with the normal skeleton, although it is formed 
independently of the normal skeleton. This fusion of the heterotopic skeleton with the normal 
skeleton results in impaired muscle movement. Heterotopic bone formation usually begins in the first 
decade of life and by the time the patient is in his/her thirties, he/she is unable to move independently 
anymore, except for some small movements such as chewing and grasping.
The heterotopic bone is formed through the process of endochondral ossification, and 
heralded by large, painful, tender, highly vascularised, soft-tissue swellings (lesions) that develop 
rapidly and spontaneously, but can also develop following minor traumas such as cuts, bruises and 
intramuscular injections (388). The lesions consist of many cell types including lymphocytic cells, 
mast cells and smooth muscle cells of vascular origin (389-391).
According to current ideas, the combination of symptoms in FOP patients is caused by 
alterations in the BMP signaling cascade. It has been shown that in lymphocytic cells of FOP lesions 
expression of BMP-4 is up-regulated due to enhanced transcription of the gene (389, 392), but this 
probably reflects more a consequence than the cause of the disease, since the gene loci of FOP (see 
below) have not been mapped to the BMP-4 locus on human chromosome 14 (393). In addition, no 
mutations in the BMP-4 gene have been described in FOP patients (394).
One of the gene loci for FOP has been mapped to human chromosome 4q27-31, which 
includes genes for BMP signaling intermediates such as Smad-1 and BMPR1B as well as interleukin 
15 (IL-15) and Lef1 (395). Another locus for FOP has been mapped to human chromosome 17q21- 
22, which includes the gene for noggin, an inhibitor of BMP signaling (396). In support of this 
observation, several mutations in the noggin gene have been identified in non-related FOP patients 
(397, 398). These mutations all result in the inability of the noggin protein to become acetylated at 
amino acid residues 89 ^  94, which probably results in impaired protein activity (398). Furthermore, 
it has been shown that the elevated BMP-4 activity in FOP lesional cells is not primarily caused by 
the over-expression of BMP-4 itself, but more by the lack of active noggin, which renders the cells 
responsive to BMP-4 for a longer period of time than observed normally (399). Moreover, in a mouse 
model of BMP-4-induced heterotopic ossification, restoration of the noggin-BMP feedback loop 
inhibited in vivo ossification (400). These data suggest that in FOP patients the feedback loop for 
BMP signaling is defect, specifically in lesional cells, causing an attenuated BMP response and 
induction of endochondral bone formation. However, the question why these patients develop 
spontaneous lesions, and why the effect of a defect BMP-feedback loop is so devastating particularly 
in these lesions, but not in other cells, has not yet been solved.
The Hunter-Thompson Chondrodysplasia (HTC), Grebe Syndrome and 
Brachydactyly C disorders belong to the acromesomelic type of chondrodysplasias, where the skeletal 
phenotype exhibits abnormalities predominantly in the middle and distal segments of the upper and 
lower limbs (387). Both HTC and Grebe Syndrome are characterized by severe long bone shortening 
which progresses in a proximodistal fashion: the tips of hands and feet are more affected than the 
arms and legs, and the feet and legs are more affected than the hands and arms. However, patients 
with Grebe Syndrome are more affected than HTC patients. In Brachydactyly C, the individual bones 
in the hands and feet are altered in size and/or shape, but the rest of the skeleton is hardly affected 
(387).
It has been shown that all these diseases result from mutations in the gene for CDMP-1 
(cartilage-derived morphogenic protein-1), also known as Gdf-5 in mice, which belongs to the Gdf-
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subfamily of BMPs. Gdf proteins are mainly involved in cartilage development, and their bone- 
promoting activity both in vivo and in vitro is relatively limited when compared with BMPs. 
Moreover, the expression pattern of CDMP-1/Gdf-5 predominates in and around the developing 
limbs, with striking expression in the joint interzones (387).
HTC patients display a homozygous mutation in the CDMP-1 gene which is caused by a 22- 
bp insertion, resulting in an altered open-reading frame after the third cysteine codon, thereby 
completely disrupting the tri-dimensional form of the protein, which consequently results in loss of 
protein function (401). Grebe Syndrome patients have a tyrosine-for-cysteine mutation at amino acid 
400 (C400Y), which impairs secretion of the protein. Moreover, the mutated protein also behaves as a 
dominant-negative form, which suppresses not only the other CDMP-1 allele, but also selectively 
interferes with the secretion of other BMPs, which might explain the severity of Grebe Syndrome in 
comparison with HTC (402). In Brachydactyly C patients, various mutations in CDMP-1 have been 
observed that all lead to functional haploinsufficiency of the protein, causing a less severe type of 
chondrodysplasia (403, 404).
1.6 Aim of the thesis
The aim of the present research was to identify genes that act as key- or co-regulators of 
BMP-induced osteoblast differentiation and that may function as focal points for the interaction of the 
BMP pathway with other signal transduction pathways relevant in osteoblast differentiation. A 
characterization of BMP-induced regulation of the differentiation of MSCs to osteoblasts is very 
important for understanding the bone forming part of bone homeostasis. Such knowledge might 
facilitate the identification of new putative drug targets that promote bone formation by enhancing 
osteoblast differentiation. Ultimately, these new drug targets might enable the development of novel 
therapies to treat serious clinical disorders such as osteoporosis in which bone homeostasis is 
disturbed. To address these questions, a detailed description of the molecular processes by which 
BMPs regulate osteoblast differentiation is needed. In this context, the gene expression regulation of 
several thousands of genes was studied during BMP-induced osteoblast differentiation using the 
mouse mesenchymal C2C12 cell line. This cell line was used as a model system since it differentiates 
into osteoblasts upon BMP stimulation, whereas it differentiates towards myoblasts in the absence of 
BMPs. Moreover, TGF-P has been shown to block both differentiation pathways in these cells (111, 
405). To determine gene expression profiles, the “gene expression microarray” (GEM) technology 
was used. This approach allows the simultaneous monitoring of expression of several thousands of 
genes under different experimental conditions (406-410).
In Chapter 2, gene expression profiles were determined of C2C12 cells stimulated for two 
hours by either BMP2, TGF-P or activin A. This enables differential expression analysis of immediate 
early response genes as induced by these growth factors. The growth factors tested are all members of 
the TGF-P superfamily, but they exhibit different capacities in regulating osteoblast differentiation. 
Four transcripts, one gene and 3 ESTs, were identified to be regulated by BMP2 and TGF-P in an 
opposite manner, indicating that these transcripts might be important novel regulators of growth 
factor-induced osteoblast differentiation.
In Chapter 3, regulators of osteoblast differentiation were identified by BMP-induced gene 
expression pattern analysis during the early phases of osteoblast differentiation. A large set of genes 
(184 genes and ESTs) was identified that could be subdivided into several clusters according to their
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time-dependent expression patterns. These clusters contain functionally related genes, representing 
the various phases of osteoblast differentiation. Signal transduction regulatory factors are mainly 
represented in the clustered subset of immediate early genes, whereas the intermediate early and late 
early clusters consisted primarily of genes related to processes that modulate morphology, basement 
membrane formation and synthesis of extracellular calcified matrix. Two genes were identified that 
exhibited very similar expression characteristics to the osteoblast-specific type II isoform of Cbfal, 
one belonging to the Wnt signal transduction pathway (Tcf7) and one belonging to the Notch signal 
transduction pathway (Heyl). Subsequent transfection experiments showed that ectopic expression of 
Tcf-7 regulates the expression of osteoblast differentiation marker genes which suggests that Tcf-7 
enhances BMP-2 induced osteoblast differentiation.
In Chapter 4, gene expression profiles were determined to identify novel genes that are 
differentially regulated by BMP-2 and TGF-P during early phase osteoblast differentiation. Genes 
that are highly induced by BMP-2, but not by TGF-P or are repressed by TGF-P, and those of which 
the BMP-induced expression levels are inhibited by TGF-P might be important regulators of BMP- 
induced osteoblast differentiation. A small set of genes exhibiting these expression profiles was 
identified, including several genes involved in the Notch signal transduction pathway such as Heyl 
and Lfng. This result suggests that the Notch signal transduction pathway is a major regulator of early 
phase osteoblast differentiation. In addition, potential focal points of interaction of the BMP and 
Notch signal transduction pathways were identified.
Osteoblast differentiation is not only regulated by the BMP/Smad signal transduction 
pathway, but also by other signal transduction pathways such as Erk1/2 MAP-kinase and Notch 
pathways. In Chapter 5, a model for the time-dependent influence of the different pathways on 
osteoblast differentiation is presented. This model is based on the results of inhibition of the Erk1/2 
pathway and transfection of C2C12 cells with various Smads, Heyl and Lfng on expression profiles 
of genes that are representative for the different phases of osteoblast differentiation. The implications 
of the results of our research for the identification of drug targets for bone diseases are discussed in 
Chapter 6.
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Chapter 2
Abstract
Bone morphogenetic protein 2 (BMP2), a member of the TGF-P family, is a potent regulator 
of osteoblast differentiation. In addition, both TGF-P and activin A can either induce bone formation 
or inhibit bone formation depending on cell type and differentiation status. Although much is known 
about the receptors and intracellular second messengers involved in the action of TGF-P family 
members, still little is known about how selectivity in the biological response of individual family 
members is controlled. In the present study, we have investigated selective gene induction by BMP2, 
TGF-P1 and activin A, in relation to their ability to control differentiation of mouse mesenchymal 
precursor cells C2C12 into osteoblastic cells. TGF-P1 can inhibit BMP2-induced differentiation of 
these cells, while activin A was found to be without morphogenetic effect. Using a gene expression 
microarray approach covering 8,636 sequences, we have identified a total of 57 established genes and 
ESTs that were either up-regulated or down-regulated 2 hours after treatment with at least one of 
these three stimuli. With respect to the established genes, 15 new target genes for TGF-P family 
members were thus identified. Furthermore, a set of transcripts was identified, which was oppositely 
regulated by TGF-P1 and BMP2. Based on the inverse biological effects of TGF-P1 and BMP2 on 
C2C12 cells, these genes are important candidates for controlling the process of growth factor- 
induced osteoblast differentiation.
Introduction
The transforming growth factor P (TGF-P) family of cytokines, which includes among others 
TGF-P itself, activins and the bone morphogenetic proteins (BMPs), exerts extensive control over 
embryonic development and tissue homeostasis. Depending on the genetic make-up and environment 
of the target cell, many different responses can be triggered. One of the processes in which TGF-P 
family members play a crucial role, is bone formation and remodeling. BMP2, -4, and -7 have been 
characterized as important signaling molecules during the development of the skeleton in vertebrates 
(1, 2), and are able to induce ectopic bone formation in mammals (2-5). The effects of TGF-P1 and 
activin A are more complex. These cytokines have been shown to induce bone formation when 
injected near bone (6, 7), while on the other hand both in vitro and in vivo studies have indicated that 
they may impede bone formation by inhibiting the early differentiation of osteoblasts (8-10).
To generate biological responses, TGF-P family members use heteromeric complexes of so- 
called type II and type I serine/threonine kinase receptors, resulting in the activation of specific 
receptor-regulated Smads (R-Smads). These include Smad2 and 3, which are specific for TGF-P and 
activin A signaling, while Smad1, 5 and 8 have been shown to be primarily BMP-responsive R- 
Smads. In combination with the common-mediator Smad4, the respective R-Smads are assembled 
into heteromeric complexes, which subsequently translocate to the nucleus, where they act in concert 
with other proteins as transcription factor complexes (11-13).
Although several target genes of BMP, TGF-P and/or activin are known, some of which can 
be related to bone formation, a detailed analysis of TGF-P family member target genes involved in 
the early differentiation of osteoblast cells is still lacking. In this study, we have used the murine 
pluripotent mesenchymal precursor cell line C2C12 as a model system to study the effects of TGF-P 
family members on the early stages of osteoblast differentiation. In this cell line, BMP induces 
osteoblast differentiation, whereas TGF-P inhibits this effect (14). Here we show, using a gene 
microarray approach, that BMP2, TGF-P1, and activin A induce different sets of early response genes 
in these cells. By comparing these sets in relation to the osteoblast differentiating capacity of the three
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growth factors, various novel transcripts were identified that may play a direct role in bone 
development.
Materials and methods 
Tissue culture and growth factors
The C2C12 murine mesenchymal progenitor cell line (obtained from the American Type 
Culture Collection) was maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10% newborn calf serum (NCS), 44 mM NaHCO3, penicillin (100 U/ml) and streptomycin (100 
|ig/ml) at 37oC in a humidified atmosphere at 7.5% CO2. For the various experiments, cells were 
plated at a density of 5.7x104 cells/cm2 and grown for two days until confluence. Recombinant human 
BMP2 was kindly provided by Genetics Institute (Andover, MA), recombinant human TGF-P1 and 
recombinant human activin A were purchased from R&D Systems (Minneapolis, MN).
Alkaline phosphatase assay
Cells were seeded in 96-well tissue culture plates (Nalge Nunc International, Denmark) and 
grown as described above. Subsequently, the medium was changed to DMEM containing 0.5% NCS 
(low serum medium), supplemented with increasing doses of BMP2, TGF-P1, activin A, or 
combinations of these factors. Alkaline phosphatase activity was measured 48h after stimulation as 
described by Van der Plas and coworkers (15). Alkaline phosphatase activity was corrected for 
differences in cell number based on a measurement of neutral red staining (16).
Stimulation of cells and RNA isolation
Cells were seeded and grown in 145 cm2 culture dishes (Nalge Nunc International, Denmark) 
as described above. Subsequently, the medium was changed to low serum medium and cells were 
treated for 0.5, 1, 1.5 or 2 hours with BMP2 , TGF-P1 , or activin A . Non-treated controls were kept 
on low serum medium for 2 hours. Total RNA was extracted according to an acid guanidium 
thiocyanate-phenol-chloroform method (TriPure® Isolation Reagent, Boehringer Mannheim, 
Germany) and RNA concentrations were determined by measuring the absorbance at 260 nm. Poly A+ 
RNA was prepared from total RNA using the Oligotex™ method (Qiagen, Valencia, CA). 
Quantification of poly A+ RNA was carried out according to the Ribogreen™ RNA quantitation assay 
(Molecular Probes, Eugene, OR).
Reverse Transcriptase-PCR
Complementary DNA (cDNA) was synthesized from 2 |ig of total RNA from non-stimulated 
cells, using the SUPERSCRIPTTM II reverse transcriptase kit (GibcoBRL, Breda, the Netherlands). 
Subsequently, PCR reactions were performed (Geneamp 2400 PCR system, Perkin Elmer, Boston, 
MA) under the following conditions: initial denaturation for 2 min at 94oC followed by 30 cycles 
consisting of 1 min at 94oC, 1 min at 58oC for the receptors ActRIA, BMPRIA, ActRIB, ActRIIA, 
ActRIIB, BMPRII, and TPRII or at 62oC for TPRI, BMPRIB, and GAPDH, followed by 1.5 min at 
72oC and a final extension of 10 min at 72oC. For all PCR primers, shown in Table 1, control 
reactions without SUPERSCRIPTTMII reverse transcriptase were performed to exclude genomic DNA 
contamination as a source of amplified signal. All these samples were negative for receptor signal 
(data not shown). Aliquots of first-strand cDNA (2 |il) were used in the PCR reactions containing 20 
ng/|il of forward and reverse primers in PCR buffer (GibcoBRL) supplemented with 2 mM MgCl2 
and 3% DMSO, 200 mM dNTPs (MBI Fermentas, Vilnius, Lithuania) and 0.5 U Taq polymerase
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(GibcoBRL) in a final volume of 50 pl. The PCR products were visualized on ethidium bromide 
containing 1% agarose gels using the Geldoc2000 photosystem (Biorad, Hercules, CA).
Table 1. Primers for Reverse Transcriptase-PCR analysis T a ble 2. Primers for real-time quantitative RT-PCR analysis
Gene Primers (5’^ 3 ’) size
(bp)
ActRIA F: gga gta atg agc ctt cct gtg c 512
R: ttg gtg gtg atg agc cct tc
BMPRIA F: gat ggg taa aat gcg tgg 522
R: gat gta ggg ctg gaa atg gt
ActRIB F: cac tga cac cat aga cat tgc tcc a 331
R: gca tca tct ttc cca tca ctc gca a
TßRI F: ctg cca cct ctg tac aaa gg 721
R: cac agc tgc gtc cat gtc c
BMPRIB F: gac act ccc att cct cat c 357
R: gct att gtc ctt tgg acc ag
ActRIIA F: tct ctt gct ctt cag gtg ct 479
R: gaa caa gta cag gag ggt ag
ActRIIB F: ctg ctg gct aga tga ctt c 698
R: ttc cac gtg atg atg ttc c
BMPRII F: tca aga acg gct gtg tgc at 587
R: cgc tca tcc agg gaa cct tt
TßRII F: aca tca acc aca aca cgg agc 672
R: tca ttt ccc aga gta cca gag
GAPDH F: ccc ttc att cac ctc acc tac atg g 853
R: ggt cca cca ccc tgt tgc tgt agc c
Gene Primers (5’^ 3 ’) size (bp)
Timp3 F : gca att gca aga tca ag tcc tg 52
R : ttg gag gtc aca aaa caa ggc
CXCR4 F : atc agc ctg gac cgg tac c 52
R : tgg cct ttg act gtt ggt g
AI466638 F : atg aga cca acc ttt cac agc a 95
R : cca agg gag cat acc tgt tct t
F, forward primer; R, reverse primer
ActRIA, activin receptor type IA; BMPRIA, BMP receptor 
type IA; ActRIB, activin receptor type IB; TpRI, TGF-p 
receptor type I; BMPRIB, BMP receptor type IB; ActRIIA, 
activin receptor type IIA; ActRIIB, activin receptor type IIB; 
BMPRII, BMP receptor type II; TpRII, TGF-p receptor type 
II; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; F, 
forward primer; R, reverse primer.
Real-time quantitative RT-PCR
For real-time quantitative RT-PCR, ABI Prism Sequence Detection System 5700 and Primer 
Express™ (PE Biosystems) were used. For each gene, a set of primers was designed using sequences 
obtained from Genbank™ and amplicons of 50-100 basepairs with TM between 58 and 60°C were 
selected (Table 2). Prior to complementary DNA (cDNA) synthesis, 2 ^g of total RNA or 20 ng of 
poly A+ RNA were DNase treated for 15 min at 37°C, after which RNA was reverse transcribed from 
random hexamer primers using the SUPERSCRIPT™ II reverse transcriptase kit (GibcoBRL) (50 |il 
total volume). Subsequently, aliquots of first-strand cDNA (2|il) were amplified using SYBR Green® 
PCR Mastermix (Applied Biosystems) under the following conditions: initial denaturation for 10 min 
at 95°C followed by 40 cycles consisting of 15 sec at 94°C and 1 min at 60°C. Fold inductions and 
expression ratios were calculated from differences in threshold cycles at which an increase in reporter 
fluorescence above a baseline signal could first be detected (CT) between two samples, and averaged 
for duplicate experiments.
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Northern Blotting
Samples of 20 |ig of total RNA or 200 ng poly A+ RNA were separated electrophoretically on 
1% sodium phosphate-glyoxal-agarose gels and subsequently transferred to Hybond N+ membranes 
(Amersham Pharmacia, Piscataway, NJ) using 25 mM sodium phosphate buffer, pH 6.5. RNA was 
crosslinked to the membrane by baking the blots for two hours at 80oC. Prehybridization (30 min.) 
and hybridization (15 h) were performed in Church Buffer (0.5 M sodium phosphate buffer, pH7.2, 
7% SDS, 1 mM EDTA) at 65oC. The following mouse probes were used: JunB (17), Smad7 (18), 
Tieg (GenBank Accession Number AA476158), Myd118 (GenBank Accession Number W64388), 
Vdup1-pending (GenBank Accession Number W34721), and GAPDH (PCR product). Probes were 
labeled with 32P-a-dCTP using a random priming labeling kit (Ready-To-Go™ DNA labeling Beads, 
Amersham Pharmacia). For visualization, membranes were exposed to Kodak X-AR films at -80oC 
using intensifying screens and then quantified using the GS-700 Imaging Densitometer (Biorad), or 
the Molecular Imager FX (Biorad).
Gene Microarray and Statistical Analysis
Isolated poly A+ RNA was labeled by reverse transcriptase with nucleotides containing either 
a Cy3 or Cy5 fluorophore. The following hybridization experiments were performed in duplicate with 
a fluor reversal to minimize possible bias caused by the molecular structure of the Cy3 and Cy5 dyes: 
1) BMP2 treated versus control, 2) TGF-P1 treated versus control and 3) activin A treated versus 
control. For these hybridization experiments, the Mouse GEM™ 1 array from Incyte Genomics 
(Incyte Genomics Inc., Palo Alto, CA) was used. Incyte Genomics performed both the labeling and 
the microarray hybridizations according to their standard protocols. Incyte GEMtools™ software was 
used for image analysis. Background-subtracted element signals were used to calculate Cy3:Cy5 
ratios. Genes were selected for further analysis, if the signal to background ratio for a particular gene 
was > 2.5 and at least 40% of the area on chip could be used for signal computation in at least one of 
the two channels. To account for systematic errors caused by non-linear differences in signal 
intensities of the Cy3 or Cy5 channel, a regression analysis was performed by fitting a parabola to the 
experimentally observed expression values. Using these fitted values, genes with potentially 
differential expression were selected according to the following selection method: a normal 
distribution of non-differentially expressed genes was assumed. Next, the inter-quartile range of the 
distribution was calculated as a measure for the spread of the non-differentially expressed genes. To 
each edge of this range, 1.41 times the inter-quartile range was added, corresponding to a p-value of
0.01. Genes were considered to be significantly regulated, if they fell outside this range in both of the 
inverse duplicate experiments and if the intensity ratio was indeed inverse for both experiments. This 
selection was performed per gene for each growth factor separately. Using this technique, we were 
able to identify significantly regulated genes for the entire data set with a fold regulation as measured 
on array down to 1.3 for BMP2 and 1.5 for TGF-P1 and for activin A
Results
C2C12 cells can mediate signal transduction by BMP2, TGF-fil and activin A
To examine gene regulation induced by BMP2 during the early phase of osteoblast 
differentiation, the murine mesenchymal progenitor cell line C2C12 was used as a model system. In 
this study, we have compared the activity of BMP2 with that of two other members of the TGF-P 
family, namely activin A and TGF-P1. Since it is known that BMP-induced osteoblast differentiation 
is paralleled by the induction of alkaline phosphatase (ALP) activity, we first tested the dose-
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dependence of the effect of these three factors on osteoblast differentiation by measuring ALP 
activity under culture conditions similar to the ones we have subsequently used for the microarray 
experiments. As is shown in Figure 1A, strong up-regulation of this activity was observed when the 
cells were cultured for two days in the presence of BMP2 (IC50 = 150 ng/ml), whereas TGF-p1 and 
activin A on their own had no effect on ALP activity. TGF-p1 was able to inhibit the effect of BMP2 
on differentiation (IC50 = 0.7 ng/ml), as indicated by the inhibition of ALP activity, while activin A 
had no significant effect on the BMP2-stimulated activity (Figure 1B). In short, BMP2 has a 
stimulatory effect on differentiation of C2C12 cells, activin A has a neutral and TGF-p 1 a negative 
effect on BMP2-induced differentiation.
Figure 1. Biological activity of BMP2, TGF-P1 and 
activin A in C2C12 cells.
(A) Dose dependent induction of alkaline phosphatase 
(ALP) activity 48 hours after treatment with BMP2 
(•), TGF-p1 (■) and activin A (0). (B) Inhibition of 
BMP2 activity (100 ng BMP2/ml) by increasing 
doses of TGF-p 1 (■) and activin A (0). ALP activity 
was corrected for differences in cell density based on 
neutral red staining.
In order to examine the receptors that mediate the effects of these three TGF-P family 
members, we tested the cells for the expression of type I and type II serine/threonine kinases by 
reverse transcription (RT)-PCR. As is shown in Figure 2A, expression of the type II receptors 
ActRIIA, BMPRII and TPRII was observed, while no ActRIIB expression could be detected. In 
addition, all tested type I receptors were expressed, although expression of the BMPRIB and the 
ActRIB seemed to be lower than that of TPRI, BMPRIA and ActRIA. Together, these results show 
that C2C12 cells express receptors relevant for signal transduction of BMP2 (BMPRII or ActRIIA in 
combination with BMPRIA, BMPRIB or ActRIA), TGF-P1 (TPRII together with TPRI) as well as 
activin A (ActRIIA together with ActRIA or ActRIB). The lack of activity of activin A on C2C12 
differentiation therefore does not seem to be caused by the absence of receptor expression.
Figure 2. C2C12 cells are able to mediate signal transduction 
by BMP2, TGF-P 1 and activin A.
(A) C2C12 cells express the receptors required for signal 
transduction of BMP2, TGF-P1 and activin A. RNA of non­
stimulated cells was used for RT-PCR analysis. Primers for 
mouse sequences of TGF-P receptors I (TflRI; 721 bp) and II 
(TPRII; 672 bp), BMP receptors IA (BMPRIA; 522 bp), IB 
(BMPRIB; 357 bp), and II (BMPRII; 587 bp), and activin 
receptors IA (ActRIA; 512 bp), IB (ActRIB; 331 bp), IIA 
(ActRIIA; 479 bp) and IIB (ActRIIB; 698 bp) were used. (b,C) 
Northern blot analysis of JunB and Smad7 expression. (B) 
Total RNA from C2C12 cells treated for the indicated times 
with BMP2 (300 ng/ml) or TGF-P1 (5 ng/ml) was used. (C) 
Total RNA from C2C12 cells treated for 2 hours with BMP2 
(300 ng/ml), TGF-P 1 (5 ng/ml) or activin A (20 ng/ml) was 
used. As a control RNA was taken from cells treated with only 
low serum medium.
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We subsequently determined the optimal incubation time for studying early gene responses 
induced by TGF-P family members in our assay system.. As we observed earlier, BMP2 (300 ng/ml) 
strongly induced ALP activity after incubation for 2 days (Figure 1A), while TGF-P1 (5 ng/ml) 
strongly inhibited BMP2-induced ALP activity (Figure 1B), so these concentrations were used in the 
subsequent experiments. Activin A, which had no significant effect on BMP2-induced ALP activity 
(Figure 1B), was applied at a concentration of 20 ng/ml similarly as used elsewhere (19). To 
determine the optimal incubation time, expression regulation of two previously identified TGF-P1 
and BMP2 early response genes, JunB and Smad7, was examined (18-21). As can be seen in Figure 
2B, expression of both genes was up-regulated during the first 2 hours after addition of BMP2 or 
TGF-P1, such that these factors displayed a 5-fold and a 9-fold induction of JunB expression 
respectively, whereas activin A gave only a 2-fold induction of this gene (Figure 2C). Also expression 
of Smad7 was significantly up-regulated after 2 hours of incubation with BMP2 (3 fold) and TGF-P1 
(3 fold). These data show that a 2-hour treatment of C2C12 cells with all three TGF-P family 
members results in significant up-regulation of early response genes.
BMP2, TGF-01 and activin A-induced gene expression profiles
Despite the rapid progress in understanding the signaling mechanisms downstream of 
receptors for TGF-P-related growth factors, the relation between the biological effects of TGF-P 
family members on bone differentiation and their induced early genes is as yet poorly characterized. 
In addition, a systematic search for early target genes of BMPs, activins and TGF-Ps in osteoblasts is 
still lacking. In this study, we examined the early gene expression patterns induced by BMP2, TGF- 
P1 and activin A in C2C12 cells by using cDNA microarray analysis based on a large part of the 
available data from the mouse genome. For this analysis, we used the Mouse GEM 1 array, which 
consists of 8,636 sequences (Incyte Genomics). Similar as above, we studied expression profiles 2 
hours after addition of BMP2, TGF-P1 and activin A to the cells (Figure 2C). To examine specific 
regulation by these three factors, competitive hybridizations with stimulated versus non-stimulated 
samples were performed. To minimize possible bias caused by the molecular structure of the Cy3 and 
Cy5 dyes, each experiment was performed in duplicate with a fluor reversal. Genes were considered 
to be significantly regulated by one of the growth factors, if they exhibited inverse expression ratios 
per duplicate hybridization and if these ratios had a p-value < 0.01 according to our statistical analysis 
(see Material and Methods).
Of the 8,636 sequences spotted on the microarray, 57 sequences were identified that were 
significantly regulated by at least one of the three growth factors (1.3-fold modulation for BMP2 and
1.5 fold modulation for TGF-P1 and activin A). Subsequently, these 57 genes were further 
categorized depending on their extend of co-regulation by these factors. In our experience, regulation 
levels of 1.2 or more on microarray can generally be confirmed by other techniques like Northern 
Blot analysis and quantitative RT-PCR (see also Figure 3). Regulation levels between 1.0 and 1.2 
cannot always be confirmed by these other techniques and this group of genes generally contains a 
number of false positives. We therefore used a threshold value of 1.2 for grouping the significantly 
regulated genes into the 10 categories shown in Table 3.
A group of 44 genes was up-regulated by both BMP2 and TGF-P 1, or by all three factors 
(categories II and III), while in addition, 3 genes were down-regulated by both BMP2 and TGF-P1 or 
by all three factors (categories VIII and IX). Furthermore, 4 transcripts were up- or down-regulated 
by BMP2 only (categories I and X) and 2 transcripts were identified that were specifically regulated 
by activin A and/or TGF-P1, but not by BMP2 (categories IV and V). Moreover, 2 genes were up- 
regulated by BMP2 but down-regulated by TGF-P1 (category VI), and 2 genes were down-regulated
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by BMP2 while up-regulated by TGF-p1 and activin A (category VII). Table 3 also shows that of the 
57 genes identified, 31 were ESTs and 26 were already established genes. Based on their functions, 
these 26 genes can be subdivided into 14 transcription regulators, 5 growth factors and extracellular 
matrix proteins, 3 receptors, 1 neurotransmitter, 1 inorganic phosphate transporter, and 2 enzymes 
(Table 4).
Table 3. BMP2, TGF-(31 and activin A exhibit different sets of significantly regulated early genes (p < 0.01).
Category
Genbank  
A ccession no. Gene Name BMP2 T G F-pi activin A
I B Î AA002322 EST 1.0 1.0
AI894068 Mm. Fos-like antigen 2 1.0 1.0
II B ,T Î W 88094 Mm. Chemokine (C-X-C) receptor 4 1.0
A A 1I8626 EST 2.0 2.3 1.1
A A060806 Mm. TSC22-related inducible leucine zipper lb 1.9 1.7 1.0
W 82201 EST 1.7 1.3 1.0
W 13229 EST 1.6 1.7 1.1
A A 1I9479 Mm. Lymphoid enhancer binding factor 1 1.6 1.7 1.1
A I5I00I0 EST 1.6 1.7 1.0
AA259873 EST 1.6 1.3 1.1
AI466603 EST 1.5 1.6 1.0
AA547162 Mm. Forkhead box O l 1.5 1.5 1.1
A A033308 EST 1.5 1.5 1.1
W 98395 Mm. Discoidin domain receptor 1 1.5 1.3 1.0
A A423149 Mm. Cyr61 1.5 1.4 1.0
A A061644 Mm. Smad 7 1.4 1.5 1.0
W 14184 EST 1.4 1.5 1.0
W 852I7 EST 1.3 1.6 1.0
A A184015 EST 1.3 1.5 1.1
A A 12539I EST 1.1
III B ,T ,A Î AA036380 Mm. Snail hom olog
A A144094 EST 2.2 3.2 1.9
AA184207 EST 1.8 2.7 1.5
AA060863 EST 1.8 1.5 1.3
W 85374 EST 1.8 1.5 1.3
A A098166 Mm. Placental growth factor 1.7 1.5 1.2
W 64388 Mm. M y d ll8 1.5 3.5 1.4
AI595201 Mm. HB-EGF 1.5 2.8 1.3
W 45975 Mm. TNF receptor lb 1.5 2.0 1.2
AA271373 Mm. H eparan sulfate 6-O-sulfotransferase 1 1.5 1.4 1.2
A A 06424I Mm. Stimulated by retinoic acid 1.4 3.6 1.9
A A476158 Mm. Tieg 1.4 2.2 1.5
W 36541 Mm. Connective tissue growth factor 1.4 1.9 1.2
A A245505 Mm. Citokine inducible SH2 protein 2 1.4 1.4 1.2
A A177949 Mm. Solute carrier family 20, member 1 1.3 1.9 1.3
A A472299 EST 1.3 1.8 1.4
A A 44462I EST 1.3 1.7 1.3
AI509105 EST 1.3 1.7 1.2
AA036347 Mm. Kruppel-like factor 9 1.3 1.6 1.3
AA386857 EST 1.3 1.6 1.3
AA275737 Mm. Retinal short-chain dehydrogenase/reductase 1 1.3 1.6 1.2
W 66845 EST 1.3 1.6 1.2
A A145784 Mm. Timp3 1.3 1.5 1.2
A A260654 Mm. Tg interacting factor 1.2 2.4 1.6
AA030427 EST 1.2 1.5 1.3
W 98074 EST
IV t ,a T AI322575 Mm. Cocaine and am phetamine regulated transcript 1.1
V T Î AI390830 EST 1.0 1.1
VI b Tt ^ A A 27133I EST -1.2 1.0
W 87955 EST -1.3 -1.1
VII B ^ T ,A t AI552496 EST -1.4
W 64999 Mm. H esl -1.6
VIII B,T^ AI466638 EST -1.2 -1.7 -1.1
IX b ,t ,a 4. W 34721 Mm. Vitam in D upregulated protein 1 -1.3 -1.6 -1.3
A A432818 EST -1.2 -1.6 -1.2
X b I AA174312 EST -1.3 1.0 1.0
AI604140 EST -1.4 1.0 1.0
Genes regulated at least 1.3 times by BMP2 (300ng/ml), 1.5 times by TGF-P1 (5ng/ml) or 1.5 times by activin A (20 ng/ml) are
shown, categorized according to expression profiles, based on regulation values of at least 1.2 for all growth factors. Green, up- 
regulated; red, down-regulated; black, not regulated; B, BMP2; T, TGF-P1; A, activin A; T, up-regulated; i ,  down-regulated. Each 
value is the average of two reciprocal hybridizations. See page 138 for full color figure
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Validation of gene expression regulation by Northern blot analysis
Because the dynamic range of these cDNA microarrays is usually lower than of Northern blot 
analysis or real time quantitative RT-PCR (39), we used these latter two techniques to verify and 
validate the expression of some of the genes identified by our microarray analysis experiments. 
Figure 3 shows the expression profiles of six genes, analyzed by Northern blot analysis (Figure 3A) 
or quantitative RT-PCR (Figure 3B). The genes were chosen because they displayed different levels 
of expression regulation by BMP2, TGF-P1 and activin A that were representative of the dynamic 
range of the microarray experiment. The genes TGF-P inducible early growth response (TIEG), 
Myogenic differentiation 118 (Myd118), Tissue inhibitor if metalloproteinase 3 (Timp3) and 
Chemokine receptor 4 (CXCR4) were chosen to represent the up-regulated genes and Vitamin D- 
upregulated protein 1 (VDup-1) and the EST AI466638 were chosen to represent the down-regulated 
genes. Qualitatively, the expression profiles of the genes tested confirmed the microarray results. 
However, the level of modulation of these four genes according to Northern blot analysis and RT- 
PCR was 1-3 times stronger than obtained by microarray analysis. So, although the qualitative 
expression profiles of the microarray results were confirmed by two independent other methods, the 
extent of expression regulation differed between the techniques used.
Figure 3. Validation of selected gene expression values. (A) 
Northern Blot analysis. Poly A+ RNA similarly as in the 
microarray experiment was used to measure expression levels 
for two stimulated genes and one repressed gene. Expression 
levels (fold change ) were corrected for GAPDH and compared 
to microarray data. (B) Quantitative RT-PCR analysis. poly A+ 
RNA from the original microarray experiment and RNA from a 
biological duplo were used to measure expression levels for 
two stimulated genes and one repressed gene. Mean expression 
levels were corrected for GAPDH and the serum control and 
compared to microarray data. Error bars indicate differences 
between duplo experiments. C, 0.5% serum control; B, BMP2 
(300 ng/ml); T, TGF-P 1 (5 ng/ml); A, activin A (20 ng/ml).
Discussion
In this study, cDNA microarray analysis was used to correlate early gene expression by 
members of the TGF-P family with their ability to control osteoblast differentiation. Significant up- 
regulation of two previously reported early response genes junB and Smad7 was observed after 2 hrs 
of treatment with BMP2, TGF-P1 or activin A (Figure 2B + C). Therefore, this time point was used to 
search for additional early response genes.
Based on analysis of 8,636 mouse genes and ESTs selected to represent the mouse genome, 
we identified a group of 57 transcripts that were significantly (p<0.01) regulated for at least one of the 
three stimuli 2 hours after treatment with BMP2, TGF-P1 or activin A. The 57 transcripts identified 
here consisted of 31 ESTs and 26 established genes of which only 11 had previously been described
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as target genes for TGF-P family members. A total of 15 new target genes were therefore identified in 
this study, including various transcription factors, enzymes, a growth factor and a neurotransmitter 
(Table 4).
Table 4. Functions of the regulated genes
Accession nr. Gene name Category
Previously 
established TGF-p 
family target gene
Transcription factor
AA245505 Mm. Cish2 B ,T ,A t
W64999 Mm. Hes-1 B iT ,A t
AA547162 Mm. Foxo1 B ,T t
AI894068 Mm. Fosl-2 (Fra-2) B t
AA036347 Mm. Klf-9 B ,T ,A t
AA119479 Mm. Lef-1 B ,T t (22)
W64388 Mm. MyD118 B ,T ,A t (23,24)
AA061644 Mm. Smad 7 B ,T t (18,21,25)
AA036380 Mm. Snail (Sna) B ,T ,A t
AA064241 Mm. Stra13 B ,T ,A t
AA260654 Mm. Tgif T ,A t
AA476158 Mm. TIEG B,T ,A t (26-28)
W34721 Mm. Vdup-1 B X A i
AA060806 Mm. Tilz-1 B ,T t
Receptor
W88094 Mm. CXCR4 B ,T t (29)
W98395 Mm. Ddr1 B ,T t
W45975 Mm. Tnfr1b B ,T ,A t (30,31)
Growth factor
AA423149 Mm. Cyr61 B ,T t (32)
W36541 Mm. Fisp12 B ,T ,A t (33)
AI595201 Mm. HB-EGF B ,T ,A t (34)
AA098166 Mm. Pgf B ,T ,A t
Enzyme
AA271373 Mm. Hs6st-1 B ,T ,A t
AA275737 Mm. Rsdr-1 B ,T t
AA177949 Mm. Slc20a1 B ,T ,A t (35)
Extracellular matrix protein
AA145784 Mm. Timp3 B ,T t (36-38)
Neurotransmitter
AI322575 Mm. Cart T ,A t
It has been reported 
previously that the dynamic range of 
these cDNA microarrays is usually 
lower than more conventional 
methods like Northern Blot analysis 
or real-time quantitative RT-PCR 
(39). To verify our results, we 
checked the expression regulation of 
six of the 57 genes and ESTs 
identified, (TIEG, Myd118, VDup-1, 
Timp3, CXCR4 and AI466638) by 
either one of these two methods 
(Figure 3A and B). These six genes 
were chosen so as to represent the 
dynamic range of this microarray 
experiment. The results obtained 
showed that the qualitative expression 
profiles could be confirmed, but that, 
as reported previously, the microarray 
data underestimated the fold 
regulation observed with alternative 
techniques.
BMP2 is a strong inducer of 
osteoblast differentiation, whereas 
TGF-P1 and activin A are not capable 
of inducing osteoblast differentiation 
according to alkaline phosphatase 
activity (Fig 1A). In concurrence with 
this, our microarray analysis 
identified 4 transcripts that are 
specifically regulated by BMP2 but 
not by TGF-P1 or activin A. These 
include the transcription factor Fosl-2 
(or Fra-2) and 3 ESTs (Table 3, 
categories I and X). Interestingly, the 
Fosl-2 gene has not been described 
previously as a BMP2 early response 
gene, although it is known to be 
involved in osteoblast differentiation (40) and capable to activate the osteocalcin promoter (41).
In addition, transcripts inversely regulated by BMP2 and TGF-P1 are interesting, since, in 
agreement with previous observations (14), we found that TGF-P1 can inhibit the BMP2-induced
In this table the functions of the regulated genes are listed as were found by 
literature search. In addition, genes previously described as target genes of 
BMP-2 and TGF-p are marked
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osteoblast differentiation of the C2C12 cells (Figure 1A). In this respect, we found 2 ESTs that were 
activated by BMP2 but repressed by TGF-P1 (category VI), and we found the Hes1 gene and another 
EST to be inhibited by BMP2 but up-regulated by TGF-P1 and activin A (category VII). Since activin 
A cannot inhibit the BMP2-induced osteoblast differentiation it seems less likely that the genes in this 
latter category are key modulators of the osteoblast differentiation process. On the other hand, it has 
been shown that the Hes1 protein is a regulator of the osteoblast specific transcription factor 
Cbfa1/Osf2 (42, 43) and a repressor of osteopontin expression in osteoblasts (44). Therefore, although 
the specificity of the Hes1 activity is not exactly clear, its functioning in the BMP2-induced 
differentiation process deserves further investigation.
It has been described by Katagiri and coworkers that BMP2 can inhibit the spontaneous 
myoblast differentiation of C2C12 cells at low serum concentration by suppressing the transcriptional 
activity of myogenic factors such as MyoD and myogenin (45). In parallel with these observations, 
we show here that BMP2 can activate the expression of the discoidin domain receptor 1 (Ddr-1), 
which has been reported to be a myoblast differentiation inhibitor (46). The Ddr-1 gene was also 
found to be induced by TGF-P1, which is in agreement with previous publications showing that TGF- 
P1 mimics BMP2 in its ability to inhibit myoblast differentiation of C2C12 cells (14, 20).
TGF-P family members initiate signaling by assembling receptor complexes that activate 
Smad transcription factors. Recent data have indicated that the DNA binding affinity of Smad 
complexes for Smad binding element (SBE) consensus sequences is generally quite low in the 
absence of DNA-binding cofactors, which allow additional DNA contacts (13). For some of the 
TGF-P family member target genes identified in this study, promoter sequences have been described 
in the literature, and these regions contain a variety of SBEs and related sequences as well as 
consensus sequences for various known Smad cofactors (data not shown). For example, the promoter 
of the Vdup-1 gene contains 5 copies of the consensus sequence for the Sip1 transcription factor. This 
transcription factor has previously been reported to be involved in repression of gene expression (47, 
48), and since expression of the Vdup-1 gene was found to be down-regulated by all three growth 
factors in our study, the repressive effect of TGF-P family members on the Vdup-1 expression is most 
likely mediated by Sip1. However, analysis of these various promoter regions for the presence of 
SBEs and consensus sequences of DNA-binding cofactors did not allow us to determine a minimum 
requirement for BMP2, TGF-P1 or activin A responsiveness, particularly since no comparison with 
TGF-P family member insensitive genes could be made. Mutation analysis of the putative binding 
elements involved, as described for example for the Smad7 promoter (49), therefore remains the most 
straightforward approach, although new bio-informatic methods to perform in silico promoter 
analysis, as recently described for yeast (50, 51), hold great potential for the future.
Of the 26 target genes identified in this study, 14 encode a transcription factor. The 
observation that these transcription factors are differentially regulated by BMP2, TGF-P1 and activin 
A indicates that these three growth factors are able to control their own set of transcriptional 
regulators, thereby inducing independent intracellular pathways and finally giving rise to different 
biological responses. A more detailed analysis of these transcriptional regulators might contribute to 
the further elucidation of the signal transduction pathways induced by different TGF-P family 
members. Previous studies have also indicated that TGF-P family members can negatively control 
their own signaling efficiency by inducing expression of inhibitory Smads, such as Smad7 (18, 21, 
52). Our current results show that TGF-P1 and activin A are also able to induce the TG interacting 
factor (Tgif) gene, another known Smad co-repressor. This shows that TGF-P family members induce 
expression of multiple genes involved in an auto-regulatory feed back mechanism.
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Although a set of new target genes for the TGF-P family was identified in this study, various 
known target genes remained undetected. For example, we found only few up-regulated extracellular 
matrix genes in our analyses, in contrast to a recent study by Verrecchia et al. on expression 
regulation of a selected group of genes in fibroblast cells (53). Gene regulation by TGF-P family 
members has been reported to be strongly cell type dependent, while in addition gene expression 
patterns may depend on the time of incubation. In agreement with this consideration, we observed 
strong up-regulation of various extracellular matrix genes in the later stages of BMP-induced 
differentiation of C2C12 cells (Vaes et al., personal communication). Moreover, we are aware that 
various relevant target genes, including JunB, were not present on the microarray used in this study. 
Finally, although our statistical analysis allowed us to identify target genes down to a regulation level 
of only 1.3, the possibility of false negatives in the group of non-regulated genes can certainly not be 
excluded.
Previous studies on C2C12 cells have shown that both BMP2 and TGF-P1 can stimulate the 
expression of the bone specific transcription factor Cbfa1 (54). In addition, Alliston et al. have 
recently shown that the inhibitory effect of TGF-P1 on osteoblast differentiation is mediated by 
Smad3 due to a physical interaction with the Cbfa1 protein, which causes repression of its 
transcriptional activity through the DNA consensus sequence OSE2 (55). Based on these 
observations, transcripts that are regulated not only by BMP2 but also by the other family members 
can be directly involved in the process of bone development. Taken together, we identified a number 
of novel target genes which might directly or indirectly be involved in BMP2-induced osteoblast 
differentiation. It will be of great interest to sequence and further characterize the regulated ESTs to 
determine whether they are indeed important novel early modulators in the osteoblast differentiation 
process.
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Chapter 3
Micro Abstract
Key regulatory components of the BMP-induced osteoblast differentiation cascade remain to 
be established. Microarray and subsequent expression analyses in mice identified two transcription 
factors, Heyl and Tcf7, with in vitro and in vivo expression characteristics very similar to Cbfal. 
Transfection studies suggest that Tcf7 modulates BMP2-induced osteoblast differentiation. This study 
contributes to a better definition of the onset of BMP-induced osteoblast differentiation.
Abstract
Introduction: Elucidation of the genetic cascade guiding mesenchymal stem cells to become 
osteoblasts is of extreme importance for improving the treatment of bone-related diseases like 
osteoporosis. The aim of this study is to identify regulators of the early phases of BMP2-induced 
osteoblast differentiation.
Methods: Osteoblast differentiation of mouse C2C12 cells was induced by treatment with 
BMP2 and regulation of gene expression studied during the subsequent 24 hrs using high-density 
microarrays. The regulated genes were grouped by means of model-based clustering and protein 
functions were assigned. Real-time quantitative RT-PCR analysis was used to validate BMP2-induced 
gene expression patterns in C2C12 cells. Osteoblast specificity was studied by comparing these 
expression patterns with those in C3H10T1/2 and NIH3T3 cells under similar conditions. In situ 
hybridization of mRNA in embryos at embryonic day (E)14.5 and E16.5 of gestation and on newborn 
mouse tails were used to study in vivo expression patterns. Cells constitutively expressing the 
regulated gene Tcf7 were used to investigate its influence on BMP-induced osteoblast differentiation.
Results and Conclusions: 184 genes and expressed sequence tags (ESTs) were differentially 
expressed in the first 24 hrs following BMP2 treatment and grouped in subsets of immediate early, 
intermediate early and late early response genes. Signal transduction regulatory factors mainly 
represented the subset of immediate early genes. Regulation of expression of these genes was direct, 
independent of de novo protein synthesis and independent of the cell-type studied. The intermediate 
early and late early genes consisted primarily of genes related to processes that modulate morphology, 
basement membrane formation and synthesis of extracellular calcified matrix. The late early genes 
require de novo protein synthesis and show osteoblast specificity. In vivo and in vitro experiments 
showed that the transcription factors Hey1 and Tcf7 exhibited expression characteristics and cell type 
specificity very similar to those of the osteoblast specific transcription factor Cbfa1, and constitutive 
expression of Tcf7 in C2C12 cells differentially regulated osteoblast differentiation marker genes.
Introduction
Mesenchymal stem cells have the potential to differentiate into various cell types that include 
osteoblasts, chondrocytes, adipocytes, myoblasts and fibroblasts (1, 2) depending on the signaling 
cascades activated during the initial phase of differentiation. Each of these signaling mechanisms is 
likely to regulate a specific set of early response genes that ultimately determine the final fate of the 
differentiation process. Bone is a highly specialized tissue, but osteoblasts are nevertheless very 
similar to fibroblasts in terms of gene expression and only a very limited number of osteoblast 
specific genes have been identified (3).
Among the few established osteoblast specific genes are the transcription factors Core-binding 
factor 1 (Cbfa1) and Osterix (Osx). Cbfa1 is a key regulator of osteoblast differentiation (4-6) and its 
regulation and function have been studied extensively over the last decade. Several isoforms of Cbfa1 
have now been identified, of which the type II isoform is bone specific (7, 8). The activity of the 
Cbfa1 protein is modulated through post-translational modifications as well as through protein-
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protein interactions (9-12). Most of the well-established bone markers, such as Alkaline phosphatase, 
Collagen I, Bone Sialoprotein, Osteopontin and Osteocalcin, are known target genes of at least one of 
the Cbfa1 isoforms (4, 13-15). Moreover, the transcription factor Osx acts downstream of Cbfa1 and 
both Cbfa1 and Osx knock-out mice exhibit a complete absence of skeletal ossification (6, 16).
Osteoblast differentiation can be induced by various stimuli, but the most potent inducers are 
the Bone Morphogenetic Proteins (BMPs). Although the BMPs were first identified for their ability to 
induce ectopic bone formation in vivo (17), these proteins appear to be multifunctional regulators of 
morphogenesis during embryonal development (18). In addition to the BMP-induced Smad signal 
transduction pathway, several major signal transduction pathways, including the Wnt and Notch 
pathways, have been implicated in osteoblast differentiation. Nevertheless, only parts of the complete 
gene regulatory program guiding mesenchymal stem cells to become mature osteoblasts are currently 
known and many gaps still need to filling.
Recently, we have shown that gene expression microarray analysis is a powerful approach to 
identifying late phase bone marker genes (19) and to examine differential responses induced by 
BMP2, TGF-P1 and activin A (20). The aim of the present study was to identify novel potential 
regulators of the osteoblast differentiation process that are regulated during the early phases (within 
24 hrs) of BMP-induced osteoblast differentiation using high-density microarrays. Model-based 
clustering and functional analysis identified two osteoblast-related transcription factors, Hey1 and 
Tcf7, which exhibited very similar expression characteristics to the osteoblast-specific type II Cbfa1 
iso form. In addition, Tcf7 was shown to differentially regulate osteoblast differentiation marker 
genes.
Materials and Methods.
Tissue culture and growth factors.
The murine mesenchymal progenitor cell lines C2C12 and C3H10T1/2 and the fibroblast cell 
line NIH3T3 (obtained from the American Type Culture Collection [ATCC]) were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% newborn calf serum (NCS), 
penicillin (100 U/ml) and streptomycin (100 |ig/ml) as described previously (20). For the various 
experiments, cells were plated at a density of 2.0x104 cells/cm2 and grown for 24 hrs in DMEM 
supplemented with 10% NCS. Subsequently, medium was replaced by DMEM containing 5% NCS 
either in the presence or in the absence of 300 ng/ml recombinant human BMP2 with or without 50 
|j.M cyclohexamide (CHX). Recombinant human BMP2 was kindly provided by Wyeth (Andover). 
Cyclohexamide was purchased from Sigma.
RNA isolation
Total RNA was extracted according to an acid guanidium thiocyanate-phenol-chloroform 
method (TriPure® Isolation Reagent, Roche Diagnostics) and RNA concentrations were determined 
by measuring the absorbance at 260 nm. Poly A+ RNA was prepared from total RNA using the 
Oligotex™ method (Qiagen). Quantification of poly A+ RNA was carried out according to the 
Ribogreen™ RNA quantitation assay (Molecular Probes).
Microarray and statistical analysis
Microarray analysis was performed as described before (20). For each time point, the BMP2- 
treated samples were hybridized versus control samples that were incubated for the same period in 
DMEM supplemented with 5% NCS. For the hybridization experiments, the mouse Unigene 1 array 
from Incyte Genomics (Palo Alto) was used, and the experiments were performed in duplicate with a
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fluor reversal to minimize possible bias caused by the molecular structure of the Cy3 and Cy5 dyes. 
Background-subtracted element signals were used to calculate Cy3/Cy5 ratios. Genes were selected 
for further analysis if the signal to background ratio for a particular gene was > 2.5 and at least 40% 
of the area on chip could be used for signal computation in at least one of the two channels. To 
account for systematic errors caused by non-linear differences in signal intensities of the Cy3 and Cy5 
channel, statistical analysis was performed as described before (20). Genes with significant (p<0.01) 
differential expression regulation for at least one of the time points were selected for further analysis. 
Prior to clustering, microarray data were log transformed (base 10) according to: logI = log (ICy3/ICy5 ) 
if ICy3 > ICy5 and logI = -log (ICy5/ICy3) if ICy5 > ICy3, in which I is the intensity of each spot on 
microarray. Log values were averaged over duplicate experiments and scaled to unit vector length 
(normalization). Subsequently, normalized log values were clustered using model-based clustering 
(21). Briefly, in this method clusters are considered to be groups displaying multivariate normal 
distributions. Various models were fitted to the data and an estimation was made of the accuracy of 
the model describing the data by assuming that underlying probability distributions occur for each 
model. Subsequently, a selection was made based on maximizing Bayesian Information Criterion 
(BIC) values for the specific model and number of clusters that represented the data best. Optimal 
clustering was obtained using a clustering method in which the distribution of the expression ratios 
within a cluster were ellipsoidal, the cluster volumes variable, the cluster shapes equal and the cluster 
orientations variable (VEV-model). Protein functions of the genes were identified according to 
Incytes Protein Function Hierarchy.
Real-time RT-PCR
For real-time RT-PCR, the ABI Prism Sequence Detection System 5700 and Primer 
ExpressTM Software (PE Biosystems) were used. For each gene, a set of primers was designed using 
sequences obtained from Genbank™ and amplicons of 50-100 base pairs with TM between 58 and 
60°C were selected. Prior to complementary DNA (cDNA) synthesis, 2 ^g of total RNA were DNase 
(Invitrogen) treated for 15 min at 37°C, after which RNA was reverse-transcribed using random 
hexamer primers (Amersham Pharmacia) in a total volume of 50 |il using the SUPERSCRIPT™ II 
reverse transcriptase kit (Invitrogen). Subsequently, aliquots of first-strand cDNA (2|il) were 
amplified using SYBR Green® PCR Master mix (Applied Biosystems) under the following 
conditions: initial denaturation for 10 min at 95°C followed by 40 cycles consisting of 15 sec at 94°C 
and 1 min at 60°C. Fold inductions and expression ratios were calculated from differences in 
threshold cycles at which an increase in reporter fluorescence above a baseline signal could first be 
detected (CT) between two samples, and averaged for duplicate experiments.
In situ hybridization
Mouse embryos were collected from F1 females (Cba x C57B16) at embryonic day 14.5 and
16.5 (E14.5 and E16.5), dissected free from the uterus and membranes, fixed overnight at 4oC in 4% 
paraformaldehyde, dehydrated, embedded in paraffin wax and sectioned (6 |im) onto coated slides 
(Klinipath, Duiven, the Netherlands). Neonatal mouse tails that were kindly provided by dr. Marcel 
Karperien (Leiden University, the Netherlands) were collected from Swiss albino mice on day 5 after 
birth and fixed in 4% paraformaldehyde, decalcified by incubation in 12.5% sodium EDTA (pH 8.0) 
for 1 week at 4oC, embedded in paraffin wax and sectioned (5 |im) as described previously (22). The 
slides were dewaxed, rehydrated and pretreated with Proteinase K and acetic anhydride, and 
hybridized overnight at 55oC essentially as described previously (23). Constructs were cloned into 
pSKII- in the anti-sense orientation in the T7 promoter. RNA probes were generated by transcription 
of the T7 RNA polymerase in the presence of [a-35S]-uridine triphosphate (UTP). After hybridization,
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the slides were washed at high stringency for 30 min at 62oC, treated with RNase A for 30 min at 
37oC, washed again at high stringency, dehydrated and allowed to dry. Autoradiography was 
performed using Ilford G5 photo emulsion. The slides were exposed for 2 weeks at 4oC. Photographs 
were made from combined bright-field (blue filter) and dark-field images (red filter).
Plasmids and transfections
The mouse Tcf7 cDNA cloned in pcDNA1 was kindly provided by dr. Hans Clevers 
(Hubrecht Laboratory, the Netherlands), while the mouse Cbfa1 cDNA cloned in pBluescript and the 
p6OSE2 luciferase reporter construct were kindly provided by dr. Patricia Ducy (Baylor College of 
Medicine, Houston). The renilla reporter construct pRL-SV40 was purchased from Promega. The 
Tcf7 coding region was excised from the plasmid by HindIII / XbaI digestion and ligated into HindIII 
/XbaI-digested pcDNA3.1. The Cbfa1 coding region was excised from the plasmid by EcoRV/XbaI 
digestion and ligated into EcoR V /  XbaI-digested pcDNA3.1. The integrity of the resulting pTcf7-3.1 
and pCbfa1-3.1 plasmids was verified by DNA sequence analysis. For stable transfections, pTcf7-3.1 
was introduced into C2C12 cells using the Lipofectamin method according to the manufacturer’s 
specifications (Gibco/BRL). Monoclonal stable transfectants were selected on G418 (400 |ig/ml) and 
Tcf7 expression levels were analyzed by real-time RT-PCR. For transient transfections, pCbfa1-3.1, 
pTcf7-3.1, p6OSE2 and pRL-SV40 (Promega) were introduced into C2C12 cells using the 
Lipofectamin method according to the manufacturer’s specifications (Gibco/BRL). Twenty four hours 
after transfection, luciferase levels were measured .
Table 1. Protein functions represented on the microarray.
Group Subgroup Group Subgroup
Signal transduction and 
regulation
Extracellular messengers 
Receptors
Intracellular signaling 
Transcription factors
Adhesion and molecular 
recognition
Adhesion
Antigen recognition
Membrane Transport Channels and porins 
Transporters and pumps
Electron transfer Cytochromes 
Iron-sulphur proteins 
Flavoproteins 
Other
Protein modification and 
maintenance
Proteases 
Protease inhibitors 
Protein glycosyl transferases 
Protein lipid transferases 
Protein acetyl transferases 
Protein isomerases 
Chaperones
Localized and structural 
proteins
Extracellular matrix
Cell wall
Surface structure
Membrane
Periplasm
Cytoplasm
Cytoskeleton
Ribosome
Chromatin
Organelle
Nucleic acid synthesis and 
modification
Polymerases
Ligases
Nucleases
Methylases
Helicases
Topoisomerases
Recombinases
Splicing factors
Single stranded binding proteins 
Other
EST
Protein functions of the regulated genes were categorized according to Subgroups (Incytes Protein Function Hierarchy). 
Per gene only 1 functional group was assigned.
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Results
BMP2 induced expression profiles
Upon BMP2 treatment, C2C12 mesenchymal progenitor cells differentiate into osteoblastic 
cells, whereas they form myotubes in response to low serum conditions (24). Previously, we have 
shown that under identical experimental conditions as used here, C2C12 cells differentiate into 
osteoblasts which strongly express bone markers such as Alkaline phosphatase (ALP) and 
Osteocalcin (OCN) 2 days after BMP2 treatment (19). To identify novel potential regulators of 
BMP2-induced differentiation, we studied the onset of the differentiation process by microarray 
analysis (shown in Figure 1). Of the 9,330 genes spotted on the array, 184 sequences were found to 
exhibit significant (p<0.01) differential expression in the first 24 hours following BMP2 treatment.
Model-based clustering, a method recently described for efficient handling of microarray data 
(25, 26), was used to group the 184 genes by similarities in their expression profiles resulting in the 
identification of 10 distinct clusters. When classified into functional groups according to the function 
of their cognate protein (Table 1), the majority (94%) of the genes in our data set fell in the groups 
“Signal Transduction”, “Localized and Structural Proteins”, or “Expressed Sequence Tags” (ESTs). 
Figure 1 shows an overview of the clustering results and the distribution of the genes over the 
functional categories is indicated per cluster. Figure 1A shows the 6 clusters with genes for which the 
most notable differential expression is positive and Figure 1B shows the 4 clusters with genes for 
which this is negative. Globally, genes from clusters 2, 3, 4, 7 and 10 can be categorized as immediate 
early genes that display distinct regulation 2 hrs after BMP2 treatment. Clusters 5, 6 and 9 represent 
intermediate early genes that were regulated from 6 hrs onwards, and clusters 1 and 8 represent late 
early genes for which no expression regulation was observed until 24 hrs after BMP2 treatment.
Of the immediate early genes 90% (clusters 2, 3, 4 and 7) showed increased expression, while 
only 10% (cluster 10) exhibited decreased expression following BMP2 treatment. In contrast, the 
intermediate early responses showed a balance in up- and down-regulated genes (clusters 5, 6 and 
cluster 9 respectively). This indicates that the initial response to BMP2 is a transcriptional activation 
response. Furthermore, a time-dependent shift could be observed in the distribution of gene functions. 
Specifically, 65% (34 of 52) of the immediate early genes could be classified as Signal Transduction 
proteins, while only 12% (6 of 52) of these genes represented Structural proteins. During proceeding 
differentiation, less Signal Transduction related genes were regulated (17% and 28% for intermediate 
early and late early genes respectively), while an increasing number of Structural proteins were 
regulated (19% and 38% respectively). These Structural proteins include cell morphology-related 
genes such as the Troponins C and T and keratin complex genes, and matrix-related genes such as 
Procollagen IV a1 (Col4a1), Matrix gla protein, Nidogen1 and the Laminins a5 and P3. Using 
model-based clustering we have thus been able to distinguish different time-dependent expression 
profiles of the regulated genes that coincide with specific functions of the genes present in each 
cluster.
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Figure 1. Expression profiles of the significantly (p<0.01) regulated BMP2-responsive genes.
(A) Clusters of primarily up-regulated genes, (B) Clusters of primarily down-regulated genes. Genes regulated within 24 hrs after 
BMP2 treatment are shown, grouped according to Model-based clustering of 10log transformed microarray data (normalized on a 
scale to 1). Induction levels are indicated with different color intensities in red and blue, representing up-and down-regulation 
respectively. Protein function profile graphs show the number of genes within each cluster with a particular function. Genes with 
unknown function or other functions were labeled as “Other”. EST, expressed sequence tag; TF, transcription factor; Eme, 
extracellular messenger; IS, intracellular signaling protein; Rec, receptor; Ema, extracellular matrix protein; CPl, cytoplasmatic 
protein; CSk, cytoskeletal protein. See page 139 for full color figure
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ACCESSION# DESCRIPTION 
AA793036 Vascular endothelial growth factor 
Small inducible cytokine A2 
Gadd45a, growth arrest and DNA-damage-inducible o 
L-myc, lung carcinoma myc related oncogene 1 
Myog eni c d iff erenti ati on 1 
Si alyl transferase 4 
Cardiac morphogenesis (Xin)
ACCESSION#. 
AI 552496 
AI 391322 
AI 552711 
AA771647 
AA815689 
AA760135 
AI 465074 
AA822257 
AI 894014
I
AA117547
AA792499
W 16059
AA066615
AA067083
AI 326605
AA771566
AA116263
AA185112
AA288642
AA681235
AA690387
AA770924
AI 326574 
AA066390 
AI 549977 
AI 428595 
AA760161 
AA673869 
W76988 
AA571771
0 2 6 24 
HOURS
EXPRESSION PROFILE
DESCRIPTION
ESTs
Protein kinase inhibitor a 
Creatine kinase, muscle 
ESTs
Troponin C, cardiac/slow skeletal
Procollagen, type IV, a  1
Mesoderm specific transcript
Myosin light chain, alkali, fast skeletal muscle
Cholinergic receptor, nicotinic, y-polypeptide
Matrix y-carboxyglutamate (gla) protein
Cyclin D1
Ankyrin-like repeat protein
Glutathione S-transf erase co 1
Glycine amidinotransferase
High mobility group protein I
Cy cl in-dependent kinase inhibitor 1A (p21/WAF1)
Troponin C, fast skeletal
UDP-glucose ceram ide glucosyltransferase
ESTs
Cholinergic receptor, nicotinic, beta polypeptide 1 (muscle) 
ESTs
Xist gene (X inactivation transcript)
Troponin T3, skeletal, fast
Calsequestrin 2
Four and a half LIM domains 1
ESTs
ESTs
3-Phosphoglycerate dehydrogenase
ESTs
Mesothelin
VPS 10 domain receptor protein SORCS 2
X-linked nuclear protein
ESTs
FUNCTION PROFILE
12 16 20 24 
HOURS
n n n n
TF 1 EMe[ IS [ Re 
ESTs Signal Transductior
EMa CPI I CSk I 
Localised and 
Structural |0,hel
-2.33 -1.60 -1.25 1.25 1.60 2.33 
REGULATION ON MICROARRAY
IIIII
ACCESSION# DESCRIPTION
AI 390830 ESTs
AA124623 Ecotropic viral integration site 2
AI 552167 ESTs
AA619763 Cathepsin L
AA738820 Phosphoserine transferase
A1117310 Flavin containing monooxygenase 1
AA444581 EST
AA067625 Phosph ati date cytidylyl transferase
AA068116 Acetyl-Coenzyme A dehydrogenase, medium chain
AA386892 Dystrobrevin
AA606605 Nidogen 1
AA048101 Sema 4C precursor
AA217009 Tumor endothelial marker 8 (anthrax toxin receptor)
AA241390 Semaphorin 3E
AI607683 Semaphorin 7 A
AA684257 ESTs
AA596866 ESTs
AA879966 Laminina5
W89253 Insulin-like growth factor binding protein 5
AI325851 CD97 antigen
W36474 Metallothionein 2
W53231 CD82 antigen
AA105866 Glutathione S-transferase a 4
AI 510089 EST
AA725965 EST
AA798948 Caveolin, caveolae protein, 22 kDa
AA711869 Epidermal growth factor receptor pathway substrate 8
W34122 Bridging integrator 1 /  myc box dependent interacting protein 1
AA068464 Ect2 oncogene
AI323051 Growth associated protein 43
AA840053 Actinin alpha 2 associated LIM protein
AA617310 Zyxin
W99951 Neurofilament, light polypeptide
W13004 Prostaglandin l2(prostacyclin) synthase
AA023538 Semaphorin 6A
AA413490 Tran sferrinrece ptor
AA510298 Plasminogenactivator, urokinase
AA764163 Phospholipid scramblase 1
A1152562 Proliferin
AA867173 ESTs
AA222190 EIG180
AA516800 Death-associatedkinase2
A1152800 ESTs
AA061902 Apolipoprotein B editing complex 2
TF | EMe IS | Rec EMa| CPI | CSk
. .. Localised and 
ESTs Signal Transduction structural Otnei
ClusterlO ACCESSION# DESCRIPTION 
T~| AA475186
________  W 14224
________ AA162217
U m  AA437755 
--------------- AA596753
ESTs
Ndr1, N-myc downstream regulated 1 
Pbef, pre-B-cell colony-enhancing factor 
ESTs 
I at exin
TF I EMe I IS I Rec EMa| CPI I CSk 
. . .  Localised and 
ESTs Signal Transduction efnirhiral Otnei
Figure 1, continued. See page 140 for full color figure
Validation of the microarray data
We and others have shown previously that microarray data are highly comparable with results 
obtained using other methods such as real-time RT-PCR and Northern blotting, but that the ratio of 
expression regulation measured with these other methods vary probably due to the distinct 
hybridization conditions of the various methodologies (20, 27). To validate the expression profiles
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measured in this microarray experiment, 52 genes were tested as representatives of all 10 clusters 
both in original RNA material used for the microarray and in RNA material obtained from an 
identical but independent experiment by real-time RT-PCR. The expression profiles of 92% (48 out 
of 52) of the genes tested was confirmed (Table 2). Only the expression pattern of genes present in 
cluster 4, which were relatively weakly regulated and reached a maximum of 1.4-fold expression 
regulation, could not be confirmed. In conclusion, using real-time RT-PCR, we have been able to 
confirm both the pattern of the expression profiles as well as the level of differential expression 
regulation for the majority of the genes in this microarray experiment.
Table 2. Validation of the microarray data
Accesion # Description Cluster Expression
profile
Accesion # Description Cluster Expression
profile
AI552130 Heyl 1 + AW210425 Slc20a1 3 +
AI386062 Car3 1 + W18822 Gadd45y 3 +
AA450795 CCK 1 + AA517353 Nfkbia 3 +
AA667906 Cyr2 1 + AA982549 Placental Growth 3 +
factor
AA958693 Tcf7 1 + AA895566 Gadd45p 3 +
W81878 Osf2 (fasciclin) 1 + AA036380 Snail 3 +
AI510076 OASIS 2 + AA733791 Ddrl 3 +
W97877 Prrx2 2 + AA162153 Mcsf 3 +
AA145784 Timp3 2 + AA427234 Vegf 3 +
AA833402 Similar to Ier3 2 + AA879919 Tissue factor 3 +
W08321 Idl 2 + AA536836 bHLHB2 4 -
AI322367 Id2 2 + AI595201 HB-EGF 4 -
AA066816 Id3 2 + AA832598 EST 4 -
AA733600 Klf4 2 + AA271866 Pla2y 4 -
AA466979 Similar to CoA 2 + AA238037 Imap38 5 +
dehydrogenase
AI427265 Smad6 2 + AA796818 Isg15 5 +
AA545284 Smad7 2 + AA549591 Exportin l 6 +
AA028420 Sprrl a 2 + AA108600 CPO 6 +
AI551955 EST 2 + AA152636 Int4a 6 +
AI587984 GPR97 2 + AA796822 Siat4c 7 +
AA646509 Tieg 2 + AA501052 Xin 7 +
AI604159 Similar to frizzled 2 + AI323202 Scya2 7 +
AA415211 Musk 2 + AA437694 MyoD 7 +
AI430581 Cytidine deaminase 2 + AA606331 L-myc 7 +
AA197529 Lunatic fringe 2 + AA067083 Hmgal 8 +
W34122 Binl 9 +
W14224 Ndrl 10 +
Expression profiles identified by microarray analysis were tested for confirmation by real-time RT-PCR. +, expression pattern 
confirmed; -, expression pattern not confirmed; Hey1, hairy/enhancer-of-split related with YRPW motif; Car3, carbonic anhydrase 
3; CCK, cholecystokinin; Cyr2, cysteine-rich protein 2; Tcf7, T-cell specific transcription factor 7; Osf2 (fasciclin), fasciclin I like 
osteoblast specific factor 2; OASIS, old astrocyte specifically induced substance; Prrx2, paired related homeobox 2; Timp3, tissue 
inhibitor of metalloproteinase 3; Ier3, immediate early response 3; Id1, inhibitor of DNA binding 1; Id2, inhibitor of DNA binding 
2; Id3, inhibitor of DNA binding 3; Klf4, kruppel like factor 4 (gut); CoA dehydrogenase, coenzyme A  dehydrogenase; Smad6, 
MAD homolog 6; Smad7, MAD homolog 7; Sprr1a, small proline-rich protein 1A; EST, expressed sequence tag; GPR97, G- 
protein coupled receptor 97; Tieg, TGFp inducible early growth response; Musk, neural fold/somite kinase 2; Slc20a1, solute 
carrier family 20 member 1; Gadd45p, growth arrest and DNA damage inducible p; Ddr1, cell adhesion kinase 1; Mcsf, 
macrophage colony stimulating factor; Vegf, vascular endothelial growth factor; bHLHB2, basic helix-loop-helix domain 
containing class B2; HB-EGF, heparin binging epidermal growth factor; Pla2y, Ca2+"independent phospholipase A2 gamma; 
Imap38, immunity associated protein 38kDa; Isg15, ubiquitin cross reactive protein 15kDa; CPO, coproporphyrinogen oxidase; 
Int4a, integrin 4a; Siat4C, sialyltransferase 4C; Xin, caridac myogenesis 1; Scya2, small inducible cytokine 2; MyoD, myogenic 
differentiation 1; L-myc, lung carcinoma myc related oncogene 1; Hmga1, high mobility group protein 1; Bin1, bridging integrator 
1; Ndr1, N-myc downstream regulated 1.
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Transcriptional regulators of osteoblast differentiation
To identify novel potential regulators of osteoblast differentiation, we primarily focused on 
the transcription factors with altered expression during differentiation. In the complete set of 184 
regulated sequences, 17 transcription factors were identified (Table 3). The real-time RT-PCR 
analysis described above, confirmed the BMP2-induced differential expression for 15 out of the 17 
transcription factors. It should be noted that on the microarray, sequences uniquely representing the 
bone-specific Cbfa1 isoform (Type II) were not present. Hence, type II Cbfa1 was not included in our 
microarray data set.
Table 3. Gene expression characteristics of osteoblast differentiation related transcription factors
Accession
#
Description Type Cluster
#
Category Expression
profile
Cell type 
specificity
CHX
dependent
Cbfal, type IIa late early osteoblast yes
AI552130 Heyl Helix-loop-helix l late early + osteoblast partly
AA958693 Tcf7 HMG box l late early + osteoblast yes
AI510076 OASIS Leucine zipper 2 immediate early + no no
W97877 Prrx2 Homeo domain 2 immediate early + no no
W08321 Idl Helix-loop-helix 2 immediate early + no no
AI322367 Id2 Helix-loop-helix 2 immediate early + no no
AA066816 Id3 Helix-loop-helix 2 immediate early + no no
AI427265 Smad6 MH domain 2 immediate early + no no
AA545284 Smad7 MH domain 2 immediate early + no no
AA646509 Tieg Zinc finger 2 immediate early + no no
AA036380 Snal Zinc finger 3 immediate early + no no
AI549669 TSC22 Leucine zipper 2 immediate early - n.d. n.d.
AA536836 bHLHB2 Helix-loop-helix 4 immediate early - n.d. n.d.
AA606331 L-myc Helix-loop-helix + 7 immediate early + myoblast n.d.
Leucine zipper
AA437694 MyoD Helix-loop-helix 7 immediate early + myoblast n.d.
AA733600 Klf4 Zinc finger 2 immediate early +b no n.d.
AA067083 Hmgal HMG box 8 late early +b no n.d.
Data on the 17 transcription factors modulated by BMP in the microarray experiments were compared with type II Cbfa1. Type of 
transcription factor, cluster number and cluster category are listed. Expression profiles identified by microarray analysis were 
verified by real-time RT-PCR, +: expression pattern confirmed, -: expression pattern not confirmed. Cell type specific expression 
regulation (Figure 2) and dependence on de novo protein synthesis indicated. For the de novo protein synthesis experiment, cells 
were pretreated for half an hour with DMEM containing 5% NCS in the absence or the presence of cyclohexamide (CHX, 50^M) 
after which cells were stimulated with BMP2 (300 ng/ml) in the absence or presence of cyclohexamide. Expression regulation was 
analyzed by real-time RT-PCR. Abbreviations used: n.d., not done; Cbfa1, type II, core binding factor 1, type II isoforms; Hey1, 
hairy/enhancer-of-split related with YRPW motif 1; Tcf7, T-cell specific transcription factor 7; OASIS, old astrocyte specifically 
induced substance; Prrx2, paired related homeobox 2; Id1, inhibitor of DNA binding 1; Id2, inhibitor of DNA binding 2; Id3, 
inhibitor of DNA binding 3; Smad6, MAD homologue 6; Smad7, MAD homologue 7; Tieg, TGFp inducible early growth 
response; Sna1, snail homologue; TSC22, TGFp stimulated protein 22; bHLHB2, basic helix-loop-helix domain containing class 
B2; L-myc, lung carcinoma myc related oncogene 1; MyoD, myogenic differentiation 1; Klf4, kruppel like factor 4 (gut); Hmga1, 
high mobility group protein 1; a, not identified in the microarray experiment, but used as a positive control; b, very low levels of 
expression regulation.
Transcription factors that are specifically expressed in osteoblasts but not in other cell types 
are likely to be regulators of osteoblast differentiation. We analyzed the cell type specificity for 13 
transcription factors that showed a robust response to BMP2 treatment compared to control medium 
(Table 3). To this end, gene expression regulation by BMP2 was assessed in mouse C2C12 and 
C3H10T1/2 mesenchymal progenitor cell lines, which both can differentiate into osteoblasts, and for
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comparison, in NIH3T3 fibroblasts, which can not differentiate into osteoblasts (Figure 2). To test the 
validity of this approach, expression regulation of the bone-specific isoform of Cbfa1 (Cbfa1, type II) 
was analyzed by real-time RT-PCR in all three cell types and compared to expression regulation of 
sequences correlating with all isoforms (Cbfa1, bipartite sequences). Figure 2A shows a 5-fold BMP- 
specific induction for Cbfa1 type II in the osteoblastic cell types after 24 hrs, while no expression 
regulation was detected in the NIH3T3 fibroblasts. In contrast, the Cbfa1 bipartite sequences 
displayed low levels of BMP2-induced expression in the C2C12 cells, while no differential 
expression was observed in the C3H10T1/2 or NIH3T3 cells. These data show that this approach 
enables us to discriminate between osteoblast-restricted and common BMP responses.
Figure 2. BMP-induced expression profiles in osteoblastic and non-osteoblastic cell lines.
Expression profiles of the transcription factors in C2C12, C3H10T1/2 and NIH3T3 cells. (A) Expression profiles of Cbfal 
isoforms, (B) Expression profiles of the 13 transcription factors. Cells were seeded and grown for 24 hrs upon which the medium 
was replaced by DMEM containing 5% NCS in the presence or absence of BMP2 (300 ng/ml). RNA was isolated 0 hr, 2 hrs, 6 hrs 
and 24 hrs after stimulation. Subsequently, expression levels were measured by quantitative real time RT-PCR.
Subsequently, the expression regulation of the l3 transcription factors was tested for cell type 
specificity (Figure 2B and Table 3). Nine of these transcription factors were regulated in response to 
BMP2 treatment in all three cell lines to approximately the same extent and will further be referred to 
as “general BMP-response transcription factors”. The genes L-myc and MyoD were only expressed in 
C2Cl2 cells. C2Cl2 cells differentiate into myoblasts under low serum conditions whereas 
C3Hl0Tl/2 cells do not, therefore these transcription factors could be characteristic for the pre- 
myoblastic phenotype of C2Cl2 cells. Finally, the transcription factors Heyl and Tcf7 showed 
specific BMP2-induced up-regulation in both C2Cl2 and C3Hl0Tl/2 cells, similar to the osteoblast
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specific transcription factor Cbfa1 type II, but were not or very weakly regulated in NIH3T3 cells. 
These results suggest that the BMP2-induced regulation of Hey1 and Tcf7 is osteoblast specific.
To be able to distinguish between direct and indirect effects in response to BMP2, we 
analyzed gene expression in the presence or absence of cyclohexamide (Chx), an inhibitor of de novo 
protein synthesis. The data summarized in Table 3 shows that the immediate early general BMP- 
response transcription factors were not dependent on protein synthesis for their BMP2-induced gene 
expression, at least at the 2 hr and 6 hr time points. Messenger RNA of some of these genes was 
actually superinduced in the presence of BMP2 and Chx, probably as a result of an increase in mRNA 
stability or loss of transcriptional repressors by Chx as previously reported for Smad7 (28). 
Furthermore, the late early genes Tcf7 and Cbfa1 type II were fully impaired in their BMP2-induced 
expression in the presence of cyclohexamide. Induction of Hey1 was severely repressed due to Chx 
treatment, but its expression was still induced over 13 fold at 24 hrs in the presence of the protein 
synthesis inhibitor, which suggests that regulation of Hey1 might be both direct and indirect. These 
results indicate that the classification of the genes based on our clustering method correlates with de 
novo protein synthesis-dependent transcription regulation.
Expression of Hey1 and Tcf7 during mouse development
Results obtained from the above described experiments, indicate that Hey1 and Tcf7 could be 
potential novel regulators of osteoblast differentiation. To study the involvement of both genes in 
embryonic bone development, expression of these genes was analyzed in mouse embryos at E14.5 
and E16.5 of gestation and in neonatal mouse tails by the use of in situ hybridization. Neonatal mouse 
tails were used because their primary centers of endochondral ossification are still developing in the 
most distal vertebrae. These vertebrae consist of alkaline phosphatase-negative cartilage whereas the 
most proximal vertebrae are alkaline phosphatase-positive and mineralized (22). The expression 
patterns of Tcf7 and Hey1 were compared with that of Cbfa1, which has previously been shown to be 
expressed during early skeletal development, in cells of mesenchymal condensations, and in the 
osteoblast lineage. In later development it is expressed in ossification centers of all bones, 
independent of their embryonic origin and mechanism of ossification (intramembraneous or 
endochondral), but not in hypertrophic chondrocytes (4). We first confirmed the expression of Cbfa1 
at E14.5 in bone in transverse sections of the head at the level of the jaws (Figure 3A), at E16.5 in 
sagital sections of the head at the level of the nasal cavities (Figure 3D) and in proximal vertebrae of 
the mouse neonatal tail (Figure 3G). The ossification centers of the developing mandibular and 
maxillary bones, nasal bone, clavicle, humurus, and scapula as well as proliferating chondroblasts, 
periosteal osteoblasts and trabecular osteoblasts all showed clear expression of Cbfa1, as expected 
(4). In agreement with previous data, high levels of Cbfa1 expression were also observed in the 
mandibular region/dental mesenchyme surrounding the developing tooth (19).
The Tcf7 gene showed an expression pattern remarkably similar to that of Cbfa1 in embryos 
at E14.5 and E16.5 of gestation (Figures 3B and 3E). Except for the C1 vertebra, expression of Tcf7 
was observed in all bones analyzed, although restricted to the periosteum/compacted mesenchyme of 
these bones. In the mouse neonatal tail vertebrae, both the periosteal and trabecular osteoblasts 
showed high levels of Tcf7 expression similar to Cbfa1, but no expression of Tcf7 was observed in 
proliferating chondroblasts (Figure 3H). With respect to the Hey1 gene, no expression could be 
detected in the clavicle, humurus, scapula or C1 vertebra. However, low but significant levels of 
expression were observed in the mandibular and maxillary bones (Figures 3C and 3F). Specifically, 
Hey1 expression was restricted to the central parts of the bones (trabecular bone) and was absent in 
the periosteum. In the newborn tail vertebrae, the Hey1 gene showed specific expression in trabecular 
osteoblasts, albeit somewhat weaker than the Cbfa1 and Tcf7 genes (Figure 3I). These data show that
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the two osteoblastic transcription factors identified in this study are expressed during in vivo bone 
differentiation, with individual expression patterns similar but not equal to Cbfa1.
Cbfal Tcf7 Hey1
E14.5
E16.5
newborn 
tail vertebrae
Figure 3. In vivo expression o f Hey1 and Tcf7 in the developing mouse skeleton.
(A-C) Transverse sections of E14.5 mouse embryos at the level of the jaws for the control osteoblast marker Cbfa1 (A), Tcf7 (B) 
and Hey1 (C), (D-F) Sagital sections o f E16.5 mouse embryos at the level o f the nasal cavities for Cbfa1 (D), Tcf7 (E) and Hey1 
(F), (G-I) Mouse proximal tail vertebrae for Cbfa1(G), Tcf7 (H) and Hey1 (I). Abbreviations used: bm, bone marrow; C1v, 
cartilage primordium of C1 vertebra; cl, clavicle; h, cartilage primordium of humurus; hc, hypertrophic chondroblasts; id, 
intervertebral disc; Jo, Jacobson’s organ; M, Meckel’s cartilage; md, mandible; mx, maxilla; nc, nasal cavity; nca, nasal capsule; P, 
periosteal bone; pc, proliferating chondroblasts; sc, scapula; T, trabecular bone; tg, tongue; to, tooth; vb, vertebral body. See page 
141 for full color figure
Tcf7 differentially affects BMP2-induced osteoblast differentiation
To further investigate the role of Tcf7 and Hey1 expression during osteoblast development, 
we introduced expression vectors for their cognate genes into C2C12. We identified cells expressing 
high levels of Tcf7 (Figure 4A), but were unable to isolate clones over-expressing Hey1 (results not 
shown). The differentiation capacity of Tcf7-overexpressing cells (C2C12-Tcf7) was assessed by 
measuring ALP activity, as well as the expression of the myogenic differentiation markers Myogenin 
and MyoD and of the osteogenic differentiation markers ALP, Wnt inhibitory factor 1 (Wif1) (19), 
Cbfa1 and OCN following BMP2 treatment. The data represented in Figures 4B and 4C show that the 
C2C12-Tcf7 cells were still able to differentiate to the osteoblast lineage as evidenced by the 
induction of ALP activity and transcripts as well as the induction of the late phase differentiation 
marker Wif1. The levels of these markers were slightly elevated in the C2C12-Tcf7 cells compared to 
the control cells. In contrast, the expression of Cbfa1 was slightly lower in C2C12-Tcf7 cells whereas 
the expression of OCN was completely abrogated. These data suggest that Tcf7 differentially affects 
osteoblast differentiation.
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Figure 4. BMP2-induced osteoblast differentiation in C2C12-Tcf7 
cells.
(A) Expression of Tcf7 in C2C12-Tcf7 cells. Expression levels were 
measured by quantitative real-time RT-PCR. (B) Dose-dependent 
induction of ALP activity 48 hrs after BMP2-treatment, (■) C2C12 
cells, (• )  C2C12-Tcf7 cells. (C) BMP2-induced expression profiles. 
mRNA was used to measure the expression of two myogenic and four 
osteoblast marker genes at the indicated time points. Mean expression 
levels were corrected for GAPDH and are expressed relative to the 
basal expression level in unstimulated C2C12 cells. Error bars indicate 
differences between duplicate experiments. (D) Tcf7 represses Cbfa1- 
mediated activation of the osteocalcin promoter in C2C12 cells. Cells 
were transfected with pRL-SV40 (50 ng) and p6OSE2 (100 ng). 
Expression vectors pCbfa1-3.1 (50 ng) and/or pTcf7-3.1 (100 ng) 
were added as indicated. Reactions were supplemented with 
pcDNA3.1 vector DNA to a total of 500 ng DNA in each reaction. 
Luciferase activation levels were corrected for renilla levels and are 
represented as fold activation over control. The luciferase values 
represent the means of triplicate samples ± S.E.
In control C2C12 cells, the expression of the myogenic differentiation markers Myogenin and 
MyoD was induced during conditions that favor myoblast differentiation and repressed upon BMP2 
treatment. In contrast, the C2C12-Tcf7 cells failed to induce Myogenin and MyoD transcription under 
myogenic differentiation conditions, indicating that differentiation was impaired. The abrogation of 
OCN expression in the C2C12-Tcf7 cells could be a result of the slightly reduced Cbfa1 levels in 
these cells or from a direct action of Tcf7 on OCN transcription. The latter notion is in line with 
published data that show that Lymphoid enhancer binding factor 1 (Lef1), a functional homologue of 
Tcf7, represses Cbfa1-dependent transcription from the OCN gene promoter (29). The repression of 
Lef1 is mediated through direct interaction with Cbfa1 and could be visualized on p6OSE2, which 
contains an artificial promoter consisting of 6 Cbfa1 recognition sites upstream of the basal 
osteocalcin promoter (-34/+13), and a luciferase reporter gene. To investigate whether a similar 
mechanism could play a role in our system, we co-transfected combinations of Tcf7, Cbfa1 and 
p6OSE2 into C2C12 cells. As expected, Cbfa1 but not Tcf7 induced activity of the luciferase reporter 
(Figure 4D). Interestingly, co-expression of Tcf7 significantly reduced the Cbfa1-induced activity of 
the reporter. The SV40 promoter driven expression of the renilla-reporter gene that was co-transfected 
to monitor differences in transfection efficiency was not affected by Tcf7 (results not shown), 
indicating that the observed effect is specific for Cbfa1 driven transcription.
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Discussion
Genetic cascades regulated during the initial phase of differentiation guide mesenchymal stem 
cells to become osteoblasts, and activating and repressing transcription factors are very important in 
directing this differentiation process. In our data set of 184 regulated genes and ESTs, we observed an 
immediate up-regulation of transcription factors and other Signal Transduction proteins (2 hrs), but a 
slight delay in the repression of genes such as those related to myoblast differentiation (6 hrs). The 
near absence of repression of gene expression 2 hrs after BMP treatment observed in this study might 
be a reflection of the observation that Smads are transcriptional activators that first need to activate 
transcriptional repressors to inhibit gene expression (30). In accordance with this, a number of 
transcription factors have been identified among the immediate early genes, such as the inhibitor of 
differentiation (Id) genes (Id1, Id2 and Id3) and the Transforming growth factor pi-induced transcript 
4 (TSC-22) gene, that can function as transcriptional repressors (31, 32). The immediate early 
transcription factors may subsequently regulate the expression of genes involved in remodeling of cell 
architecture (between 6 and 24 hrs). However, commitment to the osteogenic lineage was not 
apparent until 24 hrs, when the osteoblast specific transcription factor Cbfai and the novel osteoblast- 
related genes Hey1 and Tcf7 were found to be regulated. Previously, we have shown that the onset of 
regulation of bone markers such as ALP and OCN starts around 48 hrs of BMP treatment (19). These 
results are slightly different from data reported recently by Balint and coworkers who showed both 
activation and repression of differentiation-related genes within the first hours of osteoblast 
differentiation, followed by commitment and establishment of the bone phenotype in C2C12 cells 
within 24 hrs of BMP treatment (33). It should be noted here, that there are substantial differences in 
the experimental design, such as the cell density at the onset of BMP treatment and the absence of 
serum in their experiments that might explain the observed differences.
Our study identified 15 transcription factors that are induced within the first 24 hours of 
BMP2 induced osteoblast differentiation. We investigated whether additional osteoblast related 
transcription factors might be identified among the 3 immediate early ESTs identified in this study. 
However, in silico sequence analysis did not reveal specific DNA binding domains or characteristic 
transcription activating domains, suggesting that these ESTs are not novel transcription factors 
(results not shown). Of the 15 known transcription factors in our dataset, 9 immediate early general 
BMP-response transcription factors did not display osteoblast specific expression regulation, but were 
specifically induced by BMP2 and therefore might have a function in the regulation of osteoblast 
differentiation. Indeed, 8 out of these 9 transcription factors have previously been reported to be 
involved in osteoblast differentiation or function. OASIS has been described to be expressed in pre­
osteoblasts in vivo and its expression pattern coincides with that of Osteopontin (34). Prx2 cooperates 
with Prx1 in regulating skeletogenesis in the craniofacial region, inner ear and limbs, as was shown in 
knock-out experiments (35). Transient induction of the Id genes by BMP has previously been 
described in osteoblastic cells (24, 36-38) and Id1 was found to be able to inhibit OCN gene 
expression (39). Furthermore, Smad6 and Smad7 are negative regulators of the BMP signal 
transduction pathway capable of repressing BMP-induced osteoblast differentiation (40, 41). Tieg 
was first identified in human osteoblastic cells (42) and is able to induce ALP expression and inhibit 
OCN expression in human osteoblasts similar to TGF-P (43). Until now, direct involvement of Sna1 
in osteoblast differentiation has not been reported. However, Sna1 has been described to be an 
inhibitor of E-cadherin expression in different cell types (44-46), and E-cadherin itself has been 
reported to be essential for optimal BMP-induced osteoblast differentiation (47), suggesting that Sna1 
might be indirectly involved in osteoblast differentiation.
Although bone is a highly specialized tissue, osteoblasts have previously been described as 
sophisticated fibroblasts, exhibiting only a few osteoblast specific transcription factors and marker
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genes, such as Cbfal, Osx and OCN (3). It could be postulated that to establish a highly specialized 
tissue such as bone, the action of several specific key regulatory transcription factors might not be 
required. Instead, a limited set of osteoblast-specific transcription factors in combination with general 
BMP-responsive transcription factors might be sufficient for guiding a mesenchymal stem cell to 
become a mature osteoblast. In our experiments, BMP2-induced transcription of Heyl and Tcf7 was 
restricted to osteoblastic cells, suggesting that these factors may contribute to further specifying 
osteoblast fate delineated by bone specific transcription factors like Cbfal and Osx. This notion is 
further substantiated by our observation that both Heyl and Tcf7 are expressed in developing bone 
tissues in vivo.
Heyl belongs to the Hairy and enhancer of split (Hesl) family of transcription factors and is a 
primary target of Notch (48), which has been reported to inhibit osteoblast differentiation (49, 50). 
Heyl functions as an inhibitor of myoblast differentiation in C2Cl2 cells (5l) and is able to associate 
to its family member Hesl and form stable heterodimers with Hesl upon DNA binding (48). Hesl 
has been reported to be a negative regulator of osteoblast differentiation (52), but it can also stimulate 
the trans-activating function of the osteoblast specific transcription factor Cbfal (9). To the best of 
our knowledge Heyl knock-out mice have not been reported and Heyl has not previously been 
reported to be involved in osteoblast differentiation. Our in vitro data indicate that Heyl expression 
by BMP2 is restricted to osteoblasts and not observed in fibroblasts. Furthermore, Heyl is expressed 
during in vivo bone formation with an expression pattern that partially overlaps with that of Cbfal and 
Tcf7. We speculate that Heyl might affect osteoblast differentiation in a comparable manner to or in 
association with Hesl. This putative mechanism is the subject of our current studies.
Tcf7 is a member of the T lymphocyte-specific enhancer / Lymphoid enhancer binding factor 
(Tcf/Lef) family and an effector of Wnt signaling (53). The canonical Wnt pathway has been 
implicated in the control of bone mass and osteoblast differentiation. Inactivating mutations in the 
Wnt co-receptor LRP5 decrease bone accrual during growth whereas activating mutations lead to a 
high bone mass phenotype (54), and stabilized P-catenin in osteoblasts enhances their differentiation 
capacity (55, 56). However, the downstream effectors of Wnt/p-catenin in osteoblasts remain to be 
established. Our data indicate that Tcf7 is a BMP2 target gene in osteoblasts but not in fibroblasts. In 
vivo, expression of Tcf7 has been reported during embryonic bone development up to embryonic day 
(E)l4.5 (57). Our data confirm and extend these results and show that Tcf7 expression at El4.5 and 
El6.5 of gestation is highly but not completely similar to Cbfal expression. In the developing mouse 
tail, Tcf7 expression is limited to osteoblasts and, unlike Cbfal, not seen in hypertrophic 
chondrocytes. It is tempting to speculate that Tcf7 plays a role as a downstream effector of 
BMP2/Wnt signaling and provides a molecular access point where these two signaling pathways 
integrate. In C2Cl2 cells that over-express Tcf7, we observed a down-regulation of Myogenin and 
MyoD similar to the down-regulation mediated by Cbfal (58), suggesting a role of Tcf7 in 
suppression of myogenic differentiation. In addition, we observed a BMP2-dependent differential 
effect on expression of genes that mark osteoblast differentiation. Our observation that Tcf7 
suppresses Cbfal-induced transcriptional activity of the p6OSE2 reporter is in perfect agreement with 
published work that showed that the Tcf7 family member Lefl exerts an identical effect on Cbfal- 
mediated transcription (29). The exact mechanisms by which Tcf7 modulates osteoblast and/or 
myogenic differentiation are not clear and the subject of our current investigations.
In conclusion, our results show that BMP-induced osteoblast differentiation employs a 
cascade in which the initial phase of differentiation is based on general BMP-response genes. During 
the progression of osteoblast differentiation, osteoblast commitment genes and osteoblast specific 
genes are regulated in concert with general BMP-response genes, which ultimately leads to a 
functional osteoblast. In addition, Heyl and Tcf7 have been identified with similar expression
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characteristics as the osteoblast specific transcription factor Cbfa1, and Tcf7 was shown to modulate 
BMP2-induced osteoblast differentiation. Further elucidation of the function of these transcription 
factors in osteoblast differentiation may contribute to drug target research to treat bone diseases such 
as osteoporosis.
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Abstract
The bone morphogenetic protein (BMP)-induced Smad signal transduction pathway is an 
important positive regulator of osteoblast differentiation. BMP and other members of the 
transforming growth factor P (TGF-P) family have distinct effects on osteoblast differentiation, 
depending on cell type and cell differentiation status. In C2C12 mesenchymal cells, BMP-induced 
osteoblast differentiation can be blocked by TGF-p. In a search for key regulators of osteoblast 
differentiation we have used microarray analysis to identify genes which are differentially regulated 
by BMP2 and TGF-P. Within the first 24 hours following the onset of differentiation, 61 BMP2- 
regulated genes were identified of which the BMP2 effect was counteracted by TGF-p. The majority 
of these differentially expressed transcripts are related to signal transduction. Notably, our data show 
that three Notch signal transduction pathway genes, Lfng, Hey1 and Hes1, are differentially regulated 
by BMP2 and TGF-P. This suggests that these genes might function as the focal point for interaction 
of Smad and Notch signaling during osteoblast differentiation.
Introduction
Bone morphogenetic proteins (BMPs) are the most potent of all inducers of osteoblast 
differentiation. Although the BMPs were first identified for their ability to induce ectopic bone 
formation in vivo (1), these proteins appear to be multifunctional regulators of morphogenesis during 
embryonic development (2). Transforming growth factor-P (TGF-P), a protein closely related to the 
BMPs, is also able to regulate osteoblast differentiation. However, regulation by TGF-P is more 
complex, since it can both inhibit and stimulate osteoblast differentiation depending on the cell type 
and its differentiation status (3-5).
To generate biological responses, TGF-P family members use heteromeric complexes of so- 
called type I and type II serine/threonine kinase receptors, resulting in the activation of specific 
receptor-regulated Smads (R-Smads). These include Smad-2 and -3, which are specific for TGF-P 
signaling, while Smad-1, -5 and -8 have been shown to be BMP responsive R-Smads. In combination 
with the common mediator Smad-4, the respective R-Smads are assembled into heteromeric 
complexes, which subsequently translocate to the nucleus, where they act in concert with other 
proteins as transcription factor complexes (6-8).
In addition to the Smad-mediated BMP pathway, several other major signaling pathways are 
known to play a role during osteoblast differentiation. These include the Wnt/P-catenin pathway (9­
12), the Notch pathway (13, 14) and the different MAP-kinase pathways (15-19). However, the 
interplay between these various pathways in osteoblast differentiation is still poorly understood.
In the C2C12 mouse mesenchymal progenitor cell line, osteoblastic differentiation can be 
induced by BMPs, while TGF-P1 is not able to do so, and even inhibits BMP2-induced differentiation 
(20). BMP2 and TGF-p partially share the same Smad signal transduction route and have many target 
genes in common. Given the differential effect of TGF-p and BMP2 on C2C12 differentiation, genes 
that are differentially affected by the two cytokines might function as important regulators of 
osteoblast differentiation. Previously, we have shown that the commitment to the osteoblast 
phenotype is determined within the first 24 hours following stimulation with BMP2 (21). In this 
study, we have compared BMP2-induced gene expression levels with those of TGF-P and a 
combination of these two growth factors in a 24 hour time frame. Notably, several members of the 
Notch signaling pathway were differentially affected by BMP2 and TGF-p, suggesting that BMP- 
induced modulation of Notch activity may be a key element in regulating osteoblast differentiation.
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Materials and Methods 
Tissue culture and growth factors
The C2C12 murine mesenchymal progenitor cell line (obtained from the American Type 
Culture Collection) was maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10% newborn calf serum (NCS), penicillin (100 U/ml) and streptomycin (100 |ig/ml) as 
described previously (21). For the various experiments, cells were plated at a density of 2.0x104 
cells/cm2 and grown for 24 hours in DMEM supplemented with 10% NCS. Subsequently, medium 
was replaced by DMEM containing 5% NCS (control medium) either in the presence or in the 
absence of 300 ng/ml recombinant human BMP2 with or without 5 ng/ml human recombinant TGF- 
P1. Recombinant human BMP2 was kindly provided by Wyeth (Andover, MA) and recombinant 
human TGF-P1 was purchased from R&D Systems (Minneapolis, MN).
RNA isolation
Total RNA was extracted according to an acid guanidium thiocyanate-phenol-chloroform 
method (TriPure® Isolation Reagent, Roche Diagnostics, Germany) and RNA concentrations were 
determined by measuring the absorbance at 260 nm. Poly A+ RNA was prepared from total RNA 
using the Oligotex™ method (Qiagen, Valencia, CA). Quantification of polyA+ RNA was carried out 
according to the Ribogreen™ RNA quantitation assay (Molecular Probes, Eugene, OR).
Gene Microarray Analysis
Microarray analysis was performed as described previously (22). For the hybridization 
experiments, RNA from growth factor-treated cells was hybridized versus RNA from control cells 
using the mouse Unigene 1 array from Incyte Genomics (Palo Alto). The hybridization experiments 
were performed in duplicate with a fluor reversal to minimize possible bias caused by the molecular 
structure of the Cy3 and Cy5 dyes. Background-subtracted element signals were used to calculate 
Cy3/Cy5 ratios. Genes were selected for further analysis if the signal to background ratio for a 
particular gene was >2.5 and at least 40% of the area on chip could be used for signal computation in 
at least one of the two channels. To account for systematic errors caused by non-linear differences in 
signal intensities of the Cy3 or Cy5 channel, statistical analysis was performed as described 
previously (22). Genes with significant (p<0.05, >1.5 fold) differential expression in at least one of 
the treatments were selected for further analysis. Subsequently, the genes were subdivided into 9 
categories according to their differential regulation by BMP2 (B), BMP2 plus TGF-P1 (BT), and 
TGF-P1 (T) as follows: Category 1. B>BT>T; Category 2. B<BT<T; Category 3. B>BT=T; Category 
4. B<BT=T; Category 5. B>BT<T; Category 6. B<BT>T; Category 7. B=BT<T; Category 8. 
B=BT>T and Category 9. B=BT=T, with the assumption that B=BT or BT=T when the abslolute 
difference between induction levels was less than 0.1. Protein functions of the genes were identified 
according to the Gene OntologyTM Database.
Real-time RT-PCR
For real-time RT-PCR, the ABI Prism Sequence Detection System 5700 and Primer 
ExpressTM software (PE Biosystems) were used. For each gene, a set of primers was designed using 
sequences obtained from Genbank™ All primers generated amplicons of 50-100 base pairs with 
melting temperatures between 58oC and 60oC. Prior to complementary DNA (cDNA) synthesis, 2 |ig 
of total RNA were DNase (Invitrogen) treated for 15 min at 37oC, after which RNA was reverse 
transcribed using random hexamer primers (Amersham Pharmacia) in a total volume of 50|il using 
the SUPERSCRIPTTM II reverse transcriptase kit (Invitrogen). Subsequently, aliquots of first strand
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cDNA (2 |il) were amplified using SYBR Green® PCR Mastermix (Applied Biosystems) under the 
following conditions: initial denaturation for 10 min at 94oC followed by 40 cycles consisting of 15 
sec at 94oC and 1 min at 60oC. Fold inductions and expression ratios were calculated from differences 
in threshold cycles at which an increase in reporter fluorescence above a baseline signal could first be 
detected (CT) between two samples, and averaged for duplicate experiments.
Results
Expression profiles of genes differentially regulated by BMP2 and TGF-fi
Upon BMP2 treatment, C2C12 mesenchymal progenitor cells differentiate into cuboidal- 
shaped osteoblastic cells, whereas they form myotubes in response to low serum conditions without 
BMP2 (Figure 1). TGF-P1 is unable to induce differentiation of C2C12 cells, but it inhibits BMP2- 
induced osteoblast differentiation, as well as myotube formation. This is reflected by morphology 
(Figure 1A) as well as by expression regulation of marker genes. Whereas BMP2 induces the 
expression of the osteoblast markers alkaline phosphatase (ALP) and osteocalcin (OCN), TGF-P 
inhibits this BMP2-induced expression (Figure 1B). Our previous experiments have indicated that 
C2C12 mesenchymal progenitor cells already become committed to osteoblast differentiation within 
1 day after BMP treatment, as evidenced by the up-regulation of the osteoblast-specific transcription 
factor core-binding factor a1 (Cbfa1) within this time frame (21). In this study, we therefore focused 
on genes which are regulated within the first 24 hours of growth factor treatment to identify potential 
key regulators of osteoblast differentiation.
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Figure 1. Differential activities of BMP2 and TGF-p on C2C12 cells.
(A) Differential morphological features of C2C12 cells treated with BMP2, TGF-p and combinations of these growth factors. Cells 
were seeded and grown for 24 hrs upon which the medium was replaced by control medium (CM: DMEM containing 5% NCS), 
control medium + 300 ng/ml BMP2 (B), control medium + 5 ng/ml TGF-p (T) and control medium + 300 ng/ml BMP2 and 5 
ng/ml TGF-p (BT). The figure shows micrographs taken 3 days after addition of growth factors. (B) Differential regulation of 
expression of the osteoblast marker genes alkaline phosphatase (ALP) and osteocalcin (OCN) by BMP2 and TGF-p. Cells were 
seeded and grown for 24 hrs upon which the medium was replaced by DMEM containing 5% NCS in the presence or absence of 
BMP2 (300ng/ml) with or without TGF-p (5 ng/ml). RNA was isolated 0, 2 and 6 hours, 1 day, 2 days, 3 days and 6 days after 
stimulation. Expression levels were measured by real-time quantitative RT-PCR. Mean expression levels were corrected for 
GAPDH levels. Error bars indicate standard deviations between duplicate experiments.
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Microarray analysis of C2C12 cells 24 hours after treatment with either BMP2, TGF-P or a 
combination of these factors, showed 625 sequences out of the 9,330 spotted on the array to exhibit 
significant differential expression for at least one of the conditions tested, as based on our previously 
described statistical analysis (22). Subsequently, the genes were subdivided into 9 categories 
according to their expression pattern by BMP2 (B), BMP2 plus TGF-P (BT), and TGF-P (T) as 
described in Materials and Methods. Because TGF-P inhibits BMP2-induced differentiation, genes 
with an expression pattern reflecting categories 1 to 4 (B>BT>T, B<BT<T, B>BT=T and B<BT=T) 
most likely include regulators of osteoblast differentiation. Table 1 list the 61 genes and ESTs that are 
differentially regulated by BMP2 and TGF-P to at least the level (40% difference) measured for ALP 
(Figure 1B). When classified into functional protein groups, the majority of the genes in our dataset 
fell in the groups “Signal transduction” or “Expressed sequence tags (ESTs)” (26% and 23% 
respectively). Furthermore, nearly 20% of the genes encoded “Structural proteins” with functions in 
cell adhesion, cytoskeleton or extracellular matrix and another 20% of the genes encoded “Enzymes”. 
The remaining 11% of the genes could not be classified in one of the above mentioned groups 
(Other).
Table 1. Expression profiles of the genes differentially regulated by BMP2 and TGF-P.
Expression Accession # Abbre- Description Functional Expression levels
pattern viation group B BT T
B>BT>T AI386062 Car3 Carbonic anhydrase 3 Enz 3.34 1.21 -1.91
AA062324 Dpysl3 Dihydropyrimidinase-like 3 ST 2.90 2.13 1.33
AI157520 Omd Osteomodulin CAd 2.54 1.58 1.00
W97877 Prrx2 Paired related homeobox 2 ST 2.34 1.72 -1.20
AA028346 Krt1-19 Keratin complex 1, acidic, gene 19 Cy 2.33 1.78 -1.21
AI427265 Madh6 MAD homolog 6 ST 2.33 1.56 1.13
AA821963 Dnpep Aspartyl aminopeptidase Enz 2.14 1.50 1.00
AI552130 Hey1
Hairy/enhancer-of-split related with YRPW 
motif 1 ST 2.11 1.21 -1.10
AA197529 Lfng Lunatic fringe ST 2.06 1.56 1.00
AA981032 Emilin2 Elastin microfibril interfacer 2 EM 2.05 1.51 1.18
AA450795 Cck Cholecystokinin ST 2.01 1.89 -1.07
AA596753 Lxn Latexin Enz 1.90 1.23 1.00
AA545032 Ppap2b Phosphatidic acid phosphatase 2a Enz 1.77 1.21 -1.30
AI323002 Nsg1 Neuron specific family member 1 Other 1.76 1.00 -1.15
AA242413 Asgr1 Asialoglycoprotein receptor 1 ST 1.73 1.19 1.00
AI325697 Ly6a Lymphocyte antigen 6 complex Other 1.69 -1.13 -1.54
AI606539 EST 1.69 1.21 1.00
AA415211 Musk muscle, skeletal, receptor tyrosine kinase ST 1.65 1.29 -1.58
AA606242 Ecm1 Extracellular matrix protein 1 EM 1.59 1.34 -1.05
AA517588 ALP Alkaline phosphatase 2, liver Enz 1.53 1.31 1.00
W16221 Col6a1 Procollagen, type VI, alpha 1 EM 1.30 -1.61 -1.94
W18632 EST 1.24 -1.52 -1.86
AA450440 Ddef1 Development and differentiation enhancing Enz 1.00 -1.16 -1.79
AI552157 EST 1.00 -1.25 -1.58
AA462389 Camk2d Calcium/calmodulin-dependent protein kinase II delta
ST 1.00 -1.40 -1.62
AA067331 EST -1.02 -1.34 -1.62
Genes significantly (P<0.05, >1.5 fold) regulated for either BMP2 (B, 300 ng/ml), BMP2 + TGF-P (BT, 300 ng/ml + 5 ng/ml 
respectively) or TGF-P (T, 5 ng/ml) are shown for the expression pattern categories 1-4 (B>BT>T, B<BT<T, B>BT=T, and 
B<BT=T). Functional protein groups were assigned using the GeneOntology™ database. CAd, cell adhesion; Cy, cytoskeletal 
component; EM, extracellular matrix component; Enz, enzyme; EST, expressed sequence tag; ST, signal transduction.
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Table 1, continued
B<BT<T AA261149 Col18a1 Procollagen, type XVIII, alpha 1 EM -1.20 1.24 1.75
AA437677 Col18a1 Procollagen, type XVIII, alpha 1 EM -1.28 1.27 1.84
W09641 Tmsb4x Prothymosin beta 4 Cy -1.29 1.00 1.76
AA619789 Mthfd2 Methylenetetrahydrofolate dehydrogenase Enz -1.62 -1.11 1.00
AA536716 Map4k4 Mitogen activated protein kinase kinase kinase kinase 4
ST -1.62 -1.33 -1.15
AW209351 EST -1.62 -1.19 1.00
AA815681 Pdlim1 PDZ and LIM domain 1 / elfin Cy -1.69 -1.16 1.24
W12942 Tnc Tenascin C Cy -1.69 1.27 2.38
AA624579 EST -1.75 -1.35 -1.07
AA106557 Dgkd Diacylglycerol kinase d ST -1.90 -1.44 1.00
W16059 Gsto1 Glutathione S-transferase like Enz -1.94 -1.39 1.59
AA596866 EST -1.98 -1.38 1.00
AA117547 Ccnd1 Cyclin D1 Other -1.98 -1.56 1.00
AI390830 EST -2.02 -1.27 1.00
AA413490 Trfr Transferrin receptor ST -2.07 -1.33 1.00
AA066390 EST, similar to sarcalumenin Other -2.11 -1.60 -1.24
W99951 Nefl Neurofilament, light polypeptide Cy -3.37 -1.91 -1.34
AI325851 Cd97 CD97 antigen CAd -3.37 -2.25 -1.40
B>BT=T AA067147 Mod1 Malic enzyme, supernatant Enz 1.72 1.35 1.27
AA590599 EST 1.52 1.30 1.31
AA879919 F3 Coagulation factor III ST 1.22 -1.52 -1.58
AA518187 Ogn Osteoglycin ST 1.00 -1.62 -1.61
AA414208 Sdfr1 Stromal cell derived factor receptor 1 ST -1.18 -1.50 -1.49
AA755873 Mgrn1 Mahogunin, ring finger 1 Other -1.19 -1.43 -1.52
W17626 Snap25bp Synaptosomal-associated protein 25 binding protein
Other -1.24 -1.66 -1.66
AI425448 Socs5 Supressor of cytokine signaling 5 ST -1.28 -1.56 -1.56
AA106098 Cfh Complement component factor H Other -1.30 -1.60 -1.51
AA413899 Sat1 Spermidine/spermine N1-acetyl transferase Enz -1.30 -1.61 -1.56
B<BT=T AA689893 EST 1.27 1.58 1.55
AA473948 EST -1.56 -1.31 -1.33
AA638889 Rabggtb RAB geranylgeranyl transferase, b subunit Enz -1.56 -1.33 -1.25
AA794206 EST -1.66 -1.15 -1.07
AA684321 EST, similar to protein phosphatase Enz -1.69 1.00 1.00
AA545397 EST -1.72 -1.42 -1.35
AI877091 Xist inactive X-specific transcripts Other -1.77 -1.26 -1.21
Expression of Notch pathway genes during osteoblast differentiation
We subsequently focussed on signal transduction genes that had similar expression profiles as 
ALP, i.e. the signal transduction genes present in Category 1 (B>BT>T). As can be seen from Table
1, these genes include dihydropyrimidinase-like 3 (Dpysl3), paired related homeobox 2 (Prrx2), MAD 
homologue 6 (Madh6), hairy/enhancer o f split with YRPW motif 1 (Hey1), lunatic fringe (Lfng) and 
calcium/calmodulin dependent kinase II delta (Camk2d). To validate the expression profiles measured 
in this microarray experiment, the expression of these 6 genes was tested by quantitative real time 
RT-PCR both in original RNA used for the microarray and in RNA obtained from an identical but 
independent experiment. Figure 2 shows that the expression profiles for 5 out of 6 genes were 
confirmed. Only for Camk2d the expression regulation for the various growth factor combinations 
was moderate and statistically not significant.
Of the 61 genes and ESTs identified in our study, two belong to the Notch signal transduction 
pathway: the transcription factor Hey1 and the signal modulator Lfng. Previously, we have identified 
another transcription factor of this signal transduction pathway, hairy/enhancer o f split 1 (Hes1), to be 
differentially regulated between BMP2 and TGF-P (22). Because this gene was not present on our 
current microarray, we validated the differential effect of BMP2 and TGF-P on expression of Hes1 by 
quantitative real time RT-PCR in both sets of RNA. As can be seen from Figure 2, Hes-1 is down-
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regulated by BMP2 and up-regulated by TGF-p. In addition, TGF-P inhibited the BMP2-induced 
down-regulation and caused an up-regulation of gene expression similar to that induced by TGF-P 
alone. The combined results indicate that at least three genes of the Notch signal transduction 
pathway are differentially modulated by BMP2 and TGF-P in C2C12 cells, which suggests that this 
pathway plays an important role in regulating the early phase of osteoblast differentiation.
Figure 2. BMP2 and TGF-p differentialy regulate expression of signal 
transduction related genes.
Cells were seeded and grown for 24 hrs upon which the medium was 
replaced by DMEM containing 5% NCS in the presence or absence of 
BMP2 (300ng/ml) with or without TGF-p (5 ng/ml). RNA was isolated 
from untreated cells (day 0) and 1 day after stimulation. Expression 
levels were measured by real-time quantitative RT-PCR. Mean 
expression levels were corrected for GAPDH levels. Error bars indicate 
standard deviations between duplicate experiments. Camk2d, 
calcium/calmodulin dependent kinase II delta; Dpysl3, 
dihydropyrimidinase-like 3; Heyl, hairy/enhancer of split with YRPW 
motif 1; Hesl, hairy/enhancer of split 1; Lfng, Lunatic fringe; Madh6, 
MAD homologue 6; Prrx2, paired related homeobox 2.
Discussion
Modulation of the activity of signal transduction pathways during the initial phase of 
differentiation guides mesenchymal stem cells to become osteoblasts, and activating and repressing 
transcription factors are very important in directing the differentiation process. In our data set, we 
observed that “Signal transduction” genes constituted over a quarter of the total set of genes regulated 
24 hours after growth factor treatment. Previously, we have shown that commitment of the C2C12 
cells to the osteoblastic lineage occurs around 24 hours after BMP treatment, when the osteoblast 
specific transcription factor Cbfal and the novel osteoblast related genes Tcf7 and Heyl become 
regulated (21). Genes with expression patterns that associate with the differential effects of BMP2 
and TGF-P on osteoblast differentiation in C2C12 cells might be mediators of osteoblast 
differentiation. Therefore, in search of novel genes implied in the commitment of mesenchymal 
progenitor cells to osteoblast diferentiation, we have analysed the effects of BMP2 and TGF-P on 
gene expression at 24 hours post stimulation.
Our study identified 5 signal transduction related genes that exhibited similar expression 
profiles as the osteoblast marker ALP after 24 hours of stimulation. Of these, 4 genes have previously 
been reported to be involved in osteoblast differentiation or function. Prrx2 cooperates with Prrx1 in 
regulating the skeletogenesis of the craniofacial region, inner ear and limbs, as was shown in knock­
out experiments (23). Madh6 is a negative regulator of the BMP signal transduction pathway capable 
of repressing BMP-induced osteoblast differentiation (24, 25). The function of Hey1 and Hes1 in 
osteoblast differentiation will be discussed below. The observation that four out of the five signal 
transduction genes identified here have been implicated before in osteoblast differentiation indicates 
that screening for genes differentially affected by BMP2 and TGF-P is a valid strategy for the
- 97 -
Chapter 4
identification of novel regulators of osteoblast differentiation. The dyhydropyrimidinase like protein 3 
(Dpysl-3) has not previously been implicated in osteoblast differentiation. Dpysl-3 is a member of a 
family of dihydropyrimidinase related proteins which have been shown in humans to be intracellular 
components of a signalling cascade involved in the development of the nervous system (26, 27). 
Furthermore, studies in which we compared the expression regulation of Dpysl-3 in osteoblastic cells 
and in non-osteoblastic cells showed that Dpysl-3 is specifically regulated in osteoblastic cells ((21) 
and data not shown). These results indicate that Dpysl-3 might also be a regulator of osteoblast 
differentiation. We investigated whether additional osteoblast-related transcription factors might be 
identified among the 4 ESTs identified in this category. However, in silico sequence analysis did not 
reveal specific DNA binding domains or characteristic transcription activating domains, suggesting 
that these ESTs are not novel transcription factors (results not shown).
In this study, we identified 3 members of the Notch signalling pathway, Lfng, Heyl and Hesl, 
to be differentially regulated by BMP2 and TGF-p. Hey1 belongs to the Hairy and enhancer of split 
(HES) family of transcription factors and is a primary target of Notch (28). Previously, we have 
shown that Heyl is expressed in bone during mouse embryonic development with an expression 
pattern that partially overlaps with that of Cbfal (21). Hey1 functions as an inhibitor of myoblast 
differentiation in C2C12 cells (29). This finding is consistent with our data that show that Hey1 
expression is induced when transdifferentiation of C2C12 cells to the osteoblast lineage is induced 
with BMP2. Hey1 is able to associate with its family member Hes1 and form stable heterodimers with 
Hes1 upon DNA binding (28). The role of Hes1 in osteoblast differentiation is unclear as it has been 
reported to be both an inhibitor and activator of osteoblast differentiation (30, 31). Our finding that 
Hes1 is downregulated by the osteogenic factor BMP2, whereas it is induced by the inhibitory factor 
TGF-P, would be consistent with an inhibitory role of Hes1 in osteoblast differentiation.
In addition to the effect on the Notch target genes Hes1 and Hey1, we observed a differential 
effect of BMP2 and TGF-P on expression of Lfng. This protein is a modulator of Notch signalling 
because of its O-fucose-specific glycosyltransferase activity on both the Notch receptors and their 
ligands. However, no direct evidence has been obtained so far for a functionally relevant modification 
of the Notch ligands, while fucosylation of the Notch receptors occurs in a cell autonomous fashion 
(32-35). O-fucosylation is an essential step in Notch signalling, since loss of the protein that transfers 
fucose to the EGF-like repeats of Notch (O-FucT-1), causes embryonic lethality of mice at 
midgestation with severe defects in somitogenesis, vasculogenesis, cardiogenesis and neurogenesis. 
Inactivation of Lfng in mice causes fusion of somites, skeletal defects and perinatal death (36, 37). It 
has been suggested that Lfng changes the sugar structures on Notch and thereby causes alterations in 
binding of Jagged and Delta. However, the reports on the effect of Lfng on Notch signaling in 
osteoblast differentiation as well as the effect of the different ligands on Notch signalling in osteoblast 
differentiation are contradictory (13, 14, 33, 38, 39). Strikingly, in many cases during embryonic 
development, it is the distribution of fringe proteins, rather than of the Notch receptors or their 
ligands, that is the key determinant of where Notch signalling will be active and in which form (40). 
In our study, we have shown that Lfng and Heyl are regulated in a very similar manner by BMP2 and 
TGF-P, and that expression regulation of Hesl is negatively correlated with that of Lfng and Heyl. 
Expression of Lfng was shown to be initiated already 2 hours after BMP2 treatment, while Heyl 
expression was induced 24 hours after BMP treatment (21). These results suggest that expression of 
Lfng causes a switch in the Notch signaling pathway such that Heyl becomes up-regulated and Hesl 
down-regulated.
In conclusion, we have shown that several members of the Notch signal transduction pathway 
are differentially regulated by BMP2 and TGF-P in C2C12 mouse mesenchymal progenitor cells. We 
hypothesize that Lfng might function as one of the the focal points for interaction of the Smad and
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Notch signal transduction pathways during osteoblast differentiation: Lfng expression is induced by 
BMP2 and subsequently the altered distribution of this gene might induce changes in the activity and 
form of Notch signalling, which in turn could modulate BMP-induced osteoblast differentiation. 
Further elucidation of the function of these members of the Notch signalling pathway in osteoblast 
differentiation may contribute to the identification of new therapeutics for the treatment of bone 
diseases such as osteoporosis.
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Abstract
Bone morphogenetic proteins (BMPs) are the primary regulators of osteoblast differentiation. 
BMPs exert their activity through type I and type II serine/threonine kinase receptors and BMP- 
specific Smad proteins as second messengers. However, activation of Smad signaling alone is not 
sufficient for full osteoblast differentiation and cooperation with other major signal transduction 
pathways, such as MAP-kinase, Wnt and Notch signaling, is required.
At present, little is known about how these different pathways interact, but most likely specific 
genes act as focal points for their interaction. To identify such focal points, expression profiles were 
determined in C2C12 cells of a number of genes that are known to be regulated during different 
stages of osteoblast differentiation with respect to their regulation by Smads, Erk1/2 MAP-kinase and 
the Notch signaling modulator Lunatic fringe. The results show that Smad signaling is important but 
not sufficient to drive full expression of BMP target genes during osteoblast differentiation, whereas 
Erk1/2 MAP-kinase appears to be particularly important during late phase osteoblast differentiation. 
Although it could not definitively be proven that Lfng, a modulator of Notch, is expressed in vivo 
during bone formation, we did find indications that Notch signaling is also important for late phase 
differentiation. Finally, one immediate early and one intermediate gene, Tieg and Heyl respectively, 
were found to be regulated by Smad and Erk1/2 MAP-kinase pathways independently, indicating that 
these two genes may serve as focal points for integration of the different signaling pathways during 
osteoblast differentiation.
Introduction
Bone morphogenetic proteins (BMPs) are the most potent inducers of osteoblast 
differentiation. Although the BMPs were first identified for their ability to induce ectopic bone 
formation in vivo (1), these proteins appear to be multifunctional regulators of morphogenesis during 
embryonic development (2). To generate biological responses, BMP family members use heteromeric 
complexes of so-called type I and type II serine/threonine kinase receptors. For BMPs, three distinct 
type II receptors have been identified, in particular BMPR-II (BMP type II receptor), ActR-II (activin 
type II receptor) and ActR-IIB (activin type IIB receptor). Moreover, three type I receptors, also 
referred to as activin receptor-like kinases (Alks) have been identified, namely BMPR-IA/Alk3 (BMP 
type IA receptor), BMPR-IB/Alk6 (BMP type IB receptor) and Alk2 (activin receptor-like kinase 2) 
(3). Upon ligand binding, a complex is formed between two type I and two type II receptors, upon 
which the constitutively active kinase of the type II receptor phosphorylates and activates the type I 
receptor which subsequently activates specific receptor-regulated Smads (R-Smads). Smad-1, -5 and - 
8 have been shown to be BMP responsive R-Smads, while Smad-2 and -3 are responsive to TGF-P 
and activins, both proteins that are closely related to BMPs. In combination with the common 
mediator Smad-4, the respective R-Smads are assembled into heteromeric complexes, which 
subsequently translocate to the nucleus, where they act in concert with other proteins as transcription 
factor complexes (3-5).
In addition to the BMP-activated Smad pathway, several other major signaling pathways are 
known to play a role during osteoblast differentiation. These include the different MAP-kinase 
pathways (6-10) and the Notch pathway (11, 12). Moreover, it has been shown that BMPs not only 
activate various MAP-kinase pathways, but also stimulate the activity of various transcriptional 
mediators of the MAP-kinase pathway (AP-1 members), and regulate the expression of several AP-1 
members (13-15). Recently, it has been shown that BMP receptor binding results in a direct activation 
of the Tab1 (Tak1 binding protein 1)/Tak1 (TGF-P activated kinase 1)/p38 MAP-kinase pathway (16­
19). Interestingly, p38 MAP-kinase has been shown to be a positive regulator of bone cell
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differentiation, since its inhibition results in down-regulation of the genes for the osteoblast markers 
Cbfal (Core binding factor a l) , Alp2 (Alkaline phosphatase type liver, bone, kidney), Colla 
(Collagen type Ia), Ocn (Osteocalcin), Opn (Osteopontin) and Opg (Osteoprotegerin), as well as in 
decreased matrix mineralization (9, 10, 20-25).
In contrast to p38, Erkl/2 MAP-kinase has been shown to be mainly a negative regulator of 
osteoblast differentiation. Although complete inactivation of Erkl/2 MAP-kinase activity inhibits 
osteoblast differentiation (26), this effect is mainly due to the finding that Erkl/2 MAP-kinase- 
mediated phosphorylation of Cbfal is necessary for Cbfal activity (6). Partial inhibition of Erkl/2 
MAP-kinase is sufficient for residual Cbfal activity and enhancement of BMP-induced osteoblast 
differentiation, as shown by the up-regulation of Alp2 activity as well as matrix mineralization. 
Furthermore, expression of constitutively active MEKl, which activates Erkl/2 MAP-kinase, results 
in reduced BMP-induced osteoblast differentiation, as shown by repressed Alp2 activity (8).
BMP is able to regulate the activity of Notch signaling based on the observation that the Notch 
intracellular domain (NICD), which functions as a transcription factor, can interact with both TGF-P- 
and BMP-specific Smads. TGF-P rapidly induces the expression of Hesl in a NICD- and Smad- 
dependent manner, and it has been shown that NICD can bind to Smad-3 at its MH2-domain. This 
interaction is necessary for the activation of NICD- and Smad- binding promoters (27). Moreover, it 
has been shown that interaction of the BMP-specific Smad-l with NICD results in the inhibition of 
both myogenesis and BMP-induced osteogenesis of the C2Cl2 mesenchymal progenitor cell line, 
probably through up-regulation of specific Notch target genes (28). However, the interplay between 
the various pathways in osteoblast differentiation is still poorly understood.
Recently, we identified Lunatic fringe (Lfng) and Heyl (Hairy and enhancer of split related 
with YRPW motif l) as potential focal points for the integration of the Smad and Notch signaling 
pathways in osteoblast differentiation (29, 30). Lfng belongs to the family of Fringe proteins, which 
are glycosyltransferases that modulate the activity of the Notch receptors (3l, 32), and Heyl belongs 
to the Hes/Herp family of transcription factors that function in the Notch signal transduction pathway 
(33, 34). To investigate the influence of various signal transduction pathways on osteoblast 
differentiation, we studied the role of Smads, Erkl/2 MAP-kinase and Notch on gene expression 
regulation during various stages of osteoblast differentiation. Our results show that during BMP- 
induced osteoblast differentiation, gene expression is regulated, at least in part, by Smads, and that 
particularly for the expression of late phase bone markers, Smads act in combination with Erkl/2 
MAP-kinase and Notch signaling. Moreover, we identified two genes as potential focal points for the 
integration of the Smad and Erkl/2 signaling pathways.
Materials and Methods 
Tissue culture and growth factors
The C2C12 murine mesenchymal progenitor cell line (the American Type Culture Collection) 
was maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% newborn 
calf serum (NCS), penicillin (100 U/ml) and streptomycin (100 |ig/ml), as described previously (35). 
For the various experiments, cells were plated at a density of 2.0x104 cells/cm2 and grown for 24 hrs 
in DMEM supplemented with 10% NCS unless stated otherwise. In the Erk1/2 MAP-kinase 
experiment, the medium was subsequently replaced by DMEM containing 5% NCS either in the 
presence or in the absence of 5|iM of the MEK inhibitor U0126, and incubated for 2 hrs. After 
incubation, the medium was replaced by DMEM containing 5% NCS either in the presence or in the 
absence of 300 ng/ml recombinant human BMP2 with or without 5|iM of the MEK inhibitor U0126.
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In the other experiments, the medium was subsequently replaced by DMEM containing 5% NCS 
either in the presence or in the absence of 300 ng/ml recombinant human BMP2, 5 ng/ml TGF-P or a 
combination of these growth factors, unless stated otherwise. The MEK1/2 inhibitor U0126 was 
purchased from Sigma and recombinant human BMP2 was kindly provided by Wyeth (Andover, 
MA).
Adenoviral infections
Cells were plated at density of 2.5x104 cells/cm2 and grown for 12 hrs in DMEM 
supplemented with 10% fetal calf serum (FCS). Subsequently, the cells were infected with the various 
virus stocks at a MOI of 2000. Before harvesting, the cells were washed extensively and starved for 
10 hrs in serum-free medium supplemented with 0.2% bovine serum albumin (BSA; Sigma). Virus 
stocks containing expression constructs for LacZ (P-galactosidase expressing control), constitutively 
active Alk2 receptor (caAlk2), Smad1, Smad4, Smad5 and Smad8 were kindly provided by dr. K. 
Miyazono (36).
RNA isolation and Real-time RT-PCR
Total RNA was extracted according to an acid guanidium thiocyanate-phenol-chloroform 
method (TriPure® Isolation Reagent, Roche Diagnostics) and RNA concentrations were determined 
by measuring the absorbance at 260 nm. For real-time RT-PCR, the ABI Prism Sequence Detection 
System 5700 and Primer Express™ Software (PE Biosystems) were used. For each gene, a set of 
primers was designed using sequences obtained from Genbank™ and amplicons of 50-100 base pairs 
with Tm between 58 and 60°C were selected. Prior to complementary DNA (cDNA) synthesis, 2 ^g 
of total RNA were DNase (Invitrogen) treated for 15 min at 37°C, after which RNA was reverse- 
transcribed using random hexamer primers (Amersham Pharmacia) in a total volume of 50 |il using 
the SUPERSCRIPTTM II reverse transcriptase kit (Invitrogen). Subsequently, aliquots of first-strand 
cDNA (2|il) were amplified using SYBR Green® PCR Mastermix (Applied Biosystems) under the 
following conditions: initial denaturation for 10 min at 95°C, followed by 40 cycles consisting of 15 
sec at 94°C and 1 min at 60°C. Fold inductions and expression ratios were calculated from differences 
in threshold cycles at which an increase in reporter fluorescence above a baseline signal could first be 
detected (CT) between two samples, and averaged for duplicate experiments.
Protein Isolation and Western Blotting
Cells were lysed in IPB-0.7 buffer (50 mM Tris pH7.5, 0.7 M NaCl, 0.5% NP40, 0.25% 
sodium deoxycholic acid, 1 mM EDTA) supplemented with 1 |J.M PMSF, 1 ng/ml leupeptin, 1 ng/ml 
pepstatin, 0.5 ng/ml aprotein, 1 mM Na3VO4 and 1 mM NaF. Proteins from the cell lysates were 
separated on SDS 10% polyacrylamide gel electrophoresis and transferred to Protran Nitrocellulose 
membranes (Schleicher & Schuell). Phosphorylated Erk1/2 MAP-kinase was detected using a 
phospho-p44/42 MAP kinase (Thr202/Tyr204) antibody (Cell Signaling Technology), while total 
Erk1/2 MAP-kinase was detected using the K-23 antibody (Santa Cruz). All antibodies were used at a 
1:1000 dilution. After incubation with HRP-conjugated secondary antibodies (Tebu-bio, 1:2000 
dilution), the proteins were visualized by enhanced chemo-luminescence (ECL, Roche Diagnostics).
Plasmids and stable transfections
The human LFNG cDNA cloned in pCMV-Sport6 was purchased from the German Research 
Center for Genome Research (RZPD). The LFNG coding region was excised from the plasmid by 
Sall/Notl digestion and ligated into Sall/Notl digested pcDNA3.1. The integrity of the resulting 
pLFNG -3.1 plasmid was verified by DNA sequence analysis. For stable transfections, pLFNG-3.1
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was introduced into C2C12 cells using the Lipofectamin 2000 method according to the 
manufacturer’s specifications (Gibco/BRL). Monoclonal stable transfectants were selected in the 
presence of G418 (400 |ig/ml) and LFNG expression levels were analyzed by real-time RT-PCR.
Alkaline phosphatase assay
Cells were seeded in 96-well tissue culture plates (Nalge Nunc International, Denmark) and 
grown as described above. Subsequently, the medium was changed to DMEM containing 5% NCS, 
supplemented with increasing doses of BMP2. Alkaline phosphatase activity was measured 48h after 
stimulation as described by Van der Plas and coworkers (37). Alkaline phosphatase activity was 
corrected for differences in cell number based on a measurement of neutral red staining (38).
Calcium deposition assay
Cells were seeded in 24-well tissue culture plates (Nalge Nunc International, Denmark) and 
grown as described above. Subsequently, the medium was changed to DMEM containing 5% NCS in 
the presence or absence of BMP2 (300 ng/ml) supplemented with P-glycerophosphate (12.5 mM). 
Calcium deposition was measured 8 days after stimulation using the Sigma calcium release assay 
system.
In situ hybridization
Mouse embryos were collected from F1 females (Cba x C57B16) at embryonic day 14.5 
(E14.5), dissected free from the uterus and membranes, fixed overnight at 4oC in 4% 
paraformaldehyde, dehydrated, embedded in paraffin wax and sectioned (6 |im) onto coated slides 
(Klinipath, Duiven, the Netherlands). Neonatal mouse tails, kindly provided by Dr. Marcel Karperien 
(Leiden University Medical Center, the Netherlands), were collected from Swiss albino mice on day 5 
after birth and fixed in 4% paraformaldehyde, decalcified by incubation in 12.5% sodium EDTA 
(pH8.0) for 1 week at 4oC, embedded in paraffin wax and sectioned (5 |im) as described previously 
(39). The slides were dewaxed, rehydrated and pretreated with Proteinase K and acetic anhydride, and 
hybridized overnight at 55oC, essentially as described previously (40). Constructs were cloned into 
pSKII- in the anti-sense orientation in the T7 promoter. RNA probes were generated by transcription 
of the T7 RNA polymerase in the presence of [a-35S]-uridine-triphosphate (UTP). After 
hybridization, the slides were washed at high stringency for 30 min at 62oC, treated with RNase A for 
30 min at 37oC, washed again at high stringency, dehydrated and allowed to dry. Autoradiography 
was performed using Ilford G5 photo emulsion. The slides were exposed for 4 weeks at 4oC. 
Photographs were made from combined bright-field (blue filter) and dark-field (red filter) images.
Results
Expression regulation by Smads
Previous data have shown that C2C12 mesenchymal cells undergo osteoblastic differentiation 
upon infection with the genes encoding the constitutively active type I receptors Alk2, Alk3 and 
Alk6, as shown by the induction of Alp2 activity (36). Furthermore, these BMP type I receptors are 
known to have different effects on bone formation in vivo (41, 42), but in C2C12 mesenchymal cells 
no difference could be observed between these three receptors in their ability to induce osteoblast 
differentiation, as measured by gene expression patterns and induction of Alp2 activity (36, 43). In 
addition to the type I BMP receptors Alk2, Alk3 and Alk6, C2C12 cells are also able to undergo 
osteoblastic differentiation upon infection with the genes encoding Smad1 and Smad5, as shown by 
the induction of Alp2 activity (36). Moreover, co-infection with the gene encoding the common
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mediator Smad-4 potentiated the effect of Smad-1 and Smad-5 (36). At present, little is known about 
the ability of the third BMP-specific R-Smad, Smad-8, to induce osteoblast differentiation. 
Furthermore, it is not known whether the different BMP-specific R-Smads induce different genes 
during osteoblast differentiation. In this study, we therefore examined the involvement of the various 
BMP-specific R-Smads alone and in combination with Smad-4 in the regulation of genes expressed 
during osteoblast differentiation.
To obtain an general overview of the involvement of the Smad signal transduction pathway in 
osteoblast differentiation, we examined the expression of transcription factor genes known to be 
regulated during the early phases of osteoblast differentiation (29), as well as a number of established 
osteoblast markers and several novel late osteoblast differentiation marker genes that we identified in 
a previous study (44). The genes studied include Id-1, Id-2, Id-3 (Inhibitor of differentiation genes 1­
3), Oasis (Old astrocyte specifically induced substance), Prrx2 (Paired related homeobox 2), Smad-6, 
Smad-7 (MAD homologues 6 and 7), Snail and Tieg (TGF-P-induced early growth factor) as 
immediate early regulated genes; Cbfal, Heyl and Tcf7 (T-cell specific factor 7) as intermediate 
genes; and Alp2, Ocn, Col6a2 (Collagen type 6 a2), Prdc (Protein related to DAN and Cerberus), 
Wif-1 (Wnt inhibitory factor 1) and the ESTs (Expressed sequence tags) AA222756, AA709999 and 
AA794190 as late phase genes.
As shown in Figure 1A, expression of several of the immediate early and intermediate genes 
was induced by over-expression of either a single Smad cDNA alone or in combination with Smad-4, 
which is considered to be the typical manner in which BMP responsive genes react to Smad signaling. 
In particular, expression of Smad-7, Tieg and Heyl was moderately induced 24 hrs and 48 hrs after 
infection with genes encoding Smad-1, Smad-4, Smad-5 or Smad-8, and this effect was strongly 
enhanced upon co-infection of the R-Smads with the Smad-4 cDNA. Furthermore, expression of Id-1, 
Id-2 and Id-3 was shown to be induced by the various Smads tested here, but in this case co-infection 
with Smad-4 did not significantly potentiate expression levels. Intriguingly, the immediate early 
genes Snail, Prrx2, Oasis and Smad-6, as well as the intermediate genes Tcf-7 and Cbfal, were not 
induced by infection with Smad genes, even upon co-infection with Smad-4. However, these genes 
were induced by addition of BMP as well as upon infection with a cDNA encoding caAlk2. These 
results imply that for Snail, Prrx2, Oasis, Smad-6, Tcf-7 and Cbfal the Smad signal transduction 
pathway is either not or only weakly involved in their expression regulation.
Figure 1B shows that 6 out of 8 late phase genes, in particular Alp2, Prdc, Wif-l and the ESTs 
AA222756, AA794190 and AA709999, were moderately regulated by infection with only Smad-1, 
Smad-4, Smad-5 or Smad-8 cDNA, and co-infection with Smad-4 cDNA potentiated this effect not 
only for Smad-8 (Wif-l) but also for Smad-1 and Smad-5 (Alp2, Prdc, AA222756, AA794190 and 
AA709999). It should be noted, however, that for 4 of these 6 genes their gene expression levels 
induced by Smads were considerably lower than those observed after infection with caAlk2 or 
treatment with BMP2. Most probably this is due to the fact that the transfected Smads were not 
activated. After infection of caAlk2 or BMP2 treatment, the endogenous levels of activated Smads are 
probably higher than those achieved by over-expression without ligand stimulus.
Furthermore, our data show that in the case of Col6a2, co-infection with Smad-4 cDNA did 
not significantly potentiate its expression regulation as compared to the single Smad infections. 
Finally, it was shown that expression of Ocn could not be induced by either single Smads or by co­
infection of the R-Smads with Smad-4. Since Cbfa1 is the major transcription factor that regulates 
Ocn expression (45), and Cbfal expression was not affected by Smads in the present experiment, it is 
likely that also expression of Ocn cannot be regulated by infection with Smads.
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Figure 1. Smad- 
mediated expression 
during osteoblast dif­
ferentiation.
C2C12 cells were 
seeded and grown for 
12 hrs after which 
they were infected 
with the various virus 
stocks at an MOI of 
2000. Before harves- 
ing, the cells were 
washed extensively 
and starved for 10 hrs 
in serum-free medium 
supplemented with 
0.2% BSA. RNA was 
isolated 0 hr, 1 day, 2 
days and 3 days after 
infection. As a 
control, C2C12 cells 
were plated at a 
density of 2.0x104 
cells/cm2 and grown 
for 24 hrs in DMEM 
supplemented with 
10% NCS. Subse­
quently, the medium 
was replaced by 
DMEM containing 
5% NCS either in the 
presence or in the 
absence of BMP2 
(300 ng/ml). RNA 
was isolated 0 hrs, 1 
day and 3 days after 
stimulation. Subse­
quently, expression 
levels were measured 
by quantitative real 
time RT-PCR. (A) 
Expression regulation 
of immediate early 
and intermediate 
osteoblast differen­
tiation genes, (B) 
Expression regulation 
of late phase osteo­
blast differentiation 
genes. LacZ = P- 
galactosidase expres­
sing control, caAlk2 = 
constitutively active 
Alk2 receptor.
In conclusion, these experiments show that the expression of 55% (5 out of 9) of the 
immediate early and 75% (6 out of 8) of the late phase genes are regulated by Smads, although it is 
realized that the obtained expression levels of the late phase genes were sub optimal. Furthermore, for 
44% (4 out of 9) of the immediate early genes and 66% (2 out of 3) of the intermediate genes, Smads
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alone did not appear sufficient to induce expression of these genes. Finally, these results indicate that 
most of the genes that can be induced by Smads in C2C12 cells are regulated by all three BMP- 
specific R-Smads without preference.
Regulation by the Erk1/2 MAP-kinase signal transduction pathway
For full differentiation of C2C12 cells into mineralizing osteoblasts, cells have to be treated 
with BMP2 in the presence of at least 5% serum. At lower serum concentrations, cells die around day 
3 (results not shown). Serum has been reported to activate signal transduction pathways such as the 
Erk1/2 MAP-kinase pathway independently of BMP2 and previous studies have shown that Erk1/2 
MAP-kinase plays a role in osteoblast differentiation next to the BMP-induced Smad signal 
transduction pathway (5, 6, 8, 10). Continuous inhibition of the Erk1/2 MAP-kinase signaling 
pathway has been shown to enhance BMP-induced osteoblast differentiation and mineralization of the 
matrix (8), and Erk1/2 MAP-kinase is able to activate the osteoblast-specific transcription factor 
Cbfa1 (6). Therefore we also examined the involvement of Erk1/2 MAP-kinase in the expression 
regulation of the above-mentioned genes during BMP-induced osteoblast differentiation.
Figure 2. Influence of inhibition of Erk1/2 MAP-kinase phosphorylation on BMP2-induced gene expression.
C2C12 cells were seeded and grown for 24 hrs upon which medium was replaced by DMEM containing 5% NCS in the presence 
or absence of the MEK inhibitor U0126 (5|iM). After 2 hrs, the cells were stimulated with BMP2 (300 ng/ml) in the presence or 
absence of the inhibitor. (A) Western Blot analysis of Erk1/2 phosphorylation. Proteins were isolated from whole cell lysates 0 hrs, 
15 min, 1 hr, 2.5 hrs, 5 hrs and 24 hrs after treatment, (B) Expression regulation of immediate early and intermediate osteoblast 
differentiation genes. RNA was isolated 0 hrs, 2 hrs, 6 hrs and 24 hrs after treatment. Subsequently, expression levels were 
measured by quantitative real-time RT-PCR, (C) Expression regulation of late phase osteoblast differentiation genes. RNA was 
isolated 0 hrs, 2 hrs, 6 hrs, 1 day and 3 days after treatment. Subsequently, expression levels were measured by quantitative real­
time RT-PCR.
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As is shown in Figure 2A, Erk1/2 MAP-kinase is readily phosphorylated by freshly added 
serum also in the absence of BMP2. Within 24 hrs after BMP2 treatment, this phosphorylation 
gradually declined. Phosphorylation of Erk1/2 MAP-kinase is completely blocked in the presence of 
the U0126 MEK inhibitor. We therefore tested the effect of U0126 on BMP2-induced expression 
regulation of the transcription factors identified in this study. As shown in Figure 2B, no inhibitory 
effect could be observed on BMP2-induced expression regulation for any of the transcription factors 
tested. Moreover, BMP-induced regulation was either not affected, or up-regulated on at least one 
time point in the presence of the MEK inhibitor as observed for Prrx2, Tieg, Heyl and Cbfal. To 
verify whether U0126 represses Erk1/2 MAP-kinase-mediated transcription regulation under our 
experimental conditions, we analyzed expression of the cholecystokinin (CCK) gene in more detail. 
This gene is an intermediate BMP response gene (29) and previous studies have shown that its 
expression is regulated by Erk1/2 MAP-kinase (46, 47). As shown in Figure 2C, BMP-induced 
expression regulation of this gene was indeed completely blocked in the presence of U0126.
Of the 9 immediate early BMP target genes that encode transcription factors, only the 
expression of Prrx2 and Tieg appeared to be regulated by Erk1/2 MAP-kinase (Figure 2B). It is 
known from previous studies that Erk1/2 MAP-kinase inhibition enhances osteoblast differentiation 
and matrix mineralization (8), and therefore we speculated that Erk1/2 MAP-kinase might affect the 
expression regulation of the late phase osteoblast differentiation genes more strongly than that of the 
early phase genes. To investigate this hypothesis, Erk1/2 MAP-kinase-mediated expression regulation 
was analyzed for the late phase osteoblast marker genes, including Alp2 and Ocn. As shown in Figure 
2C, the BMP-induced expression of Ocn was blocked in the presence of the inhibitor in a similar 
manner as reported previously (6, 10). In addition, the expression of Prdc, Col6a2 and all three ESTs 
was up-regulated, while expression of Alp2 and Wif-l remained unaffected by the inhibitor. In 
conclusion, our data indicate that indeed Erk1/2 MAP-kinase induces a more pronounced regulation 
of the genes expressed in late phase than of those expressed in early phase osteoblast differentiation.
The results of these experiments in combination with the Smad infection experiments provide 
more insight into the question by which signal transduction pathway and underlying mechanism the 
various osteoblast differentiation-related genes are regulated. Table 1 summarizes these data, from 
which it is shown that expression of the immediate early genes Smad-7, Id-l, Id-2 and Id-3, as well as 
of the late phase genes Alp2 and Wif-l can be induced by Smads, whereas inhibition of Erk1/2 MAP- 
kinase activation has no effect. Furthermore, expression of the immediate early gene Tieg, the 
intermediate gene Heyl and the late phase gene Prdc as well as the ESTs AA222756, AA794190 and 
AA709999, can be induced by Smads while inhibition of Erk1/2 activation enhances BMP-induced 
expression levels, indicating that the Erk1/2 MAP-kinase signal transduction pathway negatively 
regulates the expression of these genes. Moreover, Table 1 shows that Smads are not sufficient to 
induce the expression of the immediate early gene Prrx2, the intermediate gene Cbfal and the late 
phase genes Col6a2 and Ocn, whereas Erk1/2 MAP-kinase negatively regulates the expression of 
Prrx2, Cbfal and Col6a2, and positively regulates the expression of Ocn. Finally, neither Smads nor 
the Erk1/2 MAP-kinase signal transduction pathway are by themselves sufficient to regulate the 
expression of the immediate early genes Snail, Oasis and Smad-6, as well as the intermediate gene 
Tcf7. This indicates that expression regulation of these genes depends mostly on other signal 
transduction pathways, thereby suggesting that a combination of multiple signal transduction 
pathways is needed for gene expression regulation.
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Table 1. Expression regulation of BMP-response genes by Smads and Erk1/2 MAP-kinase
Gene BMP effect caALK2 Smads U0126/Erk
Smad-7 ▲ ▲ ▲ ▲
Id1 ▲ ▲ ▲ ▲
Id2 ▲ ▲ ▲▲ ▲
Id3 ▲ ▲ ▲▲ ▲
Tieg ▲ ▲ ▲ ▲
Prrx2 ▲ ▲ ▲ - ▲
Snail ▲ ▲ -
Oasis ▲ ▲▲ ▲ -
Smad-6 ▲ ▲ ▲ -
Hey ▲ ▲ ▲▲ ▲ ▲ ▲ ▲
Cbfa-1 ▲▲▲ ▲ ▲ - ▲ ▲
Tcf7 ▲ ▲ -
Alp2 ▲
Wif-1 ▲
AA222756 ▲ ▲ ▲ ▲ ▲▲
Prdc ▲ ▲ ▲ ▲▲▲ ▲ ▲
AA794190 ▲ ▲▲▲▲ ▲ ▲ ▲▲
AA709999 ▲▲▲▲▲▲ ▲ ▲
Col6a2 ▲ ▲ ▲ - ▲
Ocn ▲
<
▲ ▲ ▲ - ▼ ▼▼
Summary of Figures 1 and 2. ▲ = upregulation, ▼ = down-regulation, the number of triangles indicate relative levels of 
expression. See page 142 for full color table
Regulation by the Notch signal transduction pathway
One of the signal transduction pathways that are potentially involved in the expression 
regulation of osteoblast differentiation-related genes, is the Notch signal transduction pathway. Upon 
ligand binding, the Notch receptor becomes activated and the majority of its intracellular part, the so- 
called Notch intracellular domain (NICD), is subsequently released by presenilin-dependent cleavage. 
The NICD then translocates to the nucleus where it functions in concert with the transcription factor 
Su(H)/RBP-J/CBF1 (Suppressor of Hairless / recombining binding protein suppressor of hairless) in a 
complex (48, 49) that induces the expression of members of the family of Hairy and Enhancer of Split 
(Hes/Herp) transcription factors (33, 50).
Previously, we have reported that Heyl, Hesl and Lfng (lunatic fringe, a modulator of Notch 
receptor activity) are specifically regulated by BMP2 during osteoblast differentiation (30). In order 
to study the role of Notch signaling in the regulation of osteoblast differentiation related genes, it is 
therefore of interest to investigate the influence of ectopic expression of the NICD as well as of Heyl, 
Hesl and Lfng on osteoblast differentiation. Ectopic expression of NICD has previously been reported 
to induce the expression of both Heyl and Hey2 (34, 51). However, since Hey2 was not expressed in 
our previous experiments (results not shown), we decided to study the involvement of Notch 
signaling on BMP-induced osteoblast differentiation by focusing on the effect induced by ectopic 
expression of Heyl and Lfng.
Expression vectors containing the human Lfng (LFNG) and human Heyl (HEY1) genes were 
introduced into C2C12 cells, and stably expressing cells were identified for LFNG (Figure 3A), but 
could, for unknown reasons, not be established for HEYl. The differentiation capacity of the LFNG- 
expressing cells (C2C12-LFNG) was assessed by measuring Alp2 activity, Ca2+ deposition, 
morphological changes, as well as by expression regulation of early, intermediate and late osteoblast 
markers, and the myoblast differentiation marker myogenin (Myog) upon treatment of the cells with 
BMP2, TGF-P or a combination of both stimuli. Treatment of the cells with TGF-P and a
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combination of TGF-P and BMP2 was included in these experiments to study the effect of ectopic 
expression of LFNG on the capacity of TGF-P to inhibit osteoblast differentiation. Since we have 
previously shown that BMP-induced expression of endogenous Lfng was inhibited by TGF-P (30), we 
postulated that Lfng could be a positive regulator of osteoblast differentiation and might be able to 
counteract the inhibitory effect of TGF-P on BMP-induced osteoblast differentiation.
Figure 3. BMP2-induced osteoblast differentiation in C2C12-LFNG cells
(A) Expression of LFNG in C2C12-LFNG clones. Expression levels were measured by quantitative real-time RT-PCR, (B) Dose- 
dependent induction of ALP activity 48 hrs after BMP2-treatment in C2C12 (□) and C2C12-LFNG (o) cells, (C) Ca2+ deposition 
in C2C12-LFNG cells. Cells were seeded and grown for 24 hrs upon which medium was replaced by DMEM containing 5% NCS 
in the presence or absence of BMP2 (300 ng/ml) supplemented with P-glycerophosphate (12.5 mM). Calcium deposition was 
measured 8 days after stimulation, (D) Morphological features of C2C12-LFNG cells. Cells were seeded and grown for 24 hrs 
upon which medium was replaced by DMEM containing 5% NCS in the presence or absence of BMP2 (300 ng/ml), TGF-P 
(5ng/ml) or a combination of these growth factors. Photographs were taken 3 days after treatment, (E) Gene expression profiles in 
C2C12-LFNG cells. Cells were seeded and grown for 24 hrs upon which medium was replaced by DMEM containing 5% NCS in 
the presence or absence of BMP2 (300 ng/ml), TGF-P (5ng/ml) or a combination of these growth factors. Messenger RNA was 
used to measure the expression of 3 immediate early, 3 intermediate , 2 late phase osteoblast differentiation genes and 1 myogenic 
marker gene at the indicated time points. Mean expression levels were corrected for GAPDH and are expressed relative to the 
basal expression level in un-stimulated C2C12 cells. Error bars indicate differences between duplicate experiments.
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As shown in Figure 3A, expression of LFNG had no influence on the expression of 
endogenous Lfng, neither under control conditions nor upon TGF-P stimulation, but the BMP2- 
induced levels were approximately 2-fold increased in the LFNG expressing clones. Furthermore, the 
data represented in Figure 3B and 3C show that the C2C12-LFNG cells had lost their ability to 
differentiate into osteoblast cells, as evidenced by a complete lack of Alp2 activity and Ca2+ 
deposition, in comparison with control C2C12 cells. Remarkably, the C2C12-LFNG cells were 
morphologically very similar to normal C2C12 cells, such that they became elongated and fused 
under myogenic conditions (5% serum), and showed a cuboidal morphology after BMP2 treatment. 
Moreover, TGF-P was able to inhibit the morphological changes related to both myogenesis and 
osteogenesis (Figure 3D).
To investigate the genomic basis of these findings, the expression regulation of the immediate 
early BMP2 response genes Smad6, Prrx2 and Id-l, as well as that of the intermediate genes Cbfal, 
H eyl and Tcf7, was analyzed. In addition, the late osteoblast marker genes Alp2 and Ocn, the non­
osteoblast-specific late phase BMP2-regulated gene decorin (Dcn), and the myoblast marker Myog 
were analyzed as well. Figure 3E shows that the expression regulation profiles of Smad6, Id-l and 
Prrx2 were not or only slightly affected in LFNG-expressing cells. These results indicate that the 
immediate early gene regulation by BMP2 is probably not affected by Lfng. However, the 
intermediate osteoblast differentiation markers Cbfal and H eyl, as well as the osteoblast markers 
Alp2 and Ocn, showed strong inhibition of their BMP2-induced gene expression in the C212-LFNG 
cells. Furthermore, the expression levels of these genes were strongly reduced in the additional 
presence of TGF-P. These results indicate that Lfng might affect the overall ability of the cells to 
differentiate into osteoblasts. On the other hand, expression profiles of Tcf7, a transcription factor of 
the Wnt signaling pathway, were not or only very slightly affected. Expression of the decorin gene 
varied extensively between duplicate experiments in wild-type C2C12 cells (results not shown), and 
therefore no solid conclusions could be drawn from these results on the C2C12-LFNG cells.
Inhibition of osteoblast differentiation by Lfng might be due to a general inhibition of 
differentiation capacity of the C2C12 cells. Therefore, we investigated the expression of the myoblast 
differentiation marker Myog. Figure 3E shows that in wild-type C2C12 cells expression of Myog is 
extensively induced under myogenic differentiation conditions (control), whereas it is greatly reduced 
by BMP2 as well as by TGF-P. In the C2C12-LFNG cells, Myog was normally regulated under 
control conditions. However, inhibition of Myog expression by BMP2 was much less rigorous than in 
wild-type C2C12 cells, and inhibition of Myog expression by TGF-P was completely abolished. 
These results indicate that the C2C12-LFNG cells can still normally differentiate into myoblasts, and 
that the effect of Lfng on osteoblast differentiation is not an effect of a general inhibition of cellular 
differentiation.
In summary, our results indicate that over-expression of Lfng specifically inhibits the 
functional differentiation of C2C12 cells into osteoblasts. Most likely, Lfng has no influence on the 
initiation of osteoblast differentiation, but it inhibits the differentiation process at a later stage, such 
that no functional osteoblasts are formed.
Expression of Lfng during embryonal development
Results obtained from the above described experiments implicate that Lfng could play a role 
in modulating osteoblast differentiation. To study the role of Lfng during embryonic bone 
development, expression of this gene was analyzed in mouse embryos at E14.5 of gestation and in 
neonatal mouse tails by the use of in situ hybridization. Neonatal mouse tails were used because their 
primary centers of endochondral ossification are still developing in the most distal vertebrae. These 
vertebrae consist of alkaline phosphatase-negative cartilage whereas the most proximal vertebrae are
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alkaline phosphatase-positive and mineralized (39). The expression pattern of Lfng was compared to 
that of Cfbal and Heyl, which have previously been shown to be expressed in embryonic bone 
development with similar but distinct patterns (35, 45). We first confirmed the expression of Cbfal 
and Heyl at E14.5 in bone in transverse sections of the head at the level of the jaws (Figure 4D and 
4E), and in proximal vertebrae of the mouse neonatal tail (Figure 4G and 4H). The ossification 
centers of the developing mandibular and maxillary bones, nasal bone, dental mesenchyme 
surrounding the developing tooth, as well as proliferating chondroblasts, periostal osteoblasts and 
trabecular osteoblast all showed clear expression of Cbfal as expected (29, 44, 45). In addition, low 
but significant levels of expression of Heyl were observed in the mandibular and maxillary bones, as 
well as in the trabecular bone of the mouse neonatal tail vertebrae as expected (29).
Remarkably, Lfng did not display any detectable level of expression in the bones analyzed, as 
shown in Figure 4F and 4I. Possibly the probe used for this experiment may not have been sensitive 
enough for detection of Lfng expression. However, sagital sections of the head at the level of the 
ventricles at E14.5 of gestation showed significant levels of expression of Lfng (Figure 4C) and Heyl 
(Figure 4B) as expected (52-54), whereas Cbfal did not show any expression here (Figure 4A). 
Therefore, most likely in vivo expression of Lfng in bone is below the detection level of this 
technique.
Figure 4. In vivo expression o f Heyl and Lfng  in the developing mouse skeleton.
(A-C) Sagital sections of E14.5 mouse embryos at the level of the ventricles for the control osteoblast marker Cbfal (A), Heyl (B) 
and Lfng (C), (D-F) Transverse sections of E14.5 mouse embryos at the level o f the jaws for Cbfal (D), H eyl (E) and Lfng (F), 
(G-I) Mouse proximal tail vertebrae for Cbfal (G), H eyl (H) and Lfng (I). Abbreviations used: bm, bone marrow; D, 
Diencephalon; hc, hypertrophic chondroblasts; id, intervertebral disc; Jo, Jacobson’s organ; md, mandible; Mo, Medulla oblongata; 
mx, maxilla; nc, nasal cavity; nca, nasal capsule; P, periosteal bone; pc, proliferating chondroblasts; T, trabecular bone; tg, tongue; 
Sb, Skull bones, V, Ventricular zone; vb, vertebral body. See page 14 2for full color figure
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Discussion
The contribution of the various BMP-specific R-Smads (Smad-1, Smad-5 and Smad-8) as well 
as that of other signal transduction pathways, such as Erk1/2 MAP-kinase and Notch, in regulating 
BMP-induced gene expression during osteoblast differentiation is only known for a couple of genes 
and has not yet been related to time-dependent expression profiles. In this study, we examined the 
involvement of the BMP-specific R-Smads alone and in combination with Smad-4 on the expression 
regulation of various genes regulated during osteoblast differentiation and compared their effects with 
those of Alk2 and BMP2. Based on their responsiveness to Smads and the synergistic effects of 
Smad-4, we identified Smad-7, Tieg, Heyl, Alp2, Prdc, Wif-l and the ESTs AA222756, AA794l90 
and AA709999 as typical BMP-inducible genes.
However, we also identified two groups of genes with distinct Smad responsiveness. The first 
group, including Id-l, Id-2, Id-3 and Col6a2, consists of genes for which expression was modulated 
by over-expression of single BMP-specific Smads, without additional effects of co-expressed Smad-
4. In contrast to our results, it has been shown elsewhere that the Id genes are immediate target genes 
of BMPs (15, 55), and that expression regulation of Id-l by Smads resembles that of typical BMP- 
inducible genes (56). More experimental data will be required before it can be decided which of the 
two options is correct.
The second group, including Snail, Prrx2, Oasis, Smad-6, Tcf-7, Cbfal and Ocn, consists of 
genes for which expression was not affected after transfection by either single Smads or combinations 
with Smad-4. For these genes, the Smad signal transduction pathway is either not involved in their 
expression regulation, or is not sufficient on its own to induce expression. Tcf-7 is a major 
transcription factor of the Wnt/P-catenin signal transduction pathway, and it has been shown that both 
Tcf-7 and L efl, which encodes a family member of Tcf-7, can be induced by BMP (29, 57). It is 
unknown, however, whether this induction requires the activity of BMP-specific Smads. Expression 
of the gene for Cbfa1, the major transcription factor of the osteoblast specific marker Ocn (45), is 
mainly induced by p38 MAP-kinase (25). Furthermore, Smads are able to induce Cbfal expression 
through a JunB/p38 MAP-kinase cascade (25). In addition, it has recently been shown that 
PKA/CREB (protein kinase A/cAMP responsive element binding protein) signaling cooperates with 
BMP-specific R-Smads to enhance the expression of Smad-6, a BMP-specific inhibitory Smad (58). 
Therefore, it seems likely that expression of Snail, Prrx2, Oasis, Smad-6, Tcf-7, Cbfal and Ocn is 
regulated by Smads, but that Smads alone are not sufficient and the cooperation of other signal 
transduction pathways is required to induce their expression. Further research is required to establish 
whether these genes are indeed induced by Smads.
In addition to the BMP-induced Smad signal transduction pathway, the Erk1/2 MAP-kinase 
pathway has been implicated to play a role in osteoblast differentiation (6 , 8, 10). Here, we report that 
Erk1/2 MAP-kinase has a negative effect on the expression of a small number of the transcription 
factors tested, in particular Prrx2, Tieg, Heyl and type II Cbfal. In addition, most late phase bone 
marker genes, including Prdc, Col6a l  and the ESTs AA709999, AA794190 and AA222756, were 
also negatively regulated by Erk1/2 MAP-kinase. In conclusion, our results support the theory that 
inhibition of Erk1/2 MAP-kinase promotes osteoblastic differentiation, as postulated previously by 
Higuchi and coworkers (8).
Although it is known that the coordinated action of multiple pathways is required for optimal 
osteoblast differentiation, only few genes are known to act as focal points for interaction of the 
various pathways. As described above, Smads have been shown to induce expression of the osteoblast 
specific transcription factor Cbfal in an indirect manner through a JunB/p38 MAP-kinase cascade 
(25). In addition, Cbfa1 activation is regulated by Erk1/2 MAP-kinase (6). Therefore, Cbfa1 is one of
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the focal points for integration of both the p38 and Erk1/2 MAP-kinase pathways in osteoblast 
differentiation. In this study, we identified a total of six genes (Tieg, H eyl, Prdc, AA222756, 
AA794190 and AA709999) that were regulated by both the Smad and Erk1/2 MAP-kinase pathways, 
indicating that these genes also may act as key regulatory targets that integrate the two pathways in 
the process of osteoblast differentiation.
Tieg is an immediate early TGF-P/BMP response gene that has previously been shown to be 
regulated during BMP-induced osteoblast differentiation (29). Furthermore, it has been shown that 
Tieg acts as an enhancer of TGF-P signaling and mimics TGF-P action in human MG-63 osteoblastic 
cells, which for these cells results in induction of osteoblast differentiation (59, 60). Therefore, it 
seems likely that Tieg has a similar function in BMP-induced osteoblast differentiation.
Hey1 is a transcription factor of the Notch signal transduction pathway and has previously 
been proposed by us to be the focal point of Smad/Notch signaling during osteoblast differentiation 
(30). Since we have shown in this report that Heyl is also regulated by Erk1/2 MAP-kinase, this gene 
might be one of the major regulators of osteoblast differentiation. Indeed, Zamurovic and coworkers 
have recently shown that Hey1 is a negative regulator of osteoblast differentiation, which exerts its 
effect by binding to Cbfa1 and thereby inhibits its transcriptional activity (61).
Prdc and the ESTs AA222756, AA794190 and AA709999 are markers of late osteoblast 
differentiation (44), which suggests that these genes might be important in regulating the function of 
the mature osteoblast. Recently, it has been shown that Prdc is a specific BMP antagonist (62), which 
suggests that Prdc is a negative regulator of osteoblast function.
The Notch signal transduction pathway has been implicated in osteoblast differentiation, 
although contradictory results have been reported (11, 12, 63). In most studies, over-expression of the 
NICD has been used to measure the effect of Notch signaling on osteoblast differentiation. However, 
over-expression induces not only the expression of H eyl, but also that of Hey2, which is not 
expressed under physiological conditions during BMP-induced osteoblast differentiation in C2C12 
cells. As a consequence, over-expression of the NICD may result in aberrant regulation of osteoblast 
differentiation due to the additional presence of Hey2. Therefore we chose instead to use Fringe 
proteins to examine the effect of Notch signaling on osteoblast differentiation. This is particularly 
relevant, since in many cases the distribution of Fringe proteins is the key determinant that controls 
where and in which form Notch signaling is active (64).
Our results indicate that over-expression of LFNG specifically inhibits the expression of 
intermediate and late phase osteoblast markers whereas myogenic differentiation remains unaffected. 
Therefore, despite the large variation of Fringe expression levels in individual C2C12 clones and our 
inability to demonstrate Fringe expression in differentiating bone, we hypothesize that LFNG 
specifically inhibits the functional differentiation of C2C12 cells into osteoblasts. Most likely, Lfng 
has no influence on the onset of osteoblast differentiation, but inhibits further progression of the 
differentiation process so that no functional osteoblasts are formed.
Previously, we have shown that during osteoblast differentiation genes with specific functions 
are coordinately regulated in time (29, 44). These data in combination with the results obtained in this 
study suggest a model in which multiple rounds of transcription regulation, induced and modulated by 
various signal transduction pathways, are involved in BMP2-mediated osteoblast differentiation as is 
outlined in the model presented in Figure 5. The basis of this model is formed by a set of immediate 
early and intermediate early general BMP-response genes that are regulated at the onset of 
differentiation. These genes are likely to be direct target genes of BMP2 and are primarily Signal 
Transduction related genes. The transcription factors expressed at this stage of osteoblast 
differentiation might subsequently regulate the expression of the late early genes in the second layer 
of transcription regulation. Here, an increasing number of regulated genes encode Structural proteins
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that, in combination with a number of osteoblast-specific transcription factors such as Heyl, Tcf7 and 
Cbfal, reflect the commitment of the cells to the osteogenic lineage. The ultimate signal for 
osteoblast differentiation is provided by expression of osteoblast marker genes in the third layer as a 
result of the action of osteoblast-specific transcription factors. During the entire process, gene 
expression is regulated, at least in part, by BMP-specific R-Smads, often in combination with Erkl/2 
MAP-kinase and Notch signaling, particularly for the expression of late phase bone markers. The 
effect of Erkl/2 MAP-kinase on expression regulation is probably indirect through Erkl/2-dependent 
phosphorylation of Cbfal (6) and possibly of other transcription factors.
Figure 5. Model of multi-layered BMP induced osteoblast differentiation 
For details see text, CHX = cyclohexamide. See page 143 for color figure
In conclusion, our results show that BMP-induced osteoblast differentiation employs a multi­
layered cascade in which the initial phase of differentiation is based on general BMP-response genes. 
During the progression of osteoblast differentiation, osteoblast commitment genes and osteoblast 
specific genes are regulated in concert with the general BMP-response genes. In addition, Erkl/2 
MAP-kinase and Notch signaling become more and more effective in modulating expression profiles, 
which ultimately leads to a functional osteoblast characterized by the deposition of a calcified 
extracellular matrix.
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6General Discussion
Chapter 6
The skeleton is continually being regenerated by the concerted action of bone forming cells, 
the osteoblasts, and bone resorbing cells, the osteoclasts (1). In adults, bone formation and 
degradation are in a delicate balance, and serious clinical skeletal disorders may arise from a 
disturbed bone homeostasis. For instance, in so-called sclerosing bone diseases such as osteopetrosis, 
sclerosteosis and Van Buchem’s disease, the balance has been shifted towards the osteoblasts and too 
much bone is formed, whereas in osteoporosis this balance has been shifted towards the osteoclasts 
and too much bone is resorbed. To date, no treatment is available for patients suffering from 
sclerosing bone diseases, while current therapies for osteoporosis focus primarily on inhibiting the 
function of the osteoclasts. However, therapies that target induction or enhancement of bone 
formation may also be effective for osteoporosis patients. In this thesis, we studied the regulation of 
osteoblast differentiation with the aim to discover new drug targets that may be used for induction of 
bone formation and that are the basis of novel treatments of skeletal disorders.
Mesenchymal stem cells (MSCs) have the potential to differentiate into a variety of cell types 
including osteoblasts, chondroblasts, myoblasts, adipocytes and fibroblasts, depending on the 
signaling cascades activated during the initial phase of differentiation (for review see ref. 2). The 
most important inducer for differentiation of MSCs into osteoblasts are the BMPs, which are known 
to be involved in various differentiation processes during embryonic development (for review see ref. 
3). The observation that BMPs and components of the BMP signaling cascade are involved in skeletal 
disorders suggests that a search for additional components of the BMP signaling pathways may reveal 
new genes that also play a role in bone-related diseases. In order to develop effective and selective 
therapies, it is therefore important to understand the molecular mechanisms of BMP signaling in more 
detail. Currently, only a few key- or co-regulators of BMP-induced osteoblast differentiation are 
known. Since such genes may be attractive targets for therapy, it is of great importance to identify 
additional regulators.
Particularly transcription factors are potential key- and co-regulators of osteoblast 
differentiation because these proteins are generally considered to be major regulators of 
differentiation processes. Using the gene expression microarray (GEM) technique, it is possible to 
study gene expression patterns of thousands of genes simultaneously during the differentiation 
process. By comparing the expression profiles of transcription factors regulated during osteoblast 
differentiation with those in fibroblasts, it is possible to identify specific key- and co-regulators of 
osteoblast differentiation.
6.1 Regulators of BMP-2-induced osteoblast differentiation
In this thesis, the identification of novel regulators of BMP-2-induced osteoblast 
differentiation in mouse cells is described. Microarray analysis revealed a set of 184 transcripts to be 
regulated by BMP-2 during the first 24 hrs of osteoblast differentiation (Chapter 3, Figure 1A and 
1B). In addition, 61 transcripts were identified to be differentially regulated by BMP-2 and TGF-P 24 
hrs after treatment of the cells with these growth factors (Chapter 4, Table 1). In addition to 
established osteoblast differentiation-related genes, we identified various ESTs (expressed sequence 
tags) as well as several genes that have not been implicated before in osteoblast differentiation, such 
as the Wnt pathway transcription factor gene Tcf7 (T-cell specific transcription factor 7), and the 
Notch pathway genes Hey1 (Hairy/enhancer of split related with YRPW motif 1) and Lfng (Lunatic 
fringe) (Chapters 3 and 4).
Evidence is provided that Tcf7 is a positive regulator of osteoblast differentiation (Chapter 3), 
whereas Lfng is most likely a negative regulator of osteoblast differentiation (Chapters 4 and 5).
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Since MSCs are also able to differentiate into other cell types such as myoblasts and fibroblasts, it 
cannot be excluded that Lfng is a positive regulator of the differentiation of MSCs towards one of 
these cell types, thereby indirectly inhibiting osteoblast differentiation. However, we demonstrated in 
Chapter 5 that over-expression of Lfng has no effect on myoblast differentiation. This result suggests 
that Lfng inhibits osteoblast differentiation without promoting differentiation towards other cell types. 
Heyl has recently also been shown to act as a negative regulator of osteoblast differentiation (4). 
Potentially, also the ESTs identified in our studies may therefore encode regulators of osteoblast 
differentiation (the immediate early ESTs) or of osteoblast function (the intermediate and late early 
ESTs). Elucidating the genes from which these ESTs originate, as well as determining the encoded 
protein, is therefore an important step in identifying potential additional novel regulators of osteoblast 
differentiation.
Regulation of differentiation processes is not only mediated by the level of transcription 
modulation of key- or co-factors, but also by the activity and stability of the encoded proteins. In 
Chapter 5 we show that Lfng is still most likely a negative regulator of osteoblast differentiation 
although the level of Lfng mRNA transcripts in developing bone is below the detection level. It is 
therefore important to study the regulation of the protein expression of Lfng and other potential key 
regulators during osteoblast differentiation.
Ducy and others have postulated that osteoblasts are essentially “sophisticated fibroblasts”, 
that can respond selectively to a set of physiological signals to induce differentiation. As a result, 
osteoblasts originating from different parts of the body exhibit different gene expression patterns (5, 
6). In this thesis, we have shown that many genes that are regulated during early phase osteoblast 
differentiation, encode proteins that function as signal transduction regulators, enzymes and 
modulators of cell adhesion, cytoskeleton formation and extracellular matrix formation, and that 
several members of the same protein family are regulated during osteoblast differentiation (Chapters 
3 and 4). It can therefore be postulated that, in order to establish a highly specialized tissue such as 
bone, a limited set of osteoblast-specific transcription regulators is sufficient for guiding MSCs to 
become mature osteoblasts provided that they act in combination with general BMP-responsive 
transcriptional regulators.
This so-called “all in the balance” theory requires that both the key-regulatory proteins and 
general proteins are present at the correct level and time to achieve a balance between inductive and 
repressive differentiation processes. Any shift in this balance during osteoblast differentiation, or 
disturbance in the inductive and repressive signals could then lead to either more bone formation, or 
less bone formation, according to the time at which the disturbance occurs. This balance concept also 
ensures that at different places in the body, osteoblastic cells can respond differently to physiological 
signals. As a consequence, osteoblast-specific transcriptional regulators are potentially good 
candidates for drug targeting.
We focused in this study on the transcription factors that are regulated during the early phase 
of osteoblast differentiation and compared the expression profiles of these genes in differentiating 
osteoblasts with those in BMP-2 treated fibroblasts. In Chapter 3 (Table 3 and Figures 2 and 3) it is 
shown that the transcription factors Tcf7 and Hey1 are specifically regulated in differentiating 
osteoblasts, both in vitro and in vivo. Moreover, over-expression of Tcf7 results in increased 
osteoblast differentiation as measured by ALP (alkaline phosphatase) activity and calcium deposition 
(Chapter 3, Figure 4). As mentioned above, Hey1 has been shown to be an inhibitor of osteoblast 
differentiation. Therefore, Tcf7 might be considered a potential drug target for therapies in which 
osteoblast differentiation should be stimulated (osteoporosis), whereas Hey1 might be a drug target 
for bone overgrowth diseases. Potential strategies to develop drugs that regulate Heyl and Tcf7 
protein activity are described in more detail below in section 6 .2 .2 .
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6.2.1 Diagnosing bone diseases
Traditionally, the diagnosis of bone-related diseases is based on the clinical analysis of 
skeletal abnormalities. These abnormalities are usually identified by autoradiography of the skeleton 
and bone mineral density (BMD) measurements (7). BMD is influenced by both genetic and 
environmental factors. In recent years, genetic research has provided major breakthroughs in the 
understanding of hereditary clinical conditions that are characterized by increased bone density (for 
review see ref. 8). Particularly the positional cloning approach, which aims at the identification of 
disease-causing genes, has benefited greatly from the increasing DNA sequence information available 
from the Human Genome Project.
Disease-causing genes are genes whose cognate protein is either defective or misexpressed 
ultimately causing the particular disease. Defective proteins are the consequence of mutations in the 
DNA sequence of these genes, whereas misexpression (either over- or under-expression, or 
expression at the wrong point in time) of disease-causing genes is usually the result of mutations in 
the regulatory DNA sequences of the gene. Misexpression of normal genes can also occur due to the 
altered activity of gene expression regulatory proteins, but in that case, the latter are designated as the 
disease-causing genes.
In positional cloning, linkage analysis among patient families is used to determine the 
chromosomal localization of potential disease-causing genes. Subsequently, genes located at the 
identified genome position are tested for mutations. Using this approach, disease-causing genes have 
recently been identified for several bone diseases including sclerosteosis (the SOST gene), 
osteopetrosis (with renal tubular acidosis and cerebral calcifications; the carbonic anhydrase II gene) 
and Blomstrand dysplasia (a neonatal severe osteosclerotic dysplasia; the PTH receptor 1 gene) (8).
In contrast to this “from clinic to gene” approach, it is also possible to identify disease-causing 
genes using the reverse methodology, referred to as “from gene to clinic”. In the latter approach, 
disease-causing genes are identified by generating knockout mice, or by down-regulating gene 
expression by RNA interference. When a knockout mouse is presented with a phenotype that 
resembles a human skeletal disease, the human orthologue of this particular gene can subsequently be 
screened for mutations that might cause defective proteins or impaired expression of the protein. For 
example, knockout mice for Cbfa1 (Core binding factor 1/AML1/Runx2/PEBP2aA) were shown to 
exibit a phenotype resembling the human disease Cleidocranial dysplasia (9). Since the human 
orthologue of this gene was shown to map to the chromosome locus 6p21 (10, 11), the locus for 
Cleidocranial dysplasia (12), it was suggested that mutations in Cbfa1 caused this disease (9). Indeed, 
subsequent analysis in human patients revealed the existence of several mutations in this gene causing 
a defective protein, and it was shown that different levels of Cbfa1 protein activity corresponded with 
Cleidocranial dysplasia symptoms (13).
The GEM technique may be an important tool specifically for the identification of 
misexpressed disease-causing genes. Although to our knowledge this approach has not been described 
for bone diseases, it is an established approach in cancer diagnosis and establishment of the most 
optimal therapy for treatment (14-18). In human acute lymphomas, gene expression profiling has 
been described in combination with in silico clustering of the profiles to identify specific gene 
expression profiles between acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) 
as well as all of the subtypes of ALL (T-ALL, hyperdiploid with >50 chromosomes, BCR-ABL, E2A- 
PBX1, TEL-AML1 and MLL gene rearrangement) (15, 17). Moreover, within each ALL subgroup, 
distinct expression profiles were identified that predicted relapse after therapy. Importantly, no single
6.2 BMP-induced gene expression profiles in diagnosis, drug target discovery and therapy
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gene was identified to be of use to predict relapse, but rather patterns of expression of a combination 
of genes were found to be predictive (17).
In analogy, MSCs from patients can be harvested from bone, myogenic or fatty tissue, and 
induced to differentiate into osteoblasts (for review see ref. 19). Gene expression profiles of such 
“diseased” osteoblasts can then be compared to those of “healthy” osteoblasts using the GEM 
technique, and differentially expressed genes can be identified. Depending on the time point of 
expression and the function of the identified genes, it would then be possible to determine whether in 
a patient with a particular bone-related disease, osteoblast differentiation, function or apoptosis is 
impaired. The GEM technique used in this manner can therefore become of primary importance for 
the diagnosis and prognosis of individual patients. The GEM technique can also be used to select 
appropriate drug targets for therapy, as will be discussed in another section of this chapter (see section 
6 .2 .2 ).
In this thesis, gene expression profiles of a “healthy” mouse osteoblast during the first 24 hrs 
of differentiation upon BMP treatment have been described. This dataset can be used as a reference to 
identify bone diseases that are caused by impaired or enhanced osteoblast differentiation according to 
the methodology described above. However, this approach will only be the first step in identifying 
misexpressed disease-causing genes in the “from gene to clinic” approach. Subsequent research in 
mouse models in which potential genes are knocked-out or over-expressed, in combination with 
mutational analysis in patients, are just one of the steps needed to positively identify the disease- 
causing genes.
6.2.2 Drug target discovery
Gene expression profiling is a relatively new approach to identify potential drug targets. The 
most common application compares gene expression levels in diseased tissues with those from 
normal tissues, obtained from either humans or animal model systems, or by analyzing cells or tissues 
that were drug treated (20). For example, several investigators have compared gene expression 
profiles of postmortem samples of the frontal lobes of patients with schizophrenia with those of 
healthy persons. It was shown in these experiments that the expression of synapsin and of genes 
involved in both presynaptic function as well as postsynaptic responsiveness is down-regulated in 
patients with schizophrenia. Furthermore, it was found that five specific metabolic pathways 
previously not implicated to play a role in schizophrenia were also down-regulated (21-23). These 
results not only contributed to the understanding of the molecular basis of schizophrenia, but also 
provided a list of genes that might be potential targets for drug development. Although these GEM 
experiments have greatly attributed to the understanding of schizophrenia, many questions regarding 
the initial causal changes leading to the disease remain to be answered. Moreover, it should be noted 
here that although GEM experiments can provide a list of potential drug target genes, additional 
research in the field of systematic analysis of gene function, proteomics and high troughput screening 
of potential drugs has to be performed before effective therapies based on GEM data can be realized.
Potential drug targets could also be discovered by gene expression profiling of normal tissue 
or cells. It is important to note here that drugs should be efficient in enhancing or inhibiting the 
normal function of its target, preferably specific for its target tissue, and easy to administer. 
Therefore, clinically relevant drugs include small soluble growth factors or cytokines, antibodies and 
protein antagonists, while clinically relevant drug targets include cell membrane receptors, nuclear 
receptors, and small soluble growth factors or cytokines. In order to identify potential drug targets 
from gene expression profiling of normal cells, it is not only important to know the function of the 
genes, but also whether they are expressed in a transient or sustained manner. Therefore, time-based
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expression profiling in combination with in silico data mining is one of the best options to identify 
potential drug targets from normal cells.
In this thesis, we provide a list of genes that are expressed within the first 24 hrs of BMP- 
induced osteoblast differentiation (Chapter 3, figure 1). Using in silico data mining, we identified 16 
genes encoding receptors, 17 genes encoding transcription factors and 9 genes encoding growth 
factors/cytokines to be regulated by BMP-2 during early phase osteoblast differentiation. Of the genes 
encoding receptors, 9 were found to be down-regulated while 7 were up-regulated (Chapter 3). These 
up-regulated genes include Gpr97 (G-protein coupled receptor 97), an EST highly similar to the 
frizzled receptor, MuSK2 (Neural fold/somite kinase 2), cholecystokinin and TF (Tissue 
factor/coagulation factor 3), P-selectin (Platelet selectin), and Gadd45y (growth and differentiation 
factor 45y). For some of these receptors (including GPR97 and Gadd45Y), no function has yet been 
established in osteoblast differentiation. Using mouse knock-out and ectopic over-expression studies, 
as well as RNA inhibition approaches in combination with BMP-induced differentiation experiments, 
a systematic analysis of the functions of these genes during osteoblast differentiation should first be 
established. If  these genes are indeed involved in osteoblast differentiation, they might be used as 
potential drug targets and research should focus on identifying small molecules that specifically 
enhance or inhibit their activity, depending on their role in osteoblast differentiation.
Cholecystokinin has been shown to be important for dietary needs (24, 25) and both P-selectin 
and TF are important factors for angiogenesis. Since both diet and angiogenesis influence bone 
formation, these receptors might be very important in bone formation. Indeed, both cholecystokinin 
and TF have been shown to regulate bone formation in vivo (26, 27). Cholecystokinin is a potential 
negative regulator of cartilage formation in vivo, since an antagonist of this receptor was shown to 
magnify cartilage formation when administered in vivo. Subsequently, it was shown in rabbit primary 
chondrocytes that this magnification of cartilage formation was not due to increased chondrocyte 
differentiation, but enhanced chondrocyte proliferation (maturation) (26).
A paste of human recombinant tissue factor (hrTF), autologous calvarial bone chips, platelet- 
rich plasma and tetracyclin has been shown in a clinical study to induce maxillary bone graft 
regeneration. Histology of the maxillary bone graft revealed a normal vascularization and bone 
formation in the bone graft (27). Since TF is an important factor in angiogenesis, it is very likely that 
hrTF influences the regeneration of the bone graft by regulating blood vessel formation, while having 
no influence on osteoblast differentiation directly. However, since we observed an increase in TF 
expression in our experiments, it might also be possible that TF directly influences osteoblast 
differentiation. To establish whether TF directly influences osteoblast differentiation, further research 
is needed.
Finally, the EST exhibiting high similarity to the Frizzled receptor might constitute a novel 
member of the Frizzled receptor family. This family is known to transduce Wnt-signals, which has 
been shown to be very important in regulating osteoblast differentiation (28-34). However, due to the 
fact that Wnt signaling is also very important for normal embryonic development and tissue 
formation, Frizzled proteins are not very likely candidates for drug targetting. On the other hand, if 
this EST indeed constitutes a novel member of the Frizzled receptor family, it might also be possible 
that it functions in an osteoblast specific manner, rendering it potentially suitable to use as a drug 
target. Therefore, identifying the gene to which this EST localizes and its cognative protein as well as 
a systematic analysis of its protein function is required first to establish whether this EST might 
constitute a potential drug target.
In addition to receptors, transcription factors are potential drug targets. In this thesis we 
identified 17 transcription factors that are regulated during osteoblast differentiation of which 14 are 
up-regulated by BMP-2 (Chapter 3, figure 1). These include several general BMP-response factors,
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such as the Id genes (Inhibitor of differentiation genes), as well as two osteoblast specific 
transcription factors, Hey1 and Tcf7 (Chapter 3, figure 1 and Table 3). As mentioned above, Tcf7 has 
been shown to be an enhancer of BMP-induced osteoblast differentiation, and might therefore be 
considered a drug target for therapies in which osteoblast differentiation should be stimulated 
(osteoporosis). In contrast, Heyl has been shown to be an inhibitor of osteoblast differentiation, and 
might therefore be a drug target for therapies in which osteoblast differentiation should be inhibited 
(bone overgrowth diseases).
In order for Hey1 and Tcf7 to function as drug targets, it will be necessary to regulate their 
expression levels and activity indirectly through activation of relevant cell surface receptors. Tcf7 is a 
member of the Lef/Tcf7 transcription factor family that transduces Wnt signals, and the receptors of 
the Wnts are the Frizzled proteins (30, 35-37). Therefore, small molecules that induce specific 
Frizzled proteins or that enhance the function of specific Wnts, could function as potential drugs for 
regulation of Tcf7 activity. However, due to the fact that Wnt signaling is also very important for 
normal embryonic development and tissue formation, developing drugs that specifically target Tcf7 in 
osteoblasts will be very challenging. Hey1 is a member of the Hes/Herp family of transcription 
factors that transduce Notch signals (38). Both the Notch receptor and its ligand are transmembrane 
proteins (39) and are therefore potential drug targets. However, soluble ligands are known to inhibit 
Notch signaling instead of activating it (39), and therefore developing drugs that stimulate Notch 
signaling and hence stimulate the function of Hey1 through its receptors will be very difficult. In 
contrast to the stimulation of Hey1 activity in therapies in which osteoblast differentiation should be 
inhibited, down-regulation of Hey1 activity might be used in therapies in which osteoblast 
differentiation should be stimulated. In these therapies, inhibition of Hey1 activity through the use of 
soluble ligands might abolish its negative regulation of osteoblast differentiation, and might therefore 
stimulate osteoblast differentiation.
Other potential drug targets are cytokines and other soluble extracellular factors. In this thesis, 
we identified several of such factors that were regulated during osteoblast differentiation (Chapter 3). 
These include amongst others Vegf (vascular endothelial growth factor), Plgf (placental growth 
factor), Mcp-1/Scya2 (Monocyte chemoattractant protein 1/Small inducible cytokine A2) and Mcsf 
(Macrophage colony stimulating factor). Vegf is known to stimulate angiogenesis and has recently 
been described to promote bone formation in tissue engineering (see section 6.2.3).
As mentioned above, bone formation and bone homeostasis are the net result of a balance 
between the activities of osteoblasts and osteoclasts. These activities are coupled to each other, since 
differentiated osteoblasts express factors such as Rankl that promote osteoclast differentiation from 
monocyte/macrophage precursors (40). In this respect, the three growth factors Plgf, Mcp-1 and Mcsf 
have all been shown to be expressed by osteoblasts (41-43), and Mcp-1 and Mcsf have been shown to 
regulate bone formation by positively regulating the differentiation and activity of osteoclasts (42, 
43). In addition, Plgf has also been proposed to regulate osteoclast differentiation or function since it 
has been shown to activate monocytes during inflammation (41, 44). Therefore, the transient up- 
regulation of these three growth factors by BMP-2 as shown in this thesis (Chapter 3, figure 1), might 
be linked to the onset of recruitment and differentiation of osteoclast precursors, similarly as happens 
in vivo. On the other hand, we and others have shown that Mcp-1 is able to enhance BMP-2-induced 
osteoblast differentiation and function, implying that the transient expression of Plgf, Mcp-1 and M csf 
might also be necessary for the induction of osteoblast differentiation (M. Kuijer, personal 
communication; E.A. Kaiser, abstract on ASBMR 2003 meeting). As a consequence, these three 
factors might be potential drug targets for bone diseases. In order to investigate their role in osteoblast 
differentiation, mouse knockout and ectopic over-expression experiments, as well as RNA inhibition 
approaches coupled to BMP-induced osteoblast differentiation experiments are required. The next
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step in drug development will then be the development of small molecules resembling Plgf, Mcp-1 or 
Mcsf, which specifically target osteoblasts and not osteoclasts.
To asses the efficiency of potential new drugs BMD measurements can be used in 
combination with measurements on bone strength (fracture rate). However, these methods require 
long term follow-up procedures. Therefore, researchers are now focusing on the identification of 
“biomarkers” that can be tested quickly and efficiently and give a good prognosis on the efficacy of 
the treatment. Gene expression profiling is one of the methods that might be used to monitor the 
function of potential drugs on bone formation. In this thesis, we provide a list of genes that are 
regulated by BMP-2 during the early phase of osteoblast differentiation (Chapter 3, Figure 1). 
Researchers who want to establish whether a potential drug is able to affect osteoblast differentiation, 
can use this list as a reference by which they can correlate gene expression profiles of drug-treated 
‘healthy’ cells and drug-treated ‘diseased’ cells. Alternatively, the list may be used to select a number 
of marker genes to test the effect of the drug on osteoblast differentiation (“biomarkers”). However, it 
should be noted here, that also these new biomarkers should first be validated clinically before they 
can be used in general to predict efficiency of novel drugs on osteoblast differentiation and function.
6.2.3 Tissue engineering therapies
Millions of people all over the world suffer from skeletal tissue loss due to injury, disease or 
congenital malformation (45). With a progressively aging population, there is an increasing demand 
for therapies to regenerate or replace the lost tissue. Bone grafting and joint prostheses have been 
effective in alleviating much of the disability associated with loss of bone or cartilage, but these 
therapies suffer from serious limitations such as lack of either autogenic (from the patient itself) or 
allogenic (from another person) donor tissue, rejection of allogenic or alloplastic (fabricated) donor 
tissue or susceptibility to infections. Therefore, in recent years, much research has focused on tissue 
engineering approaches for the development of biological substitutes in tissue replacement.
Tissue-engineering strategies utilize specific combinations of bioactive factors, scaffolds, and 
cells. In skeletal tissue engineering, recombinant BMP-2 and BMP-7/OP-1 have been used 
successfully to treat open tibia fractures, tibial nonunions and to enhance fusion of the spine (for 
review see ref. 46). However, supraphysiological doses of these recombinant proteins are required for 
the induction of bone formation, which renders this procedure inefficient. Moreover, in difficult 
clinical situations where there is not much bone left, a single dose of recombinant protein may not 
provide a sufficient osteogenic response (46).
Due to the limitations on using bone grafts as scaffolds, current research on tissue engineering 
focuses on the use of synthetic, preferentially biodegradable, sponge-like scaffolds that provide a 
solid framework for cell growth and differentiation at a local site, allowing cell attachment and 
migration. The scaffold may be implanted alone to induce host cell migration to the wound site and 
initiate tissue regeneration, but more frequently, tissue engineers focus on the inclusion in the 
scaffolds of cell types capable of differentiating to osteoblasts (for review see ref. 47). Cells can be 
obtained from a number of sources at various stages of differentiation, and, in many cases, tissue 
regeneration requires or is enhanced by the introduction of biochemical signals, in the form of growth 
factors, cytokines or other environmental cues, such as mechanical stimulation, which direct cellular 
responses including proliferation, differentiation and matrix synthesis (47).
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6.2.3.1 Stem cells in bone tissue engineering
Numerous cell types are available for tissue engineering strategies, including embryonic stem 
cells (ES cells), mesenchymal stem cells and differentiated osteoblast cells. ES cells are the most 
optimal type of cells to use for tissue engineering, since they exhibit unlimited proliferation in vitro 
and have the ability to differentiate into any cell type in the human body. However, due to scientific, 
legal, political and ethical questions regarding the use of these ES cells, alternative sources such as 
bone marrow, muscle, fat and brain are currently investigated for obtaining mesenchymal stem cells 
(MSCs), which are capable to differentiate into osteoblasts (46). Although transplanted stem cells 
induce tissue regeneration, until recently no prove could be found for the integration of these 
transplanted stem cells into the new tissue. Recently, however, several groups have shown that 
transplanted neural progenitor cells as well as bone marrow stromal cells (BMSCs) not only 
contribute to tissue regeneration, but differentiate and integrate into the newly formed tissue (48-51).
Both in animal and human studies BMSCs have been reported to enhance critical size bone 
fracture repair (for review see ref. 19). Critical size bone fractures are fractures that are too large to 
heal naturally. Usually, tissue engineering is required for the repair of these fractures. The crucial step 
in this BMSC-based procedure is the harvesting and ex vivo expansion of the BMSCs. Expansion of 
the BMSC population is generally required since the harvesting of BMSCs (preferentially autogenic) 
is a painful procedure and there is a limit on donor sites suitable for harvesting the BMSCs. On the 
other hand, harvesting MSCs from muscle or fat is a much less invasive procedure and usually yields 
a larger pool of stem cells. Ex vivo expansion of MSCs generally leads to a progressive decrease of 
proliferation and loss of the multilineage differentiation potential (19). Therefore, the development of 
optimal culture conditions to select or isolate a stem cell subpopulation, that can self-renew for a long 
period of time while maintaining its multi-differentiation potential, is very important for using MSCs 
in therapy. An approach that has been used to maintain the indefinite, multipotential proliferation of 
MSCs is to transfect these cells with the human telomerase reverse transcriptase (hTERT) gene to 
overcome telomere shortening and senescence (19). These hTERT-transduced human MSCs, when 
implanted in immunodeficient mice, showed enhanced bone formation compared to normal cells (52, 
53), indicating that this procedure can be used to stimulate bone formation. However, reports on the 
carcinogenic capacity of these cells are contradictory (52, 54, 55). Therefore, this approach needs 
further investigation before it can be implemented in human therapy.
The finding that carrier-bound recombinant BMPs can be used to restore bone defects 
suggests that BMPs are able to recruit autologous mesenchymal stem cells to the site of injury and 
induce their differentiation into osteoblasts. It is not known whether this process depletes the local 
stock of stem cells or whether BMPs are able to initiate differentiation of the stem cell population 
while also maintaining the pool of undifferentiated cells by inducing self-renewal. It has recently been 
described that BMPs support the self-renewal of ES cells, but the precise mechanism remains unclear 
(56, 57). In this thesis, we observed that BMP-2 induces the expression of Sca-1/Ly6a (Stem cell 
antigen 1/lymphocyte antigen 6) 24 hrs after treatment, while this expression was down-regulated 
upon TGF-P treatment (Chapter 4). Recently, it has been reported that Sca-1/Ly6a is required for the 
self-renewal of mesenchymal stem cells (58), and therefore our results indicate that BMPs may be 
capable of maintaining and regulating the pool of undifferentiated stem cells by regulating Sca- 
1/Ly6a expression during osteoblast differentiation. In light of these findings, BMPs might possibly 
be used to optimize the expansion of multi-potent MSC cultures, for example by applying BMP at 
concentrations that are insufficient to induce osteoblast differentiation.
In addition to engineering MSCs to maintain their multi-potentiality and proliferation 
capacity, MSCs have been transfected with BMP genes and introduced in vivo in order to enhance 
their own differentiation capacity as well as that of local stem cells, and thereby to enhance the
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effectiveness of bone therapy (46). Although it has been shown that these BMP-expressing MSCs are 
much more efficient in inducing osteoblast differentiation and repairing bone defects than normal 
MSCs, the efficiency of this approach is less than the often used but very invasive bone grafting 
therapy. This suggests that the former approach still needs further optimization. Indeed, it has recently 
been reported that using a pool of BMP-4-expressing MSCs and VEGF-expressing MSCs is much 
more potent in restoring bone defects than BMP-4-expressing MSCs alone (59). Important to note 
here is that the ratio of VEGF-expressing cells to BMP-4-expressing cells was critical to ensure the 
enhancement of bone healing elicited by these cells. In other words, too much expression of VEGF 
compared to BMP-4 inhibited bone formation instead of stimulating it (59).
The use of genetically engineered MSCs should therefore not only be tested for the short-term 
effects, such as restoration of bone formation within a couple of weeks, but also for long-term effects 
in order to exclude the occurrence of detrimental side effects. In this thesis, we have identified several 
genes that have not previously been correlated with osteoblast differentiation (Chapters 3 and 4). 
Moreover, we have shown that the product of one of these genes, the transcription factor Tcf7, is an 
enhancer of BMP-induced osteoblast differentiation (Chapter 3). Therefore, this factor might be used 
to further optimize MSC-based bone therapies, e.g. by engineering MSCs expressing Tcf7 and using 
these Tcf7-expressing MSCs in combination with the BMP- and VEGF-expressing MSCs. In addition 
to Tcf7, the lists of genes involved in osteoblast differentiation provided by us could also help 
researchers to identify additional genes that enhance osteoblast differentiation and might therefore be 
used in engineering MSCs for various bone therapies.
In conclusion, gene expression profiles can help to optimize diagnosis, drug target discovery 
and tissue engineering therapies of bone diseases. Novel key- and co-regulators of BMP-induced 
osteoblast differentiation have been identified and some of the many genes regulated during 
osteoblast differentiation may be novel potential drug targets. To investigate the actual potential of 
these genes for use in therapies in more detail, a comprehensive analysis of their function during 
osteoblast differentiation is required first. This may be achieved by using mouse knockout and ectopic 
over-expression studies, as well as by RNA inhibition strategies in combination with BMP-induced 
differentiation experiments. Subsequently, MSCs expressing drug target genes might be developed, 
and tested for efficiency in restoring bone formation in vivo. Furthermore, small biochemical 
molecules could be engineered that enhance, inhibit or mimic specific functions of drug targets, and 
subsequently tested for their efficiency in restoring bone formation in vivo.
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Figure 3 (C hapter 1). Signal transduction via BMP receptors and regulation of BMP-induced signaling.
Signal transduction via BMP receptors can be mediated 1) by binding of BMP to two preformed type I/II dimeric complexes, 
subsequently inducing a conformational change that activates this complex, or 2) by binding of BMP to high affinity type I homo- 
/heterodimeric receptor complexes, subsequently recruiting unliganded BMPR-II homodimers into the complex. Furthermore, each 
of the different receptor oligomers may allow association of different cytoplasmatic proteins (indicated as X, Y and Z) which may 
participate in the regulation of distinct pathways. See text for details. Regulation of BMP-induced signaling is achieved by I) 
extracellular agonists and antagonists, II) pseudoreceptors, III) inhibitory Smads, IV) Smad binding proteins and IV) proteasomal 
degradation. See text for details. (Adopted from Canalis et al. (2003), see ref. 209)
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Figure 4 (C hapter 1). Interactions o f the MAPKinase and Smad signal transduction pathways.
To regulate osteoblast differentiation, multiple points of convergence between the MAPKinase and Smad pathways can be 
identified: I) BMPs differentially activate p38, Erk1/2 and Jnk, II) BMPs activate individual API components, III) BMPs regulate 
the expression of API components, IV) p38 MAPKinase stimulates Smad-1 phosphorylation, V) Erk1/2 MAPKinase activates the 
Cbfal protein, VI) Erk1/2 MAPKinase can phosphorylate R-Smads, and VII) Erk1/2 and Jnk MAPKinase can regulate the activity 
of Smad binding proteins. See text for details.
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Figure 5 (C hapter 1). Interactions of the Wnt and Smad signal transduction pathways.
Points of convergence between the Wnt and Smad pathway: I) BMPs induce the expression of Wnt signal transduction genes 
including Wnt, Frizzled and Lef1, II) Smad-4 is a co-activator of p-catenin, III) Lef/p-catenin regulates activity of Cbfa1, and IV) 
b-catenin regulates the activity of Smad binding proteins. See text for details.
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Figure 6 (Chapter 1). Interaction o f the Notch and Smad signal transduction pathway.
The Notch intracellular domain (NICD) interacts with R-Smad/Co-Smad complexes in the nucleus thereby inducing the expression 
o f Notch transcription factors such as Hes-1. See text for details.
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Table 3 (Chapter 2). BMP2, TGF-(3l and activin A exhibit different sets of significantly regulated early genes (p < 0.01).
Category
Genbank  
Accession no. Gene Name BMP2 T G F -pi activin A
I B t AA002322 EST 1.5 1.0 1.0
A I894068 VI m. Fos-like antigen 2 1.3 1.0 1.0
II b ,t T W 88094 Mm. Chemokine (C-X-C) receptor 4 2.4 1.7 1.0
A A II8626 EST 2.0 2.3 1.1
A A060806 Mm. TSC22-related inducible leucine zipper lb 1.9 1.7 1.0
W 8220I EST 1.7 1.3 1.0
W 13229 EST 1.6 1.7 1.1
A A II9479 Mm. Lymphoid enhancer binding factor 1 1.6 1.7 1.1
A I510010 EST 1.6 1.7 1.0
AA259873 EST 1.6 1.3 1.1
AI466603 EST 1.5 1.6 1.0
AA547162 Mm. Forkhead box O l 1.5 1.5 1.1
A A033308 EST 1.5 1.5 1.1
W 98395 Mm. Discoidin domain receptor 1 1.5 1.3 1.0
A A423149 VI m. Cyr61 1.5 1.4 1.0
A A061644 Mm. Smad 7 1.4 1.5 1.0
W 14184 EST 1.4 1.5 1.0
W 852I7 EST 1.3 1.6 1.0
A A I84015 EST 1.3 1.5 1.1
A AI25391 EST 1.3 1.4 1.1
III B,T,a T AA036380 Mm. Snail hom olog 2.2 3.7
A A I44094 EST 2.2 3.2 1.9
A A I84207 EST 1.8 2.7 1.5
AA060863 EST 1.8 1.5 1.3
W 85374 EST 1.8 1.5 1.3
A A098166 Mm. Placental growth factor 1.7 1.5 1.2
W 64388 Mm. IYI v(1118 1.5 3.5 1.4
AI595201 Mm. HB-EGF 1.5 2.8 1.3
W 45975 Mm. TNF receptor lb 1.5 2.0 1.2
AA271373 Mm. H eparan sulfate 6-O -sulfotransferase 1 1.5 1.4 1.2
AA064241 Mm. Stimulated by retinoic acid 1.4 3.6 1.9
A A476158 VI m. Tieg 1.4 2.2 1.5
W 3654I Mm. Connective tissue growth factor 1.4 1.9 1.2
A A245505 VI m. Citokine inducible SH2 protein 2 1.4 1.4 1.2
A A I77949 VI m. Solute carrier family 20, member 1 1.3 1.9 1.3
A A472299 EST 1.3 1.8 1.4
AA444621 EST 1.3 1.7 1.3
A I509105 EST 1.3 1.7 1.2
AA036347 VI m. Kruppel-like factor 9 1.3 1.6 1.3
AA386857 EST 1.3 1.6 1.3
AA275737 Mm. Retinal short-chain dehydrogenase/reductase 1 1.3 1.6 1.2
W 66845 EST 1.3 1.6 1.2
A A I45784 Mm. Timp3 1.3 1.5 1.2
A A260654 Mm. Tg interacting factor 1.2 2.4 1.6
AA030427 EST 1.2 1.5 1.3
W 98074 EST 1.2 1.5
IV t ,a T A I322575 Mm. Cocaine and am phetamine regulated transcript 1.1 2.0
V t T A I390830 EST 1.0 1.6 1.1
VI b Tt ^ AA271331 EST 1.4 -1.2 1.0
W 87955 EST 1.6 -1.3 -1.1
VII B^T,AT A I552496 EST -1.4 1.3
W 64999 VI m. H esl -1.6 1.3
VIII B,T^ A I466638 EST -1.2 -1.7 -1.1
IX B,T,A^ W 3472I Mm. Vitam in D upregulated protein 1 -1.3 -1.6 -1.3
A A432818 EST -1.2 -1.6 -1.2
X B^ AA174312 EST -1.3 1.0 1.0
A I604140 EST -1.4 1.0 1.0
Genes regulated at least 1.3 times by BMP2 (300ng/ml), 1.5 times by TGF-^1 (5ng/ml) or 1.5 times by activin A (20 ng/ml) are
shown, categorized according to expression profiles, based on regulation values of at least 1.2 for all growth factors. Green, up- 
regulated; red, down-regulated; black, not regulated; B, BMP2; T, TGF-p1; A, activin A; T, up-regulated; i ,  down-regulated. Each 
value is the average o f  two reciprocal hybridizations.
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¡
AA727967 
AA7261G2 
AI 386062 
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G ap junction m em brane channel protein a.1
Cysteine-rich protein 2
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Laminin p3 
EST s
Keratin com plex 1, acidic, g en e  12 
Choi ecyst oki nin
Transcription fac tor 7, T-cell specific
ACCESSION# DESCRIPTION
_ AA536836 
" AI595201 
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‘ AA271866
EXPRESSION PROFILE
Basic helix-loop-helix domain containing, c lass  B2 (Bhlhb2), 
Heparin binding epidermal growth factor-like growth fac tor 
ESTs
Mus m usculus C a2+-independent phospholipase A2 long form
, FUNCTION PROFILE
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AA674392 
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" AA238037 
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EST s
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Im m unity-associated protein. 38  KDa 
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AA545284 
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Inhibitor of DNA binding 2
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MAD homolog 7 (Drosophila)
EST
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MAD homolog 6 (Drosophila)
Selectin, platelet
FUNCTION PROFILE
AA152636 
AA794176 
AA261535 
AA260963 
AA437585 
AA474446 
AA54S740 
AA619915 
AI595487 
AA267210 
AA5495S1 
AA623758 
AA794174 
AA546964 
AA108600 
AA267330 
AA288456 
AA444227 
AA547033 
AA5453S7 
AA064133 
AA175485 
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AA434859 
AA475858 
AI120186
Clu s t e  r  3  a c c  e s s  io n#  d e s c r ip t io n
AW 210425 Solute carrier family 20, m em ber 1
_ _  W 18822 Gadd45y, growth arrest and DNA-damage-inducible y
___ AA517353 N Fk light chain g en e  enhancer in B-cells inhibitor, a
___ AA982549 Placental growth factor
~__ AA895566 Gadd45|3, growth arrest and DNA-damage-inducible p
_ _  AA036380 Snail homolog. (drosophila)
___ AA733791 DdH, cell adhesion k inasel
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Integrin <x4 (Cd49d)
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EST
E STs
E STs
E STs
E STs
E STs
E STs
Exportin 1
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TF EMe| IS [ R eel EMa| CPI ]c S k | 
ESTsI Signal Transduction strucuTra|an r"
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EXPRESSION PROFILE
1
Figure 1 (C hapter 3) . Expression profiles o f the significantly (p<0.01) regulated BMP2-responsive genes.
(A) Clusters o f primarily up-regulated genes, (B) Clusters o f primarily down-regulated genes. Genes regulated within 24 hrs after 
BMP2 treatment are shown, grouped according to Model-based clustering o f 10log transformed micro array data (normalized on a 
scale to 1). Induction levels are indicated with different color intensities in red and blue, representing up-and down-regulation 
respectively. Protein function profile graphs show the number o f genes within each cluster with a particular function. Genes with 
unknown function or other functions were labeled as “Other”. EST, expressed sequence tag; TF, transcription factor; Eme, 
extracellular messenger; IS, intracellular signaling protein; Rec, receptor; Ema, extracellular matrix protein; CPI, cytoplasmatic 
protein; CSk, cytoskeletal protein.
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ACCESSION#
AA793036
Al323202
AA553242
AA606331
AA437694
AA796822
AA501052
DESCRIPTION
Vascular endothelial growth factor
Small inducible cytokine A2
Gadd45a, growth arrest and DNA-damage-inducible o
L-myc, lung carcinoma myc related oncogene 1
Myog eni c d iff erenti ati on 1
Sialyl transferase 4
Cardiac morphogenesis (Xin)
ACCESSION#. 
Al 552496 
Al 391322 
Al 552711 
AA771647 
AA815689 
AA760135 
Al 465074 
AA822257 
Al 894014
I
AA117547
AA792499
W 16059
AA066615
AA067083
Al 326605
AA771566
AA116263
AA185112
AA288642
AA681235
AA690387
AA770924
DESCRIPTION
ESTs
Protein kinase inhibitor a 
Creatine kinase, muscle 
ESTs
Troponin C, cardiac/slow skeletal
Procollagen, type IV, a  1
Mesoderm specific transcript
Myosin light chain, alkali, fast skeletal muscle
Cholinergic receptor, nicotinic, y-polypeptide
Matrix y-carboxyglutamate (gla) protein
Cyclin D1
Ankyrin-like repeat protein
Glutathione S-transf erase co 1
Glycine amidinotransferase
High mobility group protein I
Cy cl in-dependent kinase inhibitor 1A (p21/WAF1)
Troponin C, fast skeletal
UDP-glucose ceram ide glucosyltransferase
ESTs
Cholinergic receptor, nicotinic, beta polypeptide 1 (muscle) 
ESTs
Xist gene (X inactivation transcript)
Troponin T3, skeletal, fast
Calsequestrin 2
Four and a half LIM domains 1
ESTs
ESTs
3-Phosphoglycerate dehydrogenase
ESTs
Mesothelin
VPS 10 domain receptor protein SORCS 2
X-linked nuclear protein
ESTs
-2.33 -1.60 -1.25 1.25 1.60 2.33 
REGULATION ON MICROARRAY
Cluster 9 accession# 
Al 390830 
AA124623 
Al 552167 
AA619763 
AA738820 
Al 117310 
AA444581 
AA067625 
AA068116 
AA386892 
AA606605 
AA048101 
AA217009 
AA241390 
Al 607683 
AA684257 
__AA596866
Ì
AA879966 
W89253 
AI325851 
W36474 
W53231 
AA105866 
AI510089 
AA725965 
AA798948 
AA711869 
W34122 
AA068464 
AI323051 
AA840053 
AA617310 
W99951 
W13004 
AA023538 
AA413490 
AA510298 
AA764163 
Al 152562 
AA867173 
AA222190 
AA516800 
Al 152800 
AA061902
DESCRIPTION
ESTs
Ecotropic viral integration site 2 
ESTs
Cathepsin L
Phosphoserine transferase
Flavin containing monooxygenase 1
EST
Ph osphatidate cytidylyltransferase
Acetyl-Coenzyme A dehydrogenase, medium chain
Dystrobrevin
Nidogen 1
Sema 4C precursor
Tumor endothelial marker 8 (anthrax toxin receptor)
Semaphorin 3E
Semaphorin 7A
ESTs
ESTs
Laminin a 5
Insulin-like growth factor binding protein 5 
CD97 antigen 
Metallothionein 2 
CD82 antigen
Glutathione S-transferase a 4
EST
EST
Caveolin, caveolae protein, 22 kDa
Epidermal growth factor receptor pathway substrate 8
Bridging integrator 1 /  myc box dependent interacting protein 1
Ect2 oncogene
Growth associated protein 43
Actinin alpha 2 associated LIM protein
Zyxin
Neurofilament, light polypeptide
Prostaglandin 12 (prostacyclin) synthase
Semaphorin 6A
Transferrin receptor
Plasminogen activator, urokinase
Phospholipid scramblase 1
Proliferin
ESTs
EIG 180
Death-associated kinase 2 
ESTs
Apolipoprotein B editing complex 2
Clusterl 0 ACCESSION# DESCRIPTION 
AA475186 
W 14224 
AA162217 
AA437755 
AA596753
ESTs
Ndr1, N-myc downstream regulated 1 
Pbef, pre-B-cell colony-enhancing factor 
ESTs 
I at exin
FUNCTION PROFILE
EXPRESSION PROFILE
S -1
Figure 1 (Chapter 3), continued.
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Figure 3 (C hapter 3). In vivo expression o f Hey1 and Tcf7 in the developing mouse skeleton.
(A-C) Transverse sections of E14.5 mouse embryos at the level of the jaws for the control osteoblast marker Cbfa1 (A), Tcf7 (B) 
and Hey1 (C), (D-F) Sagital sections o f E16.5 mouse embryos at the level o f the nasal cavities for Cbfa1 (D), Tcf7 (E) and Hey1 
(F), (G-I) Mouse proximal tail vertebrae for Cbfa1(G), Tcf7 (H) and Hey1 (I). Abbreviations used: bm, bone marrow; C1v, 
cartilage primordium of C1 vertebra; cl, clavicle; h, cartilage primordium of humurus; hc, hypertrophic chondroblasts; id, 
intervertebral disc; Jo, Jacobson’s organ; M, Meckel’s cartilage; md, mandible; mx, maxilla; nc, nasal cavity; nca, nasal capsule; P, 
periosteal bone; pc, proliferating chondroblasts; sc, scapula; T, trabecular bone; tg, tongue; to, tooth; vb, vertebral body.
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Table 1 (C hapter 5). Expression regulation of BMP-response genes by Smads and Erk1/2 MAP-kinase
Gene BMP effect caALK2 Smads U0126/Erk
Smad-7 ▲ ▲ ▲ ▲
Id1 ▲ ▲ ▲ ▲
2Id ▲ ▲ ▲▲ ▲
Id3 ▲ ▲ ▲▲ ▲
Tieg ▲ ▲ ▲ ▲
Prrx2 ▲ ▲ ▲ - ▲
Snail ▲ ▲ -
Oasis ▲ ▲▲ ▲ -
Smad-6 ▲ ▲ ▲ -
Hey ▲ ▲ ▲▲ ▲ ▲ ▲ ▲
Cbfa-1 ▲ ▲▲ ▲ ▲ - ▲ ▲
Tcf7 ▲ ▲ -
Alp2 ▲
Wif-1 ▲
AA222756 ▲ ▲ ▲ ▲ ▲▲
Prdc ▲ ▲ ▲ ▲▲▲ ▲ ▲
AA794190 ▲ ▲▲▲▲ ▲ ▲ ▲▲
AA709999 ▲ ▲▲▲▲ ▲▲▲▲▲▲ ▲ ▲
Col6a2 ▲ ▲ ▲ - ▲
Ocn ▲ ▲▲ ▲ ▲ - ▼ ▼▼
Summary o f Figures 1 and 2. ▲ = upregulation, ▼ = down-regulation, the number of triangles indicate relative levels of 
expression.
Figure 4 (C hapter 5). In vivo expression of Hey1 and Lfng  in the developing mouse skeleton.
(A-C) Sagital sections o f E14.5 mouse embryos at the level of the ventricles for the control osteoblast marker Cbfa1 (A), Hey1 (B) 
and Lfng (C), (D-F) Transverse sections o f E14.5 mouse embryos at the level o f the jaws for Cbfa1 (D), Hey1 (E) and Lfng  (F), 
(G-I) Mouse proximal tail vertebrae for Cbfa1 (G), Hey1 (H) and Lfng  (I). Abbreviations used: bm, bone marrow; D, 
Diencephalon; hc, hypertrophic chondroblasts; id, intervertebral disc; Jo, Jacobson’s organ; md, mandible; Mo, Medulla oblongata; 
mx, maxilla; nc, nasal cavity; nca, nasal capsule; P, periosteal bone; pc, proliferating chondroblasts; T, trabecular bone; tg, tongue; 
Sb, Skull bones, V, Ventricular zone; vb, vertebral body.
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Figure 5 (C hapter 5). Model of multi-layered BMP induced osteoblast 
differentiation
For details see text, CHX = cyclohexamide
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Summary
Bone development can occur by two mechanisms of ossification: intramembranous 
ossification and endochondral ossification. In the process of intramembranous ossification, bone 
growth begins with the condensation of mesenchymal cells that expand and form a membranous 
structure. Subsequently, these mesenchymal cells differentiate directly into osteoblasts in the primary 
centers of ossification, and calcification by mature osteoblasts occurs in irregularly distributed 
patches. During endochondral ossification, the condensed embryonic mesenchymal cells first 
differentiate into chondroblasts, which secrete the cartilaginous matrix. Subsequently, the 
chondroblasts proliferate, differentiate into chondrocytes and eventually become hypertrophic and 
undergo programmed cell death. Osteoclasts then resorb the cartilage matrix and adjacent 
mesenchymal stem cells differentiate to osteoblasts, which form new bone in the primary center of 
ossification. Subsequent ossification occurs in a regulated fashion in secondary centers of ossification.
Osteoblast differentiation can be regulated by several hormonal and polypeptide growth 
factors, such as PTH/PTHrP (parathyroid hormone/parathyroid hormone-related protein), Indian 
hedgehog (IHH), Vitamin D, insulin-like growth factors (IGFs), fibroblast growth factors (FGFs), 
platelet-derived growth factor (PDGF), transforming growth factor P (TGF-P) and the bone 
morphogenetic proteins (BMPs). Of these factors, the BMPs are the most potent in inducing 
osteoblast differentiation.
To generate biological responses, BMP family members use heteromeric complexes of so- 
called type I and type II serine/threonine kinase receptors. Upon ligand binding, a complex is formed 
between two type I and two type II receptors, upon which the constitutively active kinase of the type 
II receptor phosphorylates and activates the type I receptor, which subsequently activates specific 
receptor-regulated Smads (R-Smads). Smad-1, -5 and -8 have been shown to be BMP responsive R- 
Smads, while Smad-2 and -3 are responsive to TGF-P and activins, both proteins that are closely 
related to BMPs. In combination with the common mediator Smad-4, the respective R-Smads are 
assembled into heteromeric complexes, which subsequently translocate to the nucleus, where they act 
in concert with other proteins as transcription factor complexes.
In addition to the BMP-activated Smad pathway, several other major signaling pathways are 
known to play a role during osteoblast differentiation. These include the different MAP-kinase 
pathways and the Notch pathway. However, the interplay between the various pathways in osteoblast 
differentiation is still poorly understood. A detailed characterization of BMP-induced regulation of 
the differentiation of MSCs to osteoblasts is therefore very important for understanding the bone 
forming part of bone homeostasis. Such knowledge might facilitate the identification of new putative 
drug targets that promote bone formation by enhancing osteoblast differentiation. Ultimately, these 
new drug targets might enable the development of novel therapies to treat serious clinical disorders 
such as osteoporosis in which bone homeostasis is disturbed.
This thesis addressed the identification of (novel) genes that act as key- or co-regulators of 
BMP-induced osteoblast differentiation and that may function as focal points for the interaction of the 
BMP signal transduction pathway with other pathways relevant for osteoblast differentiation. The 
“gene expression microarray” (GEM) technology allows the simultaneous monitoring of expression 
of several thousands of genes under different experimental conditions. Therefore, we used this 
approach to obtain a detailed characterization of gene expression regulation during the early phases of 
osteoblast differentiation (chapter 3). A large set of BMP2-regulated genes (184 genes and ESTs) was 
identified that could be subdivided into several clusters according to their time-dependent expression 
patterns. These clusters contain functionally related genes, representing the various phases of 
osteoblast differentiation. Signal transduction regulatory factors are mainly represented in the
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clustered subset of immediate early genes, whereas the intermediate early and late early clusters 
consisted primarily of genes related to processes that modulate morphology, basement membrane 
formation and synthesis of extracellular calcified matrix. Interestingly, two genes were identified that 
exhibited very similar expression characteristics as the osteoblast-specific type II isoform of C bfal: 
one belonging to the Wnt signal transduction pathway (Tcf7) and one belonging to the Notch signal 
transduction pathway (Heyl). Moreover, ectopic expression of Tcf-7 was shown to regulate the 
expression of osteoblast differentiation marker genes which suggests that Tcf-7 enhances BMP-2 
induced osteoblast differentiation.
Earlier studies revealed that members of the TGF-P family of growth factors exhibit different 
capacities in regulating osteoblast differentiation. We have subsequently exploited these differences 
by comparing gene expression profiles of cells stimulated by either BMP2, TGF-P or a combination 
of these growth factors (chapters 2 and 4). Genes that are highly induced by BMP-2, but not by TGF- 
P or are repressed by TGF-P, and those of which the BMP-induced expression levels are inhibited by 
TGF-P might be important regulators of BMP-induced osteoblast differentiation. A small set of genes 
exhibiting these expression profiles was identified, including several genes involved in the Notch 
signal transduction pathway such as Heyl, Hes and Lfng. This result suggests that the Notch signal 
transduction pathway is a major regulator of early phase osteoblast differentiation. In addition, 
potential focal points of interaction of the BMP and Notch signal transduction pathways were 
identified.
As mentioned above, osteoblast differentiation is not only regulated by the BMP/Smad 
signal transduction pathway, but also by other signal transduction pathways such as Erk1/2 MAP- 
kinase and Notch pathways. To investigate the influence of these signal transduction pathways on 
osteoblast differentiation, we studied the role of Smads, Erk1/2 MAP-kinase and Notch on gene 
expression regulation during various stages of osteoblast differentiation (chapter 5). Our results 
showed that during BMP-induced osteoblast differentiation a multi-layered cascade of expression 
regulation is employed in which the initial phase of differentiation is based on general BMP-response 
genes. During the progression of osteoblast differentiation, osteoblast commitment genes and 
osteoblast specific genes are regulated in concert with the general BMP-response genes. In addition, 
Erk1/2 MAP-kinase and Notch signaling become more and more effective in modulating expression 
profiles, which ultimately leads to a functional osteoblast characterized by the deposition of a 
calcified extracellular matrix. Moreover, several genes were identified as potential focal points for the 
integration of the Smad and Erk1/2 signaling pathways.
In short, this thesis provides an overview of the genes regulated during early phase BMP- 
induced osteoblast differentiation, and provides insights in how various signal transduction pathways 
interact to regulate osteoblast differentiation.
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Samenvatting
Gewervelde dieren hebben als kenmerk dat zij een inwendig skelet hebben. Dit skelet is bij 
zoogdieren opgebouwd uit bot en kraakbeen. In volgroeide zoogdieren is er normaal gesproken een 
evenwicht tussen botaanmaak en botafbraak. Bij een verstoring van dit evenwicht kunnen echter 
ernstige medische klachten optreden, zoals bij osteoporose, waarbij er meer afbraak dan aanmaak van 
bot plaatsvindt. De huidige medicijnen voor deze ziekte zijn zo ontwikkeld dat zij de botafbraak 
remmen, maar aanmaak van nieuw bot wordt niet of nauwelijks gestimuleerd. Medicijnen die 
botvorming stimuleren kunnen echter een belangrijke aanwinst zijn in de behandeling van 
osteoporose. Voor de ontwikkeling van dit soort medicijnen is een gedetailleerde kennis over de 
regulatie van botvorming erg belangrijk.
Botvorming kan via twee mechanismen optreden, namelijk via intramembrane ossificatie en 
via endochondrale ossificatie. Bij het eerste mechanisme begint botvorming met de groei van 
mesenchymale stamcellen tot een membraanachtige structuur. Vervolgens differentiëren de 
mesenchymale cellen direct uit tot osteoblasten, de botvormende cellen. Bij endochondrale ossificatie 
differentiëren de mesenchymale cellen eerst naar kraakbeen vormende cellen, de chondroblasten. 
Vervolgens wordt het kraakbeen afgebroken en differentiëren andere mesenchymale cellen zich tot 
osteoblasten die in de vrijgekomen ruimte botweefsel aanmaken.
De differentiatie van mesenchymale stamcellen tot osteoblasten kan gereguleerd worden 
door verschillende hormonen en groeifactoren zoals parathyroid hormoon, vitamine D, “transforming 
growth factor P” (TGF-P) en de “bone morphogenetic proteins” (BMPs). Van al deze factoren 
induceren de BMPs de differentiatie naar osteoblasten het beste. Mesenchymale cellen worden door 
middel van specifieke BMP receptoren op het oppervlak van de cel en door een cascade aan 
signaaltransductie-eiwitten gestimuleerd om te differentiëren naar osteoblasten. Deze specifiek door 
BMP gereguleerde cascade van signalen wordt ook wel de BMP/Smad signaaltransductie-route 
genoemd. Naast deze specifieke door BMPs gereguleerde route is ook een aantal andere 
signaaltransductie-routes betrokken bij de differentiatie van mesenchymale cellen naar osteoblasten, 
die niet alleen door BMPs geactiveerd kunnen worden, maar ook door andere groeifactoren en 
hormonen. Deze omvatten onder andere de MAP-kinase en de Notch signaaltransductie-routes. De 
samenwerking van deze verschillende routes binnen het proces van osteoblast differentiatie is nog erg 
onduidelijk. Kennis van de precieze eiwitten die tot expressie komen in de cel en hun interacties met 
elkaar tijdens het differentiatie proces is erg belangrijk, aangezien dit kan bijdragen aan de 
ontdekking en ontwikkeling van nieuwe medicijnen die botvorming stimuleren. Deze nieuwe 
medicijnen zouden dan, naast de al bestaande medicijnen die botafbraak remmen, voor de 
behandeling van osteoporose gebruikt kunnen worden.
Dit proefschrift bespreekt de identificatie van genen, de blauwdrukken van eiwitten, die een 
sleutelrol spelen in de regulatie van BMP-geïnduceerde osteoblast differentiatie, en die mogelijk 
functioneren als brandpunt voor de interactie van de verschillende signaaltransductie-routes die 
werkzaam zijn tijdens osteoblast differentiatie. Om een gedetailleerd overzicht te verkrijgen welke 
genen gereguleerd worden tijdens osteoblast differentiatie kan de “gene expression microarray” 
(GEM) techniek gebruikt worden. Deze techniek maakt het mogelijk om in een keer van duizenden 
genen de genexpressie te meten onder verschillende experimentele omstandigheden of in een 
tijdsverloop. Aangezien direct na stimulatie van cellen met BMP de meeste regulatie optreedt voor 
het aansturen van het differentiatieproces, hebben we de GEM techniek gebruikt om een 
gedetailleerde beschrijving te verkrijgen van genexpressie-regulatie tijdens de vroege fase van 
osteoblast differentiatie (hoofdstuk 3). Gebleken is dat een groot aantal genen (184) gereguleerd 
werd, die in verschillende groepen konden worden ingedeeld op basis van hun expressie in de loop
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van de tijd. Hierbij gold dat de genen die het vroegst tot expressie kwamen, voornamelijk coderen 
voor signaaltransductie-eiwitten en dat genen die later in het proces tot expressie kwamen, 
voornamelijk coderen voor eiwitten die de vorm van cellen veranderen en die gebruikt worden om het 
daadwerkelijke bot te vormen. Opmerkelijk genoeg werden er twee genen geïdentificeerd, Tcf7 en 
H eyl, met een expressiepatroon dat erg leek op het expressie patroon van het Cbfal gen. Het eiwit 
waar Cbfal voor codeert, is een erg belangrijke regulator van osteoblast differentiatie. Bovendien kon 
worden aangetoond dat Tcf7 de differentiatie van osteoblasten door BMP-2 kan versnellen.
Eerdere studies hebben uitgewezen dat de verwante groeifactoren BMP-2 en TGF-P in 
verschillende mate in staat zijn osteoblast differentiatie te reguleren. Gebruikmakend van deze 
verschillen hebben wij een vergelijking gemaakt tussen de genexpressie-profielen van cellen die 
ofwel met BMP-2, ofwel met TGF-P, ofwel met een combinatie van BMP-2 en TGF-P behandeld 
werden (hoofdstukken 2 en 4). Theoretisch gezien zouden genen die in hun expressie sterk 
gereguleerd worden door BMP-2, maar niet of nauwelijks door TGF-P, en waarvan de BMP- 
geïnduceerde expressie geremd kan worden door TGF-P, zeer belangrijke regulatoren kunnen zijn van 
osteoblast differentiatie. Gebleken is dat een klein aantal genen dergelijke expressieprofielen bezitten. 
Van deze kleine groep genen behoorden er drie (Heyl, Hes en Lfng) tot de Notch signaaltransductie- 
route, hetgeen een indicatie is dat deze route een belangrijke rol speelt in de vroege regulatie van 
osteoblast differentiatie. Verder zouden deze genen ook als brandpunt kunnen dienen voor de 
interactie van de Notch en BMP signaaltransductie-routes.
Osteoblast differentiatie wordt niet alleen gereguleerd door de BMP/Smad 
signaaltransductie-route, maar ook door andere signaaltransductie-routes zoals de Erk1/2 MAP-kinase 
en de Notch routes. Om te bepalen in welke mate deze routes bijdragen aan de regulatie van 
osteoblast differentiatie, hebben we onderzoek gedaan naar de rol van verschillende Smad eiwitten 
alsmede van het Erk1/2 eiwit en het Notch eiwit op genexpressie regulatie tijdens verschillende stadia 
van osteoblast differentiatie (hoofdstuk 5). Gebleken is dat tijdens BMP-geïnduceerde osteoblast 
differentiatie gelaagde expressieregulatie plaatsvindt. In de eerste laag wordt, direct na stimulatie, de 
genexpressie gereguleerd van genen die een algemene BMP respons weergeven. Vervolgens wordt de 
expressie gereguleerd van genen die de cellen “vastleggen” in het differentiatieproces, en uiteindelijk 
wordt de genexpressie gereguleerd van genen die specifiek zijn voor het osteoblast celtype. Ook geldt 
dat, naarmate het differentiatieproces vordert, de invloed van de Erk1/2 MAP-kinase en Notch 
signaaltransductie-routes op de regulatie van genexpressie steeds meer toeneemt. Dit geheel aan 
modulaties op het differentiatieproces leidt uiteindelijk tot een celtype dat botweefsel kan aanmaken, 
te weten een functionele osteoblast. Bovendien werden er enige genen geïdentificeerd die mogelijk 
brandpunten vormen van de interactie van de Erk1/2 en BMP/Smad signaaltransductie-routes.
Samenvattend geeft dit proefschrift een gedetailleerd overzicht van de genen waarvan de 
expressie gereguleerd wordt in de vroege stadia van het proces van osteoblast differentiatie. Daarmee 
draagt het bij aan het begrip van hoe verschillende signaaltransductie-routes met elkaar 
communiceren om de differentiatie van mesenchymale cellen zo te geleiden dat er functionele 
osteoblasten ontstaan.
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